# EDGAR Filing Document

**Accession Number:** 0000827187
**File Stem:** 0000827187-26-000031
**Filing Date:** 2026-4
**Character Count:** 389444
**Document Hash:** c4c3a767c945f45f660dd389056302a3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000827187-26-000031.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0000827187-26-000031

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 55

**CONFORMED PERIOD OF REPORT**: 20260103

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sleep Number Corp
- **CENTRAL INDEX KEY:** 0000827187
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOUSEHOLD FURNITURE [2510]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 411597886
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0103

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-25121
- **FILM NUMBER:** 26846538

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 THIRD AVENUE SOUTH
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55404
- **BUSINESS PHONE:** 7635517000

**MAIL ADDRESS:**
- **STREET 1:** 1001 THIRD AVENUE SOUTH
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SELECT COMFORT CORP
- **DATE OF NAME CHANGE:** 19980821

?xml version='1.0' encoding='ASCII'? snbr-20260408

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a)**

**of the Securities Exchange Act of 1934**

**(Amendment No.)**

---

| | |
|:---|:---|
| ☑ | Filed by the Registrant |
| ¨ | Filed by a party other than the Registrant |
| CHECK THE APPROPRIATE BOX: | CHECK THE APPROPRIATE BOX: |
| ¨ | Preliminary Proxy Statement |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☑ | Definitive Proxy Statement |
| ¨ | Definitive Additional Materials |
| ¨ | Soliciting Material under §240.14a-12 |

---

______________________________________________________________________

**SLEEP NUMBER CORPORATION**

(Name of Registrant as Specified In Its Charter)

______________________________________________________________________

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

______________________________________________________________________

---

| | |
|:---|:---|
| PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): | PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): |
| ☑ | No fee required. |
| ¨ | Fee paid previously with preliminary materials. |
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

---

![768231 SN 2025 Proxy Statement Cover Page_v3Revised.jpg](snbr-20260408_g1.jpg)

**NOTICE OF 2026 ANNUAL MEETING** 

**AND PROXY STATEMENT**

**FOR MAY 21, 2026**

![logo_header copy.jpg](snbr-20260408_g2.jpg)

Dear Fellow Shareholders,

Sleep Number is in a turnaround. I joined the Company in April 2025 and from day one, we were focused on driving value for

shareholders, customers and team members.

In the first few months of my tenure, we created a more streamlined operation to ensure quicker decision making, reduced

costs across the business by $136 million<sup>(1)</sup> as compared to 2024, excluding restructuring and other non-recurring costs, and

executed an amendment and extension of our bank agreement through the end of 2027.

This work has allowed us to create a strong foundation to continue to further our efforts. Our strategy forward is called *Sleep* 

*Number Shifts.* It is a focused, company-wide effort to reposition our brand, expand our reach to new customer groups, and

reignite growth.

We are refocusing on the consumer and setting the Company up for sustainable growth. Our efforts are focused on three main

initiatives that we believe will transform Sleep Number:

• First, Products: We are simplifying our offering with the goal of growing our new customer base while building on the

demand from our repeat customers,

• Second, Marketing: We are reshaping our marketing and creative to better connect with today's consumer and drive

engagement with a focus on better return on investment, and

• Third, Distribution: While we continue to see benefits in our vertically integrated model, we believe there are

opportunities to expand distribution into new channels, both physical and digital.

We still have a lot of work ahead of us, and I am optimistic about Sleep Number. This is a powerful brand, with a highly

differentiated product. We have 3,100 dedicated team members with a renewed passion for fast action and a commitment to

our purpose of improving lives by personalizing sleep.

In addition to executing against our strategic business objectives, the Board and management are committed to continuing to

enhance the Company's governance. Specifically, Proposals 2, 3 and 4 require an affirmative vote of two-thirds of the shares of

common stock outstanding as of the Record Date. While support for all of these proposals was very high with voting

shareholders at the 2025 Annual Meeting, at over 98% approval from voting shareholders, we were short of obtaining the

required affirmative vote of two-thirds of the shares of common stock outstanding last year. These matters are important to

shareholders and we remain committed to obtaining the votes required to pass each proposal.

We appreciate your support and we look forward to keeping you updated on our efforts throughout the year.

---

| |
|:---|
| Sincerely, |
| Linda Findley<br>Board Member<br>President and Chief Executive Officer<br>|

---

![LindaFindley_03.jpg](snbr-20260408_g3.jpg)

![LF signature.jpg](snbr-20260408_g4.jpg)

<sup>(1)</sup> See Annex A on page <u>[94](#i44eec75d700a4a12a1ccd8dcee0c79e2_385)</u> for reconciliation of non-GAAP financial measures to our results as reported under GAAP.

![logo_header copy.jpg](snbr-20260408_g2.jpg)

**1001 Third Avenue South**

**Minneapolis, Minnesota 55404**

**NOTICE OF 2026 ANNUAL MEETING OF SHAREHOLDERS MAY 21, 2026**

Sleep Number Corporation will hold its Annual Meeting of Shareholders (Annual Meeting) at 8:30 a.m. Central Time on

May 21, 2026. The meeting will be conducted virtually at ***www.virtualshareholdermeeting.com/SNBR2026***.

---

| | |
|:---|:---|
| | **Our Board of Directors Recommends You** <br>**Vote:** |
| 1.To elect as Directors the three persons named in the Proxy <br>Statement, each to serve for a term of three years until the 2029 <br>Annual Meeting | **FOR** the election of each director nominee |
| 2. To approve amendments to our Third Restated Articles of <br>Incorporation, as amended (Articles), and our Restated Bylaws <br>(Bylaws) to declassify the Board of Directors (Board) | **FOR** the approval of amendments to our <br>Articles and Bylaws to declassify the Board |
| 3. To approve an amendment to our Articles to eliminate the <br>supermajority voting requirement in Article XIV related to Directors  | **FOR** the approval of an amendment to our <br>Articles to eliminate the supermajority voting <br>requirement in Article XIV |
| 4. To approve an amendment to our Articles to eliminate the <br>supermajority voting requirements in Article XV related to approval <br>of certain transactions | **FOR** the approval of an amendment to our <br>Articles to eliminate the supermajority voting <br>requirements in Article XV |
| 5. To ratify the appointment of Deloitte & Touche LLP as our <br>independent auditors for the 2026 fiscal year ending January 2, <br>2027 | **FOR** the ratification of the appointment |
| 6. To approve, on an advisory basis, our executive compensation (Say <br>on Pay) | **FOR** approval, on an advisory basis |
| 7. To approve the amendment to the Sleep Number Corporation 2020 <br>Equity Incentive Plan, as amended (2020 Plan) to increase the <br>number of shares reserved for issuance by 750,000 shares | **FOR** the approval of the amendment to the <br>2020 Plan |

---

Shareholders of record at the close of business on March 23, 2026, will be entitled to vote at the meeting and any

adjournments or postponements thereof. Your vote is important. Please vote your shares in favor of the Board of Directors'

recommendations in time for our May 21, 2026 meeting date. For important information regarding attending and voting at the

Annual Meeting, see "<u>[Our Annual Meeting and Voting](#i44eec75d700a4a12a1ccd8dcee0c79e2_316)</u>" in this Proxy Statement.

---

| |
|:---|
| By Order of the Board of Directors, |
| ![Signature small - Hellfeld.jpg](snbr-20260408_g5.jpg) |
| Samuel R. Hellfeld |
| *Chief Legal and Risk Officer and Secretary* |

---

Minneapolis, Minnesota

April 8, 2026

![**Table of Contents**.jpg](snbr-20260408_g6.jpg)

---

| | |
|:---|:---|
|  | **Page** |
| **[OUR BOARD](#i44eec75d700a4a12a1ccd8dcee0c79e2_22)** | **[1](#i44eec75d700a4a12a1ccd8dcee0c79e2_22)** |
| **Who We Are** | **[1](#i44eec75d700a4a12a1ccd8dcee0c79e2_25)** |
| **[Proposal 1 - Election of Directors](#i44eec75d700a4a12a1ccd8dcee0c79e2_28)** | [2](#i44eec75d700a4a12a1ccd8dcee0c79e2_28) |
| How We Are Selected, Elected and Evaluated | [7](#i44eec75d700a4a12a1ccd8dcee0c79e2_37) |
| How We Are Governed and Govern | [10](#i44eec75d700a4a12a1ccd8dcee0c79e2_64) |
| How You Can Communicate With The Board | [14](#i44eec75d700a4a12a1ccd8dcee0c79e2_118) |
| Proposal 2 - Amendments to Our Articles and Bylaws to Declassify the Board  | [18](#i44eec75d700a4a12a1ccd8dcee0c79e2_133) |
| [Proposal 3 - Amendment to Our Articles to Eliminate the Supermajority Voting Requirement in Article XIV](#i44eec75d700a4a12a1ccd8dcee0c79e2_136)<br>[related to Directors](#i44eec75d700a4a12a1ccd8dcee0c79e2_136)<br>| [19](#i44eec75d700a4a12a1ccd8dcee0c79e2_136) |
| [Proposal 4 - Amendment to Our Articles to Eliminate the Supermajority Voting Requirements in Article XV](#i44eec75d700a4a12a1ccd8dcee0c79e2_139)<br>[related to Approval of Certain Transactions](#i44eec75d700a4a12a1ccd8dcee0c79e2_139)<br>| [20](#i44eec75d700a4a12a1ccd8dcee0c79e2_139) |
| How We Are Paid | [15](#i44eec75d700a4a12a1ccd8dcee0c79e2_121) |
| **[OUR COMPANY](#i44eec75d700a4a12a1ccd8dcee0c79e2_142)** | [21](#i44eec75d700a4a12a1ccd8dcee0c79e2_142) |
| What We Do | [21](#i44eec75d700a4a12a1ccd8dcee0c79e2_145) |
| Who We Are | [21](#i44eec75d700a4a12a1ccd8dcee0c79e2_148) |
| How We Do It | [22](#i44eec75d700a4a12a1ccd8dcee0c79e2_151) |
| [Audit Committee Report](#i44eec75d700a4a12a1ccd8dcee0c79e2_94) | [23](#i44eec75d700a4a12a1ccd8dcee0c79e2_160) |
| [Proposal 5 - Ratification of Appointment of Independent Registered Public Accounting Firm](#i44eec75d700a4a12a1ccd8dcee0c79e2_163) | [25](#i44eec75d700a4a12a1ccd8dcee0c79e2_163) |
| **[OUR PAY](#i44eec75d700a4a12a1ccd8dcee0c79e2_169)** | **[27](#i44eec75d700a4a12a1ccd8dcee0c79e2_169)** |
| Compensation Committee Report | [27](#i44eec75d700a4a12a1ccd8dcee0c79e2_175) |
| Compensation Discussion and Analysis | [28](#i44eec75d700a4a12a1ccd8dcee0c79e2_178) |
| Proposal 6 - Advisory Vote to Approve Executive Compensation (Say on Pay) | [61](#i44eec75d700a4a12a1ccd8dcee0c79e2_292) |
| Proposal 7 - Approve the Amendment to the Sleep Number Corporation 2020 Equity Incentive Plan, as <br>amended <br>| [62](#i44eec75d700a4a12a1ccd8dcee0c79e2_295) |
| **[OUR SHAREHOLDERS](#i44eec75d700a4a12a1ccd8dcee0c79e2_307)** | **[79](#i44eec75d700a4a12a1ccd8dcee0c79e2_307)** |
| [Stock Ownership of Management and Certain Beneficial Owners](#i44eec75d700a4a12a1ccd8dcee0c79e2_310) | [79](#i44eec75d700a4a12a1ccd8dcee0c79e2_310) |
| Shareholder Proposals for 2026 Annual Meeting | [80](#i44eec75d700a4a12a1ccd8dcee0c79e2_313) |
| **[OUR ANNUAL MEETING AND VOTING](#i44eec75d700a4a12a1ccd8dcee0c79e2_316)** | **[82](#i44eec75d700a4a12a1ccd8dcee0c79e2_316)** |
| Other Matters | [86](#i44eec75d700a4a12a1ccd8dcee0c79e2_346) |
| Copies of 2025 Annual Report | [86](#i44eec75d700a4a12a1ccd8dcee0c79e2_352) |
| How To Receive Proxy Materials | [87](#i44eec75d700a4a12a1ccd8dcee0c79e2_355) |
| How To Receive Future Proxy Materials Electronically | [87](#i44eec75d700a4a12a1ccd8dcee0c79e2_358) |
| The Company Bears The Proxy Solicitation Costs | [87](#i44eec75d700a4a12a1ccd8dcee0c79e2_361) |

---

*As used in this Proxy Statement, the terms "we," "us," "our," the "Company" and "Sleep Number" mean Sleep Number Corporation and its subsidiaries* 

*and the term "common stock" means our common stock, par value $0.01 per share.*

*This Proxy Statement contains "forward-looking" statements regarding our current expectations within the meaning of the applicable securities laws and* 

*regulations. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations.* 

*These risks and uncertainties include, but are not limited to, the risks detailed in our filings with the Securities and Exchange Commission (SEC),* 

*including the risk factors discussed under the heading "Risk Factors" under Part I: Item 1A. of the Annual Report on Form 10-K for the year ended* 

*January 3, 2026. We assume no obligation to update any of these forward-looking statements.*

---

| | |
|:---|:---|
| **1 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

![Our Board.jpg](snbr-20260408_g7.jpg)

**PROXY STATEMENT FOR ANNUAL MEETING**

**May 21, 2026**

This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (Board) of Sleep

Number for use at the 2026 Annual Meeting. These materials were first sent or made available to our shareholders on

April 8, 2026.

**OUR BOARD**

**WHO WE ARE**

Article XIV of our Third Restated Articles of Incorporation, as amended, (Articles) and our Restated Bylaws (Bylaws)

provides that the number of Directors must be at least one but not more than 12 and must be divided into three classes as

nearly equal in number as possible. The exact number of Directors is determined from time to time by the Board. The term

of each class is three years and the term of one class expires each year in rotation.

Immediately prior to the 2026 Annual Meeting, our Board will consist of seven members, three of which will be up for

election at the 2026 Annual Meeting: Phillip M. Eyler, Julie M. Howard, and Angel L. Mendez. Upon the conclusion of the

2026 Annual Meeting, our Board will consist of six members following the retirement of Hilary A. Schneider given new

board service limitations from her recent appointment as the Chief Executive Officer of SimpliSafe, maker of award-

winning smart home security systems. The Company and the Board sincerely thank Ms. Schneider for her leadership,

dedication and contributions to the Company, and wish her the very best in her new role.

---

| | |
|:---|:---|
| **2 \| 2026 PROXY STATEMENT** | **PROPOSAL 1 - ELECTION OF DIRECTORS** |

---

![Proposal 1.jpg](snbr-20260408_g8.jpg)

The Board, based on the recommendation of the Corporate Governance and Nominating Committee (the CGNC),

recommends that Phillip M. Eyler, Julie M. Howard and Angel L. Mendez be elected at the Annual Meeting, each of whom

will serve three-year terms expiring at the 2029 Annual Meeting, until their successor shall have been elected and

qualified, or sooner as further described below.

Mr. Eyler, Ms. Howard and Mr. Mendez have each consented to being named as a nominee in this Proxy Statement and

to serve as a Director in the class of Directors expiring in 2029, if elected, subject to the Company's Proposal 2

(amendments to the Company's Articles and Bylaws to declassify the Board). If the Company's Proposal 2 passes with

the requisite affirmative vote of two-thirds of the shares of common stock outstanding as of the Record Date for the

Company's 2026 Annual Meeting, each of the Directors who have been elected to terms expiring after the 2027 Annual

Meeting, including the Directors noted above, have irrevocably agreed to shorten their terms by resigning effective as of

the 2027 Annual Meeting and standing for re-election at the 2027 Annual Meeting for a one-year term subject to their

nomination by the CGNC. To the extent that the CGNC nominates any of the resigning Directors to stand for re-election in

accordance with the <u>[Director Selection and Nomination Processes](#i44eec75d700a4a12a1ccd8dcee0c79e2_40)</u> as described herein, such resigning Director(s), along

with any Director nominees whose term was set to expire at the 2027 Annual Meeting or any other Director nominee,

would stand for election to a one-year term at the 2027 Annual Meeting. Therefore, contingent upon the passage of

Proposal 2, beginning with the 2027 Annual Meeting, the Company's Board would be declassified and it will begin to hold

annual elections for all Directors that year and going forward.

As detailed in their individual biographies set forth below, Mr. Eyler, Ms. Howard and Mr. Mendez provide a value-add mix

of skills, qualifications and backgrounds to the Board that support and drive the Company's efforts to transform its

business, capitalize on future market opportunities and deliver meaningful, long-term value for our shareholders and all

stakeholders.

The Board recommends a vote "**For**" each of the following Director nominees, Mr. Eyler, Ms. Howard and Mr. Mendez, for

election to three-year terms expiring in 2029:

---

| | |
|:---|:---|
| **3 \| 2026 PROXY STATEMENT** | **PROPOSAL 1 - ELECTION OF DIRECTORS** |

---

---

| | | | |
|:---|:---|:---|:---|
| ![Phil_Eyler.jpg](snbr-20260408_g9.jpg) | **EXPERIENCE** | **EXPERIENCE** |  |
| ![Phil_Eyler.jpg](snbr-20260408_g9.jpg) | 2017 - 2025 | Advisor, Gentherm, a global thermal management technologies company (Dec. <br>2024 to June 2025), immediately prior President, Chief Executive Officer and <br>board member, Gentherm (2017 to Dec. 2024)<br>Various leadership roles culminating as President, Connected Car division, <br>Harman International, an audio electronics company |  |
| ![Phil_Eyler.jpg](snbr-20260408_g9.jpg) | 1997 - 2017 | Advisor, Gentherm, a global thermal management technologies company (Dec. <br>2024 to June 2025), immediately prior President, Chief Executive Officer and <br>board member, Gentherm (2017 to Dec. 2024)<br>Various leadership roles culminating as President, Connected Car division, <br>Harman International, an audio electronics company |  |
| ![Phil_Eyler.jpg](snbr-20260408_g9.jpg) |  |  |  |
| **Phillip M. Eyler**<br>**Age** 54<br>Sleep Number<sup>®</sup> <br>setting 40 | **PUBLIC COMPANY BOARDS** | **PUBLIC COMPANY BOARDS** |  |
| **Phillip M. Eyler**<br>**Age** 54<br>Sleep Number<sup>®</sup> <br>setting 40 | Sleep Number (since 2022)<br>Sensata Technologies (NYSE: ST) (since 2024)<br>Ouster Inc. (Nasdaq: OUST) (since 2025)<br>PRIOR PUBLIC BOARDS<br>Gentherm Incorporated (2017 – 2024) | Sleep Number (since 2022)<br>Sensata Technologies (NYSE: ST) (since 2024)<br>Ouster Inc. (Nasdaq: OUST) (since 2025)<br>PRIOR PUBLIC BOARDS<br>Gentherm Incorporated (2017 – 2024) |  |
| **Phillip M. Eyler**<br>**Age** 54<br>Sleep Number<sup>®</sup> <br>setting 40 | Sleep Number (since 2022)<br>Sensata Technologies (NYSE: ST) (since 2024)<br>Ouster Inc. (Nasdaq: OUST) (since 2025)<br>PRIOR PUBLIC BOARDS<br>Gentherm Incorporated (2017 – 2024) | Sleep Number (since 2022)<br>Sensata Technologies (NYSE: ST) (since 2024)<br>Ouster Inc. (Nasdaq: OUST) (since 2025)<br>PRIOR PUBLIC BOARDS<br>Gentherm Incorporated (2017 – 2024) |  |
|  | Sleep Number (since 2022)<br>Sensata Technologies (NYSE: ST) (since 2024)<br>Ouster Inc. (Nasdaq: OUST) (since 2025)<br>PRIOR PUBLIC BOARDS<br>Gentherm Incorporated (2017 – 2024) | Sleep Number (since 2022)<br>Sensata Technologies (NYSE: ST) (since 2024)<br>Ouster Inc. (Nasdaq: OUST) (since 2025)<br>PRIOR PUBLIC BOARDS<br>Gentherm Incorporated (2017 – 2024) | **QUALIFICATIONS AND EXPERTISE** |
|  | •Visionary and purpose-driven leader with significant global experience in developing <br>connected solutions that meet the needs of the increasingly digital consumer<br>•As CEO of Gentherm, driving transformational growth in thermal and battery technology <br>solutions for automotive and medical consumers across the globe<br>•Served in a series of escalating leadership roles for over 20 years at Harman International, <br>an $8 billion audio electronics company, culminating in a two-year tenure as President of its <br>Connected Car Division | •Visionary and purpose-driven leader with significant global experience in developing <br>connected solutions that meet the needs of the increasingly digital consumer<br>•As CEO of Gentherm, driving transformational growth in thermal and battery technology <br>solutions for automotive and medical consumers across the globe<br>•Served in a series of escalating leadership roles for over 20 years at Harman International, <br>an $8 billion audio electronics company, culminating in a two-year tenure as President of its <br>Connected Car Division |  |

---

---

| | | |
|:---|:---|:---|
| ![Howard.jpg](snbr-20260408_g10.jpg) | **EXPERIENCE** | **EXPERIENCE** |
| ![Howard.jpg](snbr-20260408_g10.jpg) | 2021 - 2023 | Most recently Chief Executive Officer, Riveron, a national accounting, finance, <br>technology and operations company<br>Numerous positions at Navigant Consulting, Inc., a publicly traded global <br>professional services firm, most recently as Chief Executive Officer (2012 to <br>2019) and Chairman of the Board (2014 to 2019) |
| ![Howard.jpg](snbr-20260408_g10.jpg) | 2000 - 2019 | Most recently Chief Executive Officer, Riveron, a national accounting, finance, <br>technology and operations company<br>Numerous positions at Navigant Consulting, Inc., a publicly traded global <br>professional services firm, most recently as Chief Executive Officer (2012 to <br>2019) and Chairman of the Board (2014 to 2019) |
| ![Howard.jpg](snbr-20260408_g10.jpg) |  |  |
| **Julie M. Howard**<br>**Age** 63<br>Sleep Number<sup>®</sup> <br>setting 40 | **PUBLIC COMPANY BOARDS** | **PUBLIC COMPANY BOARDS** |
| **Julie M. Howard**<br>**Age** 63<br>Sleep Number<sup>®</sup> <br>setting 40 | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) |
|  | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) |
|  | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) |
|  | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) |
|  | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) | Sleep Number (since 2020)<br>ManpowerGroup, Inc. (NYSE: MAN) (since 2016)<br>PRIOR PUBLIC BOARDS<br>Kemper Corp (2010 – 2015)<br>Navigant Consulting, Inc. (2012 – 2019) <br>InnerWorkings, Inc. (2012 – 2020) |
|  | **QUALIFICATIONS AND EXPERTISE** | **QUALIFICATIONS AND EXPERTISE** |
|  | •As former CEO of Riveron and Navigant, she provides the board with significant managerial, <br>transactional, business transformation and operational experience<br>•Has expertise in developing global growth strategies and expansion into adjacent markets, <br>leveraging technology and innovation<br>•Considerable background in investor relations matters | •As former CEO of Riveron and Navigant, she provides the board with significant managerial, <br>transactional, business transformation and operational experience<br>•Has expertise in developing global growth strategies and expansion into adjacent markets, <br>leveraging technology and innovation<br>•Considerable background in investor relations matters |

---

---

| | |
|:---|:---|
| **4 \| 2026 PROXY STATEMENT** | **PROPOSAL 1 - ELECTION OF DIRECTORS** |

---

---

| | | | |
|:---|:---|:---|:---|
| ![Mendez2025.jpg](snbr-20260408_g11.jpg) | **EXPERIENCE** | **EXPERIENCE** |  |
| ![Mendez2025.jpg](snbr-20260408_g11.jpg) | 2020 - Present | Executive Chairman, LevaData, an artificial intelligence company that powers <br>the smartest supply chains in the world<br>Executive Vice President and Chief Operation Officer, HERE Technologies, a <br>multi-national mapping, location intelligence and data services platform <br>company<br>Senior executive at Cisco. Prior senior supply chain, global procurement and <br>executive roles at Palm, Inc., Gateway, Inc., Citigroup, Allied Signal Aerospace <br>and GE |  |
| ![Mendez2025.jpg](snbr-20260408_g11.jpg) | 2016 - 2020 | Executive Chairman, LevaData, an artificial intelligence company that powers <br>the smartest supply chains in the world<br>Executive Vice President and Chief Operation Officer, HERE Technologies, a <br>multi-national mapping, location intelligence and data services platform <br>company<br>Senior executive at Cisco. Prior senior supply chain, global procurement and <br>executive roles at Palm, Inc., Gateway, Inc., Citigroup, Allied Signal Aerospace <br>and GE |  |
| **Angel L. Mendez**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 45 | 2005 - 2015 | Executive Chairman, LevaData, an artificial intelligence company that powers <br>the smartest supply chains in the world<br>Executive Vice President and Chief Operation Officer, HERE Technologies, a <br>multi-national mapping, location intelligence and data services platform <br>company<br>Senior executive at Cisco. Prior senior supply chain, global procurement and <br>executive roles at Palm, Inc., Gateway, Inc., Citigroup, Allied Signal Aerospace <br>and GE |  |
| **Angel L. Mendez**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 45 |  |  |  |
| **Angel L. Mendez**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 45 | **PUBLIC COMPANY BOARDS** | **PUBLIC COMPANY BOARDS** |  |
| **Angel L. Mendez**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 45 | Sleep Number (since 2022)<br>Kinaxis, Inc. (Toronto Stock Exchange: KXS.TO) (since 2016)<br>Peloton Interactive (Nasdaq: PTON) (since 2022) | Sleep Number (since 2022)<br>Kinaxis, Inc. (Toronto Stock Exchange: KXS.TO) (since 2016)<br>Peloton Interactive (Nasdaq: PTON) (since 2022) |  |
| **Angel L. Mendez**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 45 | Sleep Number (since 2022)<br>Kinaxis, Inc. (Toronto Stock Exchange: KXS.TO) (since 2016)<br>Peloton Interactive (Nasdaq: PTON) (since 2022) | Sleep Number (since 2022)<br>Kinaxis, Inc. (Toronto Stock Exchange: KXS.TO) (since 2016)<br>Peloton Interactive (Nasdaq: PTON) (since 2022) |  |
|  | Sleep Number (since 2022)<br>Kinaxis, Inc. (Toronto Stock Exchange: KXS.TO) (since 2016)<br>Peloton Interactive (Nasdaq: PTON) (since 2022) | Sleep Number (since 2022)<br>Kinaxis, Inc. (Toronto Stock Exchange: KXS.TO) (since 2016)<br>Peloton Interactive (Nasdaq: PTON) (since 2022) | **QUALIFICATIONS AND EXPERTISE** |
|  | •Decades of experience managing complex digital supply chains for large consumer <br>technology companies<br>•At Cisco Systems, was responsible for the company's enterprise transformation program <br>that reinvented the company's business model and drove significant revenue growth and <br>shareholder value creation<br>•Led HERE's core business, global operations, product management and corporate <br>transformation | •Decades of experience managing complex digital supply chains for large consumer <br>technology companies<br>•At Cisco Systems, was responsible for the company's enterprise transformation program <br>that reinvented the company's business model and drove significant revenue growth and <br>shareholder value creation<br>•Led HERE's core business, global operations, product management and corporate <br>transformation |  |

---

<u>Director not standing for election this year whose term expires in 2027:</u>

---

| | | | |
|:---|:---|:---|:---|
| ![SM2_Crop.jpg](snbr-20260408_g12.jpg) | **EXPERIENCE** | **EXPERIENCE** |  |
| ![SM2_Crop.jpg](snbr-20260408_g12.jpg) | 2008 - 2019 | President and Chief Executive Officer, EnPro Industries, Inc., a manufacturer <br>and provider of precision industrial components, solutions and services<br>Chief Executive Officer, Bluelinx Holdings, Inc., a wholesale distributor of <br>building and industrial products |  |
| ![SM2_Crop.jpg](snbr-20260408_g12.jpg) |  | President and Chief Executive Officer, EnPro Industries, Inc., a manufacturer <br>and provider of precision industrial components, solutions and services<br>Chief Executive Officer, Bluelinx Holdings, Inc., a wholesale distributor of <br>building and industrial products |  |
| ![SM2_Crop.jpg](snbr-20260408_g12.jpg) | 2005 - 2008 | President and Chief Executive Officer, EnPro Industries, Inc., a manufacturer <br>and provider of precision industrial components, solutions and services<br>Chief Executive Officer, Bluelinx Holdings, Inc., a wholesale distributor of <br>building and industrial products |  |
| ![SM2_Crop.jpg](snbr-20260408_g12.jpg) |  | President and Chief Executive Officer, EnPro Industries, Inc., a manufacturer <br>and provider of precision industrial components, solutions and services<br>Chief Executive Officer, Bluelinx Holdings, Inc., a wholesale distributor of <br>building and industrial products |  |
| ![SM2_Crop.jpg](snbr-20260408_g12.jpg) |  |  |  |
| **Stephen E. Macadam**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 60 | **PUBLIC COMPANY AND NONPROFIT BOARDS** | **PUBLIC COMPANY AND NONPROFIT BOARDS** |  |
| **Stephen E. Macadam**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 60 | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) |  |
| **Stephen E. Macadam**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 60 | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) |  |
|  | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) |  |
|  | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) |  |
|  | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) | Sleep Number (since 2023)<br>Atmus Filtration Technologies (NYSE: ATMU) (since 2023)<br>Louisiana-Pacific Corporation (NYSE: LPX) (since 2019)<br>PRIOR PUBLIC BOARDS:<br>Veritiv Corporation (2020 – 2023)<br>NONPROFIT BOARDS:<br>University of Kentucky, College of Engineering – Dean's Advisory Board (since 2015)<br>Purpose Built Communities (Nonprofit) (since 2020) | **QUALIFICATIONS AND EXPERTISE** |
|  | •Deep understanding of product manufacturing, distribution and procurement<br>•Extensive leadership and operations experience growing and transforming businesses in the <br>U.S. and globally<br>•At EnPro, led the company's strategic and portfolio transformation to create a more <br>streamlined, higher-margin business | •Deep understanding of product manufacturing, distribution and procurement<br>•Extensive leadership and operations experience growing and transforming businesses in the <br>U.S. and globally<br>•At EnPro, led the company's strategic and portfolio transformation to create a more <br>streamlined, higher-margin business |  |

---

---

| | |
|:---|:---|
| **5 \| 2026 PROXY STATEMENT** | **PROPOSAL 1 - ELECTION OF DIRECTORS** |

---

<u>Directors not standing for election this year whose terms expire in 2028 or sooner as described herein:</u>

---

| | | |
|:---|:---|:---|
| ![LindaFindley_03.jpg](snbr-20260408_g3.jpg) | **EXPERIENCE** | **EXPERIENCE** |
| ![LindaFindley_03.jpg](snbr-20260408_g3.jpg) | 2025 - Present | President, Chief Executive Officer and Director, Sleep Number <br>President, Chief Executive Officer and Director, Blue Apron Holdings, <br>Inc., an ingredient and recipe meal kit company <br>Chief Operating Officer, Etsy, Inc., an e-commerce company<br>Various senior executive roles at Evernote Corp., a software company, <br>including most recently as Chief Operating Officer<br>Various roles at Alibaba.com Ltd., an e-commerce, retail, internet and <br>technology company |
| ![LindaFindley_03.jpg](snbr-20260408_g3.jpg) |  | President, Chief Executive Officer and Director, Sleep Number <br>President, Chief Executive Officer and Director, Blue Apron Holdings, <br>Inc., an ingredient and recipe meal kit company <br>Chief Operating Officer, Etsy, Inc., an e-commerce company<br>Various senior executive roles at Evernote Corp., a software company, <br>including most recently as Chief Operating Officer<br>Various roles at Alibaba.com Ltd., an e-commerce, retail, internet and <br>technology company |
| ![LindaFindley_03.jpg](snbr-20260408_g3.jpg) | 2019 - 2024 | President, Chief Executive Officer and Director, Sleep Number <br>President, Chief Executive Officer and Director, Blue Apron Holdings, <br>Inc., an ingredient and recipe meal kit company <br>Chief Operating Officer, Etsy, Inc., an e-commerce company<br>Various senior executive roles at Evernote Corp., a software company, <br>including most recently as Chief Operating Officer<br>Various roles at Alibaba.com Ltd., an e-commerce, retail, internet and <br>technology company |
| ![LindaFindley_03.jpg](snbr-20260408_g3.jpg) | 2016 - 2018 | President, Chief Executive Officer and Director, Sleep Number <br>President, Chief Executive Officer and Director, Blue Apron Holdings, <br>Inc., an ingredient and recipe meal kit company <br>Chief Operating Officer, Etsy, Inc., an e-commerce company<br>Various senior executive roles at Evernote Corp., a software company, <br>including most recently as Chief Operating Officer<br>Various roles at Alibaba.com Ltd., an e-commerce, retail, internet and <br>technology company |
| ![LindaFindley_03.jpg](snbr-20260408_g3.jpg) | 2012 - 2015 | President, Chief Executive Officer and Director, Sleep Number <br>President, Chief Executive Officer and Director, Blue Apron Holdings, <br>Inc., an ingredient and recipe meal kit company <br>Chief Operating Officer, Etsy, Inc., an e-commerce company<br>Various senior executive roles at Evernote Corp., a software company, <br>including most recently as Chief Operating Officer<br>Various roles at Alibaba.com Ltd., an e-commerce, retail, internet and <br>technology company |
| **Linda A. Findley**<br>**Age** 52<br>Sleep Number<sup>®</sup> <br>setting 45 | 2009 - 2012 | President, Chief Executive Officer and Director, Sleep Number <br>President, Chief Executive Officer and Director, Blue Apron Holdings, <br>Inc., an ingredient and recipe meal kit company <br>Chief Operating Officer, Etsy, Inc., an e-commerce company<br>Various senior executive roles at Evernote Corp., a software company, <br>including most recently as Chief Operating Officer<br>Various roles at Alibaba.com Ltd., an e-commerce, retail, internet and <br>technology company |
| **Linda A. Findley**<br>**Age** 52<br>Sleep Number<sup>®</sup> <br>setting 45 | **PUBLIC AND PRIVATE COMPANY BOARDS** | **PUBLIC AND PRIVATE COMPANY BOARDS** |
| **Linda A. Findley**<br>**Age** 52<br>Sleep Number<sup>®</sup> <br>setting 45 | Sleep Number (since 2025)<br>Ralph Lauren (NYSE: RL) (since 2018)<br>PRIOR PUBLIC BOARD:<br>Blue Apron Holdings, Inc. (formerly Nasdaq: APRN) (2019-2023)<br>PRIVATE BOARD:<br>HeliosX (since 2025) | Sleep Number (since 2025)<br>Ralph Lauren (NYSE: RL) (since 2018)<br>PRIOR PUBLIC BOARD:<br>Blue Apron Holdings, Inc. (formerly Nasdaq: APRN) (2019-2023)<br>PRIVATE BOARD:<br>HeliosX (since 2025) |
|  | **QUALIFICATIONS AND EXPERTISE** | **QUALIFICATIONS AND EXPERTISE** |
|  | •Accomplished senior executive leading consumer brands that combine digital and physical <br>products, with specific expertise in operations management, organizational transformation, <br>marketing strategy, and global expansion<br>•At Blue Apron, spearheaded a turnaround strategy that culminated in the company's sale to <br>a strategic buyer<br>•At Etsy, oversight for global operations, product, marketing and brand strategy, customer <br>support, and international expansion | •Accomplished senior executive leading consumer brands that combine digital and physical <br>products, with specific expertise in operations management, organizational transformation, <br>marketing strategy, and global expansion<br>•At Blue Apron, spearheaded a turnaround strategy that culminated in the company's sale to <br>a strategic buyer<br>•At Etsy, oversight for global operations, product, marketing and brand strategy, customer <br>support, and international expansion |

---

---

| | |
|:---|:---|
| **6 \| 2026 PROXY STATEMENT** | **PROPOSAL 1 - ELECTION OF DIRECTORS** |

---

---

| | | |
|:---|:---|:---|
| ![Debcropped.jpg](snbr-20260408_g13.jpg) | **EXPERIENCE** | **EXPERIENCE** |
| ![Debcropped.jpg](snbr-20260408_g13.jpg) | 2025 - Present | Partner at Sonder Capital, a venture capital firm |
| ![Debcropped.jpg](snbr-20260408_g13.jpg) | 2014 - 2024 | Executive Chair of the Board (Aug. 2020 to Dec. 2024), Co-Chief Executive <br>Officer (Aug. 2020 to Mar. 2023) and Chief Executive Officer (Dec. 2014 to Aug. <br>2020), Evidation Health, a digital health company<br>VP, Market Development and Chief Commercial Officer, CardioDx, a molecular <br>diagnostics company<br>Director of R&D, Director of New Ventures, and Research Fellow, Guidant <br>Corporation (acquired by Boston Scientific, NYSE BSX), a medical device <br>company |
| ![Debcropped.jpg](snbr-20260408_g13.jpg) | 2006 - 2014 | Executive Chair of the Board (Aug. 2020 to Dec. 2024), Co-Chief Executive <br>Officer (Aug. 2020 to Mar. 2023) and Chief Executive Officer (Dec. 2014 to Aug. <br>2020), Evidation Health, a digital health company<br>VP, Market Development and Chief Commercial Officer, CardioDx, a molecular <br>diagnostics company<br>Director of R&D, Director of New Ventures, and Research Fellow, Guidant <br>Corporation (acquired by Boston Scientific, NYSE BSX), a medical device <br>company |
| **Deborah L.** <br>**Kilpatrick, Ph.D.**<br>**Age** 58<br>Sleep Number<sup>®</sup> <br>setting 30 | 1998 - 2006 | Executive Chair of the Board (Aug. 2020 to Dec. 2024), Co-Chief Executive <br>Officer (Aug. 2020 to Mar. 2023) and Chief Executive Officer (Dec. 2014 to Aug. <br>2020), Evidation Health, a digital health company<br>VP, Market Development and Chief Commercial Officer, CardioDx, a molecular <br>diagnostics company<br>Director of R&D, Director of New Ventures, and Research Fellow, Guidant <br>Corporation (acquired by Boston Scientific, NYSE BSX), a medical device <br>company |
| **Deborah L.** <br>**Kilpatrick, Ph.D.**<br>**Age** 58<br>Sleep Number<sup>®</sup> <br>setting 30 | **PUBLIC AND PRIVATE COMPANY AND NONPROFIT BOARDS** | **PUBLIC AND PRIVATE COMPANY AND NONPROFIT BOARDS** |
| **Deborah L.** <br>**Kilpatrick, Ph.D.**<br>**Age** 58<br>Sleep Number<sup>®</sup> <br>setting 30 | Sleep Number (since 2018) <br>PRIVATE AND NONPROFIT BOARDS:<br>NextGen Jane (private for profit) (since 2019)<br>Sutter Health (not for profit integrated healthcare delivery system in California) (since 2024)<br>Jupiter Endovascular (private, medical device company in California) (since 2024)<br>College of Engineering Advisory Board, Georgia Tech (former Chair) (since 2004) | Sleep Number (since 2018) <br>PRIVATE AND NONPROFIT BOARDS:<br>NextGen Jane (private for profit) (since 2019)<br>Sutter Health (not for profit integrated healthcare delivery system in California) (since 2024)<br>Jupiter Endovascular (private, medical device company in California) (since 2024)<br>College of Engineering Advisory Board, Georgia Tech (former Chair) (since 2004) |
|  | **QUALIFICATIONS AND EXPERTISE** | **QUALIFICATIONS AND EXPERTISE** |
|  | •Medical device, molecular diagnostic and digital health expertise and experience<br>•At Evidation Health, commercialized a new technology platform built to refine large-scale <br>sensor data for new digital measures of individual health<br>•At CardioDX, commercialized a novel gene expression test in cardiovascular disease<br>•Multiple patents in medical devices, drug delivery implant technologies<br>•Fellow, American Institute of Medical and Biological Engineering<br>•Digital Health Hall of Fame (UCSF); Engineering Hall of Fame (Georgia Tech) | •Medical device, molecular diagnostic and digital health expertise and experience<br>•At Evidation Health, commercialized a new technology platform built to refine large-scale <br>sensor data for new digital measures of individual health<br>•At CardioDX, commercialized a novel gene expression test in cardiovascular disease<br>•Multiple patents in medical devices, drug delivery implant technologies<br>•Fellow, American Institute of Medical and Biological Engineering<br>•Digital Health Hall of Fame (UCSF); Engineering Hall of Fame (Georgia Tech) |

---

<u>Director not standing for election this year and who has decided to retire as described herein:</u>

---

| | | | |
|:---|:---|:---|:---|
| ![hillary_crop.jpg](snbr-20260408_g14.jpg) | **EXPERIENCE** | **EXPERIENCE** |  |
| ![hillary_crop.jpg](snbr-20260408_g14.jpg) | 2025 - present | Chief Executive Officer, SimpliSafe, maker of award-winning smart home <br>security systems  |  |
| ![hillary_crop.jpg](snbr-20260408_g14.jpg) | 2020 - 2024 | Chief Executive Officer, Shutterfly, Inc., a photography, photography products <br>and image sharing company |  |
| ![hillary_crop.jpg](snbr-20260408_g14.jpg) | 2018 - 2019 | Chief Executive Officer, WagQ Group Co., a leading on-demand mobile dog <br>walking and dog care service |  |
| **Hilary A. Schneider**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 40 | 2010 - 2017 | Various leadership roles, including Chief Executive Officer, LifeLock, Inc., an <br>identity theft protection company |  |
| **Hilary A. Schneider**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 40 | **PUBLIC COMPANY BOARDS** | **PUBLIC COMPANY BOARDS** |  |
| **Hilary A. Schneider**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 40 | Sleep Number (since 2023)<br>DigitalOcean Holdings (NYSE: DOCN) (since 2020)<br>Getty Images Holdings (NYSE: GETY) (since 2020)<br>Vail Resorts (NYSE: MTN) (since 2010) | Sleep Number (since 2023)<br>DigitalOcean Holdings (NYSE: DOCN) (since 2020)<br>Getty Images Holdings (NYSE: GETY) (since 2020)<br>Vail Resorts (NYSE: MTN) (since 2010) |  |
| **Hilary A. Schneider**<br>**Age** 65<br>Sleep Number<sup>®</sup> <br>setting 40 | Sleep Number (since 2023)<br>DigitalOcean Holdings (NYSE: DOCN) (since 2020)<br>Getty Images Holdings (NYSE: GETY) (since 2020)<br>Vail Resorts (NYSE: MTN) (since 2010) | Sleep Number (since 2023)<br>DigitalOcean Holdings (NYSE: DOCN) (since 2020)<br>Getty Images Holdings (NYSE: GETY) (since 2020)<br>Vail Resorts (NYSE: MTN) (since 2010) |  |
|  | Sleep Number (since 2023)<br>DigitalOcean Holdings (NYSE: DOCN) (since 2020)<br>Getty Images Holdings (NYSE: GETY) (since 2020)<br>Vail Resorts (NYSE: MTN) (since 2010) | Sleep Number (since 2023)<br>DigitalOcean Holdings (NYSE: DOCN) (since 2020)<br>Getty Images Holdings (NYSE: GETY) (since 2020)<br>Vail Resorts (NYSE: MTN) (since 2010) | **QUALIFICATIONS AND EXPERTISE** |
|  | •More than two decades of experience leading consumer technology companies<br>•Significant digital and innovation expertise and a track record of delivering superior <br>customer experiences<br>•Led LifeLock through its public listing to its sale to Symantec for $2.3 billion, driving <br>meaningful revenue growth | •More than two decades of experience leading consumer technology companies<br>•Significant digital and innovation expertise and a track record of delivering superior <br>customer experiences<br>•Led LifeLock through its public listing to its sale to Symantec for $2.3 billion, driving <br>meaningful revenue growth |  |

---

---

| | |
|:---|:---|
| **7 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

![OurBoard (002).jpg](snbr-20260408_g15.jpg)

**HOW WE ARE SELECTED, ELECTED AND EVALUATED**

**How We Are Selected**

<u>Director Selection and Nomination Processes</u>

The Corporate Governance and Nominating Committee (the CGNC) administers the process for nominating candidates to

serve on our Board. The CGNC recommends candidates for consideration by the Board as a whole, which is responsible

for appointing candidates to fill any vacancy created between shareholder meetings and for nominating candidates for

election by shareholders at our Annual Meeting. Consistent with the Corporate Governance Principles adopted by our

Board, the CGNC periodically reviews with the Board the appropriate skills and characteristics required of Board members

in the context of the current membership of the Board and the strategic direction of the Company. The Corporate

Governance Principles are available in the Investor Relations section of the Company's website at *http://*

*ir.sleepnumber.com.* The information contained in or connected to our website is not incorporated by reference into, or

considered a part of, this Proxy Statement.

The CGNC casts a wide net for director candidates including individuals recommended by directors, officers, shareholders

or professional advisors retained by the CGNC pursuant to its charter.

The CGNC considers director candidates in the context of the Board's overall composition, including whether the Board

has an appropriate combination of professional experience, skills and knowledge and variety of viewpoints and

backgrounds in light of the Company's current and expected future needs. The Board is committed to seeking director

candidates who reflect diverse perspectives, including a complementary mix of professional and personal backgrounds

and experiences, which we believe is critical to the success of the Company and its ability to create long-term value for

our stakeholders.

<u>Director Selection Criteria</u>

The Board has established selection criteria, which are reviewed at least annually, approved by the Board, applied by the

CGNC, and disclosed in our Corporate Governance Principles. They stress the following characteristics along with

considerations of diversity, including gender identity, race, ethnicity, age, sexual orientation, educational and professional

experience, and differences in viewpoints:

• Independence;

• Integrity;

• Proven record of accomplishment and sound business judgment in areas relevant to the Company's business;

• Belief in and passion for the Company's purpose, principles and strategy;

• Ability to bring strategic and innovative insights to the discussion and challenge and stimulate management;

• Willingness to both speak one's mind and consider divergent ideas and opinions;

• Understanding of, and ability to commit sufficient time to, Board responsibilities and duties; and

• Subject matter expertise.

---

| | |
|:---|:---|
| **8 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

The charts below depict the diversity of our seven Board members, based on gender identity, race and ethnicity, age and

tenure on the Board.

![25](snbr-20260408_g16.gif)

![37](snbr-20260408_g17.gif)

![1](snbr-20260408_g18.gif)

![13](snbr-20260408_g19.gif)

Our Directors exhibit the skills, experiences and diversity listed below and as detailed in their individual bios above, and

these qualifications were considered in their selection to serve on our Board.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Phillip** <br>**Eyler**<br>| **Linda** <br>**Findley**<br>| **Julie**<br>**Howard**<br>| **Deb**<br>**Kilpatrick**<br>| **Stephen** <br>**Macadam**<br>| **Angel**<br>**Mendez**<br>| **Hilary** <br>**Schneider**<br>|
| CEO Experience | X | X | X | X | X |  | X |
| Executive Leadership | X | X | X | X | X | X | X |
| Current Public Company <br>Boards (incl. Sleep Number)<br>| 3 | 2 | 2 | 1 | 3 | 3 | 4 |
| Retail and Digital Commerce |  | X |  |  |  | X | X |
| Marketing & Brand Building |  | X | X | X |  |  | X |
| Product Innovations | X | X |  | X |  | X | X |
| Technology | X | X |  | X |  | X | X |
| Finance | X | X | X |  | X |  | X |
| Supply Chain, <br>Manufacturing, Logistics, <br>Delivery<br>| X |  |  |  | X | X | X |
| Human Capital | X | X | X | X |  | X |  |
| Information Technology and <br>Privacy<br>| X |  | X | X |  | X | X |
| Cybersecurity |  |  |  | X |  | X | X |
| Artificial Intelligence <br>Governance<br>|  |  |  | X |  | X |  |
| Governance and <br>Sustainability<br>| X | X | X |  | X | X | X |
| Risk Management | X | X | X |  | X | X | X |
| Gender Diversity |  | X | X | X |  |  | X |
| Racial or Ethnic Diversity |  |  |  |  |  | X |  |

---

**How Board Members Are Elected and Refreshed**

<u>Director Elections</u>

Our Articles currently provide for a classified Board serving staggered terms of three years each with a Board size of at

least one but no more than 12 Directors. The CGNC and Board annually review our Board structure and size. As part of its

regular governance review and consistent with shareholder feedback, the Board recently undertook efforts to reduce its

size. In a Letter to Shareholders filed with the SEC on October 30, 2024, the Board announced its plans to seek

shareholder approval at the 2025 Annual Meeting for amendments to the Company's Articles and Bylaws to declassify the

Board. The 2025 Proxy Statement included Proposal 2 to declassify the Board. Proposal 2 required an affirmative vote of

two-thirds of the shares of common stock outstanding as of the Record Date for the 2025 Annual Meeting, and while

---

| | |
|:---|:---|
| **9 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

approximately 99% of the shareholders who voted at the May 28, 2025 Annual Meeting supported Proposal 2, this

represented less than the requisite affirmative vote of two-thirds of all shares of common stock outstanding. As disclosed

in a Form 8-K filed on May 29, 2025, the Board unanimously agreed to resubmit Proposal 2 to shareholders at the

Company's 2026 Annual Meeting and to seek to declassify the Board on an accelerated timeline as further described in

Proposal 2 - Amendment to the Company's Articles and Bylaws to Declassify the Board on page <u>[18](#i44eec75d700a4a12a1ccd8dcee0c79e2_133)</u>.

Our Articles also provide for a majority voting standard in the case of uncontested elections and a plurality voting standard

in the case of contested elections in order to reduce the risk of a "failed election" in a contested election. If a Director

nominee who is an incumbent is not elected at a shareholder meeting and no successor to the incumbent is elected at

that shareholder meeting, that nominee shall promptly offer to tender their resignation to the Board. The CGNC shall make

a recommendation to the Board on whether to accept or reject the offer, or whether other action should be taken. The

Board, taking into account the CGNC's recommendation, will publicly disclose its decision and the rationale within 90

days, and the nominee with be recused from the process. If such nominee's resignation is not accepted by the Board, they

shall continue to serve until their successor is duly elected, or their earlier death, resignation, retirement, disqualification or

removal.

If prior to the Annual Meeting, the Board should learn that any nominee will be unable to serve, the proxies that otherwise

would have been voted for such nominee will be voted for such substitute nominee as selected by the Board, or, at the

Board's discretion, may be voted for such fewer number of nominees as result from the inability of any such nominee to

serve.

<u>Director Refreshment</u>

As noted above, the Board has undergone significant change since the 2025 Annual Meeting. With two long-tenured

Directors deciding not to stand for reelection and one Director retiring, the Board went from 12 Directors prior to the 2025

Annual Meeting to nine immediately thereafter. Then, consistent with public announcements, two additional long-tenured

Directors retired during 2025, one in November after the Company secured an amendment to its credit facility and the

other at year-end. Thus, the Company ended the year with seven Directors.

We have a number of practices or approaches that encourage continued thoughtful board refreshment including:

• The Board maintains a resignation policy for any Director who reaches the age of 72 or has a material change in their

principal employment or affiliation to promptly tender their resignation to the Chair of the CGNC to review and come

forward with a recommendation to the full Board for final determination;

• The Board considers individual and Board average tenures and refreshment rates as part of its overall nomination

assessments; and

• The Board evaluation process informs its Director refreshment oversight.

**How We Are Evaluated**

The CGNC oversees the annual evaluation of the Board's governance and effectiveness, reviews the results and makes

recommendations to the Board. The evaluation process includes an annual self-evaluation of the Board and its

committees, as well as periodic individual Director evaluations. The CGNC periodically retains an independent third party

to facilitate the Board evaluations and to help ensure the evaluation reflects best practices and outcomes.

---

| | |
|:---|:---|
| **10 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

**HOW WE ARE GOVERNED AND GOVERN**

**How We Are Governed**

<u>Provisions Applicable to All Directors</u>

The Corporate Governance Principles are applicable to all Directors and provide an important framework within which the

Board and management can pursue the strategic objectives of the Company and ensure its long-term vitality for the

benefit of all shareholders.

*Independence*

It is our Board's responsibility to ensure a substantial majority of its members are independent. The Board follows the

independence standards for companies listed on The Nasdaq Stock Market, the Securities and Exchange Commission

(SEC) and the Internal Revenue Service and determined that all committee members and all Directors who served during

any part of fiscal 2025 are independent except our Chief Executive Officer (CEO). The Board believes that the Company

should not enter into paid consulting arrangements with independent Directors.

*Service on other Boards or Audit Committees*

To help ensure that our Directors have sufficient time to fulfill their responsibilities to the Company, our Board has adopted

guidelines providing that:

• No Director shall serve on more than four public company boards including the Sleep Number Board;

• No Director who is a named executive officer of another public company shall serve on more than a total of two public

company boards including the Sleep Number Board;

• No member of the Company's Audit Committee shall serve on more than three public company audit committees

including the Sleep Number Audit Committee; and

• The Sleep Number CEO may not serve on more than two public company boards including the Sleep Number Board.

If any Director exceeds or proposes to exceed these guidelines, the Director must promptly notify the Chair of the CGNC,

and the CGNC will review the facts and circumstances and determine whether such service would interfere with the

Director's ability to devote sufficient time to fulfilling the Director's responsibilities to the Company. Currently, each of the

Directors are in compliance with the above guidelines.

*Related-Party Transactions Policy*

The Board has adopted a written policy governing the reporting and approval of transactions between the Company and

its Directors, Director nominees, executive officers, significant shareholders or entities or persons related to them that

would be required to be disclosed by the Company pursuant to Item 404 or Regulation S-K of the Federal securities laws.

Under this policy, any proposed or existing related party transaction is subject to the approval or ratification of the CGNC.

A copy of the Related Party Transactions Policy can be accessed through our Investor Relations website at *http://*

*ir.sleepnumber.com*. The information contained in or connected to our website is not incorporated by reference into, or

considered a part of, this Proxy Statement. There were no related-party transactions during the year ended January 3,

2026, and there are none currently contemplated.

<u>Board Leadership</u>

*Chair*

The Board does not have a fixed policy regarding the separation of the offices of Chair of the Board (Chair) and the CEO

and prefers to maintain the flexibility to modify its leadership structure based on the evolving best interests of the

Company and its shareholders. During any period in which the positions of Chair and CEO are combined, the Board will

appoint a Lead Director from among the independent members of the Board. Any such Lead Director will have the

significant Board leadership responsibilities specified in our Corporate Governance Principles.

---

| | |
|:---|:---|
| **11 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

The Board believes that an effective leadership structure could be achieved either by combining or separating the Chair

and CEO roles, so long as the structure balances the powers of the CEO and independent Directors and enables the

independent Directors to be fully informed and exercise appropriate oversight of management. The Board formally

separated the Chair and CEO roles following the 2025 Annual Meeting, with Phil Eyler becoming the independent Chair.

At this time, the Board continues to believe that maintaining separate roles of Chair and CEO is appropriate and that such

separation enables the Company's CEO, Linda Findley, to focus her attention on the business and her responsibilities as

CEO, while Phil Eyler, as Chair, focuses on leadership of the Board.

*Lead Director* 

During any period where there is a combined Chair and CEO role, our Corporate Governance Principles clearly define the

Lead Director role with a robust set of responsibilities to ensure the Board's effective oversight, governance and

independent leadership. At this time, the Chair and CEO roles are separated, so the Board does not currently have a Lead

Director.

<u>Board Committees</u>

The Board maintains three standing committees: Audit, Management Development and Compensation (the Compensation

Committee) and Corporate Governance and Nominating (the CGNC). Each has a charter that is posted on the Investor

Relations section of the Company's website at *http://ir.sleepnumber.com*. The information contained in or connected to

our website is not incorporated by reference into, or considered a part of, this Proxy Statement.

The current members of each of the Board committees are identified in the table below.

---

| | | | |
|:---|:---|:---|:---|
| **Independent Director** | **Audit**<br>**Committee**<br>| **Management**<br>**Development and**<br>**Compensation**<br>**Committee**<br>| **Corporate**<br>**Governance and**<br>**Nominating**<br>**Committee**<br>|
| Phillip M. Eyler |  | X |  |
| Julie M. Howard | X | X |  |
| Deborah L. Kilpatrick, Ph.D. |  | X | X |
| Stephen E. Macadam | Chair<sup>(1)</sup> |  | X |
| Angel L. Mendez | X |  | Chair |
| Hilary A. Schneider |  | Chair<sup>(2)</sup> |  |

---

<sup>(1)</sup> In September 2025, Mr. Macadam was appointed the Chair of the Audit Committee.

<sup>(2)</sup> Effective as of the 2025 Annual Meeting, Ms. Schneider was appointed the Chair of the Compensation Committee. When Ms. Schneider retires from

the Board at the conclusion of the 2026 Annual Meeting, the Board elected Ms. Howard to succeed her as Chair of the Compensation Committee.

The Board has further determined that two current members of the Audit Committee, Julie M. Howard and Stephen E.

Macadam, meet the definition of "audit committee financial expert" under rules and regulations of the SEC and meet the

qualifications of "financial sophistication" under the Marketplace Rules of the Nasdaq Stock Market. These designations

related to our Audit Committee members' experience and understanding with respect to certain accounting and auditing

matters are disclosure requirements of the SEC and the Nasdaq Stock Market and do not impose upon any of them any

duties, obligations or liabilities that are greater than those generally imposed on a member of our Audit Committee or of

our Board.

*Audit Committee*

The Audit Committee provides assistance to the Board in satisfying its fiduciary responsibilities relating to accounting,

auditing, operating and reporting practices of our Company. The Audit Committee is responsible for providing

independent, objective oversight with respect to our Company's accounting and financial reporting functions, internal and

external audit functions, systems of internal controls regarding financial matters, enterprise risk assessment and

management, information security matters, including cybersecurity and artificial intelligence, and legal, ethical and

---

| | |
|:---|:---|
| **12 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

regulatory compliance. The responsibilities and functions of the Audit Committee are further described in the Audit

Committee Report beginning on page <u>[23](#i44eec75d700a4a12a1ccd8dcee0c79e2_160)</u> of this Proxy Statement.

*Management Development and Compensation Committee*

The principal function of the Compensation Committee is to discharge the responsibilities of the Board relating to

compensation and development of current and future leadership resources. The responsibilities and functions of the

Compensation Committee are further described in the Compensation Discussion and Analysis beginning on page <u>[28](#i44eec75d700a4a12a1ccd8dcee0c79e2_178)</u> of

this Proxy Statement. The Compensation Committee annually reviews the Company's compensation philosophy and

practices. The Board, through the Compensation Committee, supports and oversees team member compensation

programs that are closely linked to business performance and long-term strategic orientation.

*Corporate Governance and Nominating Committee*

The primary functions of the CGNC are to develop and recommend to the Board Corporate Governance Principles to

govern the Board, its committees and our executive officers and team members in the conduct of the business and affairs

of our Company; to identify and recommend to the Board individuals qualified to become members of the Board and its

committees; and to develop and oversee the annual Board and committee evaluation process.

<u>How We Govern</u>

*Meetings*

The full Board met in person or virtually 13 times during 2025. The Audit Committee met eight times, the Compensation

Committee met eight times and the CGNC met nine times during 2025. Each of the members of our Board serving in 2025

attended 75% or more of all meetings of the Board and committees on which they served.

The Board's practice is to meet in executive session with the full Board present and, separately, with just the independent

Directors present, at each regularly scheduled quarterly meeting of the Board. At least annually, the independent Directors

meet in executive session to review the performance and compensation of the CEO and other executive officers.

Additional executive sessions or meetings with just the independent Directors may be held from time to time as needed.

Any member of the Board may request an executive session with the full Board or the independent Directors only.

Our policy requires our Directors to attend our Annual Meetings unless prevented by causes beyond their reasonable

control. With the excused exception of Ms. Kilpatrick, all of our Directors attended our 2025 Annual Meeting.

*Oversight of the Chief Executive Officer*

The Board selects, evaluates, provides oversight and counsel to and creates limited parameters for the CEO. One of

these parameters limits the CEO to serving on no more than one public company board other than the Sleep Number

Board.

*Chief Executive Officer Succession Planning*

Ensuring that the Company has skilled, seasoned leaders and a plan for management succession remains a top priority

for the Board. The Board has delegated primary oversight responsibility for succession planning to the Management

Development and Compensation Committee. The Committee meets regularly to discuss management succession,

candidates and process and evaluates and updates as appropriate the skills, experience and attributes the Committee

believes are important to be an effective CEO in light of our strategy. The Committee regularly reviews succession

planning with the full Board, including the identification, development and progress of internal candidates.

*Board Role in Risk Oversight*

Our Board is responsible for overseeing the Company's policies and practices with respect to risk assessment and risk

management and has delegated to the Audit Committee the responsibility of assisting the Board in fulfilling this

---

| | |
|:---|:---|
| **13 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

role. Among its duties and processes, the Audit Committee: (a) reviews and discusses with management the Company's

policies and practices with respect to enterprise risk assessment and risk management, including with respect to financial

risk exposures, internal controls over financial reporting and cybersecurity and artificial intelligence, (b) oversees the

Company's internal audit function and processes, (c) establishes and oversees procedures for receiving and addressing

complaints regarding accounting, internal controls or auditing matters, (d) reviews compliance and other legal matters with

the Company's legal counsel and (e) reports to the full Board with respect to matters within its area of responsibility.

The Audit Committee oversees the Company's internal audit function. The leader of the internal audit function reports

directly to the Audit Committee, and the Audit Committee has authority to review and approve the appointment,

replacement or dismissal of this leader. The Audit Committee reviews and approves, at least annually, the Company's

internal audit plan and receives quarterly reports on the results of internal audits. The leader of the internal audit function

meets regularly with the Chair of the Audit Committee and/or in executive session with the Audit Committee outside the

presence of the Company's management team. The Company's risk assessment and risk management process is led by

the Chief Legal and Risk Officer and the leader of the internal audit function, with guidance from outside advisors as

needed. This process includes an annual enterprise risk assessment, ongoing risk identification and quarterly

assessments of enterprise risks and mitigation strategies, with participation from and review by the Audit Committee and

the Board.

In addition to the Audit Committee's role, each of the other committees considers risks within its respective areas of

responsibility. We believe our Board leadership structure helps ensure proper risk oversight, based on the allocation of

duties among committees and the role of our independent Directors in risk oversight.

*Conflicts of Interest*

Directors are expected to avoid any action, position or interest which conflicts with an interest of the Company, or that

gives the appearance of a conflict. If any member of the Board becomes aware of any such conflicting or potentially

conflicting interest involving any member of the Board, the Director should immediately bring such information to the

attention of the Chair (and the Lead Director if the Chair and CEO is combined), the CEO and the Chief Legal and Risk

Officer of the Company.

*Performance Goals and Evaluation*

The Compensation Committee is responsible for establishing procedures for setting annual and long-term performance

goals for the CEO and for evaluation by the full Board of their performance against such goals. The Compensation

Committee meets at least annually with the CEO to receive their recommendations concerning such goals. Both the

annual goals and the annual performance evaluation of the CEO are reviewed and discussed by the independent

Directors at a meeting or executive session. The Compensation Committee is also responsible for setting annual and

long-term performance goals and compensation for all executive officers. Also, the CEO reports to the Board, at least

annually, on senior management depth and development, including a discussion of assessments, leadership

development, succession planning and other relevant factors.

*Shareholder Approval of Equity-Based Compensation Plans*

Shareholder approval will be sought for equity-based compensation plans as required by our Articles and Minnesota law.

*Provisions Applicable to Unsolicited Takeover Attempts or Proposals*

The Board periodically reviews (not less often than every three years) our Articles and Bylaws and various provisions that

are designed to maximize shareholder value in the event of an unsolicited takeover attempt or proposal. Such review

includes consideration of matters such as the Company's state of incorporation, whether the Company should opt in or out

of applicable control share acquisition or business combination statutes and provisions such as the Company's classified

Board structure. Note that, subject to shareholder approval in accordance with Minnesota law, the Board has unanimously

---

| | |
|:---|:---|
| **14 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

adopted resolutions approving and declaring the advisability of proposed amendments to the Articles and Bylaws to

declassify the Board as further described below in Proposal 2 (approve amendments to our Articles and Bylaws to

declassify the Board). The objective of this review is to maintain a proper balance of provisions that will not deter bona fide

proposals from coming before the Board and that will position the Board and the Company to maximize the long-term

value of our Company for all shareholders.

*Shareholder Engagement*

We have regular outreach to and ongoing discussions with most of our largest shareholders to learn more about their

perspectives and gather their feedback on our strategy, performance, governance, compensation and other topics. Our

engagement helps our Board and leadership team understand the issues that matter most to shareholders, so that we can

address them effectively.

Prior to our 2026 Annual Meeting, we reached out to 23 of our largest shareholders collectively representing

approximately 70% of our outstanding shares to discuss executive compensation and corporate governance topics of

interest to them. Six shareholders representing approximately 33% of our outstanding shares accepted our invitation to

speak. Six shareholders representing approximately 9% of our outstanding shares declined our invitation, and 12

shareholders representing 28% of our outstanding shares did not respond. The Chair of the Board, Phillip Eyler, led most

of these meetings with members of the management team in attendance.

In addition to this targeted outreach ahead of the 2026 Annual Meeting, we also regularly engage with our shareholders in

the ordinary course of our investor relations activities. In total, between January 2025 and March 2026, we engaged with

shareholders representing more than 60% of our outstanding shares.

*How You Can Communicate with the Board*

Our Board casts a wide net to inform and enhance its deliberations and decision making. It also maintains several means

for shareholders and others to engage, ask questions and provide input:

• Shareholders can participate in our Annual Meetings;

• Shareholders can participate in our shareholder engagement program in which members of management and, as

appropriate, Directors have in-person, virtual, phone or email engagements. Director engagements may cover topics

such as strategy, Board and corporate governance, pay and duration drivers including environmental, social and other

factors;

• Shareholders may write to our Board as a whole, its committee chairs or individual Directors, either via email at

investorrelations@sleepnumber.com or by sending a written communication addressed to our Corporate Secretary by

mail to Sleep Number Corporation, 1001 Third Avenue South, Minneapolis, MN 55404. The Corporate Secretary will

promptly forward any communication so received to the Board, any committee of the Board or any individual Director

specifically addressed in the communication;

• Shareholders can raise any concern regarding accounting, internal control or auditing matters with our Audit

Committee, confidentially and anonymously, by calling 1-800-835-5870; or

• Shareholders, team members and others can raise issues more generally by calling or emailing our privacy

department (1-800-554-0184 or privacy@sleepnumber.com) or using our confidential Ethics and Integrity Hotline

1-833-596-3092. Board-level information will be escalated as appropriate.

The Company reserves the right to revise or make exceptions to the above in the event that the process is abused,

becomes unworkable or otherwise does not efficiently serve the purposes of the process.

---

| | |
|:---|:---|
| **15 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

**HOW WE ARE PAID**

Board compensation should encourage alignment with shareholders' interests and should be at a level equitable to

comparable companies.

**Summary of Non-Employee Director Compensation**

The compensation payable to non-employee Directors of Sleep Number Corporation is determined annually by the

Compensation Committee, typically at the quarterly meeting in May.

<u>Annual Cash Retainer</u>

Each of our non-employee Directors receives an annual cash retainer of $95,000, which is paid quarterly. The Chairs of

each of the Committees of the Board receive an additional annual cash retainer of $20,000, with Co-Chairs for any

committee, when applicable, splitting the $20,000 cash retainer, each receiving $10,000. The Chair of the Board receives

an additional cash retainer of $100,000 per year.

<u>Meeting Fees</u>

Non-employee Directors generally receive meeting fees for Board and Committee meetings attended beyond the normal

number of regular or typical meetings for the Board and each Committee in a fiscal year, including: (a) Board meeting fees

of $1,000 per in-person meeting and $500 per virtual meeting after a minimum of eight Board meetings for the fiscal year

and (b) Committee meeting fees of $750 per in-person Committee meeting and $500 per virtual Committee meeting after

a minimum of eight meetings for each Committee for the fiscal year.

In 2025, the Directors elected to waive meeting fees for attendance beyond the minimum number of regular or typical

Board and Committee meetings in the fiscal year.

<u>Equity Compensation</u>

Coincident with the Annual Meeting, non-employee Directors are eligible to receive equity compensation in amounts

determined by the Compensation Committee. In 2025, in alignment with share conservation efforts undertaken for

management, 100% of the grant value was in RSUs, with the grants to vest on the earlier of one year from the date of

grant or the date of the next Annual Meeting at which Directors are elected to the Board, so long as the Director continues

to serve on our Board. At its meeting on May 20, 2025, the Compensation Committee approved the annual equity

compensation for each of our non-employee Directors to remain at $135,000 in grant value for the new equity awards

which were granted on May 28, 2025. In alignment with methodology used to determine awards granted to NEOs, the

number of RSUs granted to our non-employee Directors on May 28, 2025 was based on the average 2024 share price of

$13.81. These equity compensation grants to non-employee Directors in the fiscal year are set forth and described in the

"Director Compensation" table below.

<u>Reimbursement of Expenses</u>

Directors are reimbursed for travel expenses for attending in-person meetings of our Board or any of the Committees and

for attending approved director continuing education programs.

<u>No Director Compensation for Employee Directors</u>

Any Director who is an employee of our Company does not receive additional compensation for service as a Director.

<u>Share Ownership Guidelines for Executive Officers and Directors</u>

The Board has established the stock ownership guidelines for executive officers and Directors as further described in the

Compensation Discussion and Analysis beginning on page <u>[28](#i44eec75d700a4a12a1ccd8dcee0c79e2_181)</u> of this Proxy Statement.

---

| | |
|:---|:---|
| **16 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

<u>Director Compensation</u>

The following table summarizes the total compensation paid or earned by each of our non-employee Directors for the

2025 fiscal year ended January 3, 2026.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Fees**<br>**Earned or**<br>**Paid in**<br>**Cash**<br>**($)**<br>| **Stock**<br>**Awards**<sup>(1)</sup><br>**($)**<br>| **Option**<br>**Awards**<sup>(2)</sup><br>**($)** <br>| **All Other**<br>**Compensation**<br>**($)**<br>| **Total**<br>**($)**<br>|
| Phillip M. Eyler<sup>(3)</sup> | $145500 | $104114 |  |  | $249614 |
| Stephen L. Gulis, Jr.<sup>(3)(5)</sup> | $94096 | $104114 |  |  | $198210 |
| Michael J. Harrison<sup>(4)</sup> | $72500 | $— |  |  | $72500 |
| Julie M. Howard<sup>(3)(4)</sup> | $95000 | $104114 |  |  | $199114 |
| Deborah L. Kilpatrick, Ph.D.<sup>(3)</sup> | $95000 | $104114 |  |  | $199114 |
| Brenda J. Lauderback<sup>(6)</sup> | $107500 | $104114 |  |  | $211614 |
| Stephen E. Macadam<sup>(3)</sup> | $105808 | $104114 |  |  | $209922 |
| Barbara R. Matas<sup>(4)</sup> | $52500 |  |  |  | $52500 |
| Angel L. Mendez<sup>(3)</sup> | $115000 | $104114 |  |  | $219114 |
| Hilary A. Schneider | $105000 | $104114 |  |  | $209114 |

---

<sup>(1)</sup> Reflects the aggregate grant date fair value of restricted stock awards granted during fiscal year 2025, computed in accordance with FASB ASC Topic

718. For all Directors except Mr. Harrison and Ms. Matas, 9,776 restricted stock awards were granted. Mr. Harrison and Ms. Matas did not stand for

election in 2025 and their terms expired effective as of the conclusion of the 2025 Annual Meeting. Accordingly, no restricted stock awards were

granted to Mr. Harrison or Ms. Matas. See Note 8, Shareholders' Deficit, to the Consolidated Financial Statements included in our Annual Report on

Form 10-K for the fiscal year ended January 3, 2026, for a discussion of the relevant assumptions used in calculating these amounts. As of January 3,

2026, the aggregate number of shares outstanding under stock awards, including restricted stock units, deferred restricted stock units and phantom

stock, held by those who served as non-employee Directors through fiscal year 2025 was as follows: Mr. Eyler, 22,448; Ms. Howard, 22,513 shares;

Ms. Kilpatrick, 13,120 shares; Mr. Macadam, 21,312; Mr. Mendez, 19,428 shares; and Ms. Schneider, 9,776 shares.

<sup>(2)</sup> No stock option awards were granted during fiscal year 2025. As of January 3, 2026, the aggregate number of stock options outstanding held by those

who served as non-employee Directors through fiscal 2025 was as follows: Mr. Eyler, 4,285; Ms. Howard, 5,830; Ms. Kilpatrick, 9,860; Mr. Macadam,

2,373; Mr. Mendez, 4,285; and Ms. Schneider, 2,373.

<sup>(3)</sup> Under the Company's 2020 Equity Incentive Plan, as amended, (2020 Plan) non-employee Directors may elect to defer receipt of any shares of the

Company's common stock under an Incentive Award granted to non-employee Directors under the 2020 Plan. For fiscal 2025, the following Directors

elected to defer receipt of their 2025 Incentive Award of 9,776 shares: Mr. Eyler, Mr. Gulis, Ms. Howard, Ms. Kilpatrick, Mr. Macadam, and Mr. Mendez.

<sup>(4)</sup> Mr. Harrison and Ms. Matas decided not to stand for election in 2025 and their terms expired effective as of the conclusion of the 2025 Annual

Meeting.

<sup>(5)</sup> In March 2025, Mr. Gulis agreed to retire or resign from the Board no later than the completion of the Company's debt refinancing or at the conclusion

of the 2026 Annual Meeting, whichever occurs first. Effective November 4, 2025, Mr. Gulis retired from the Board when the Company completed its

debt refinancing. Upon his retirement from the Board, 5,463 shares related to Mr. Gulis' 2025 Incentive Award vested and the remaining 4,313 shares

were forfeited.

<sup>(6)</sup> Ms. Lauderback retired from the Board effective December 31, 2025.

---

| | |
|:---|:---|
| **17 \| 2026 PROXY STATEMENT** | **OUR BOARD** |

---

**ARTICLES OF INCORPORATION AND BYLAWS**

In a Letter to Shareholders filed with the SEC on October 30, 2024, the Board announced plans to seek shareholder

approval at the 2025 Annual Meeting for amendments to the Company's Articles and Bylaws to declassify the Board and

amendments to the Articles to eliminate the supermajority voting requirements in Article XIV for Directors and in Article XV

related to approval of certain transactions. The 2025 Proxy Statement included Proposal 2 to declassify the Board,

Proposal 3 to amend the Articles to eliminate the supermajority voting requirements in Article XIV for Directors, and

Proposal 4 to amend the Articles to eliminate the supermajority voting requirements in Article XV for approval of certain

transactions as further described therein. Each of Proposal 2, 3 and 4 required an affirmative vote of two-thirds of the

shares of common stock outstanding as of the Record Date for the 2025 Annual Meeting, and while approximately

98-99% of the shareholders who voted at the May 28, 2025 Annual Meeting supported the measures, this represented

less than the requisite affirmative vote of two-thirds of all shares of common stock outstanding.

In a Form 8-K filed on May 29, 2025, the Board acknowledged its disappointment that Proposals 2, 3 and 4 did not get the

requisite affirmative vote of two-thirds of the shares of common stock outstanding as of the Record Date for the

Company's 2025 Annual Meeting. The Board also reiterated its belief that the proposed amendments to the Company's

Articles and Bylaws to declassify the Board and eliminate the supermajority voting requirements in the Company's Articles

XIV and XV are in the best interests of the Company and its shareholders. At that time, the Board unanimously voted to

resubmit those proposals to shareholders at the Company's 2026 Annual Meeting and to seek to declassify the Board on

an accelerated timeline as further set forth in Proposal 2 - Amendment to the Company's Articles and Bylaws to Declassify

the Board on page <u>[18](#i44eec75d700a4a12a1ccd8dcee0c79e2_133)</u>.

---

| | |
|:---|:---|
| **18 \| 2026 PROXY STATEMENT** | **PROPOSAL 2 - VOTE TO APPROVE AMENDMENTS TO THE COMPANY'S ARTICLES AND BYLAWS TO** <br>**DECLASSIFY THE BOARD** |

---

![Proposal 2.jpg](snbr-20260408_g20.jpg)

Under our existing Articles and Bylaws, our Board is divided into three classes with members of each class of Directors

serving a three-year term. The classification of the Board results in staggered elections, with a different class of Directors

standing for election each year.

Shareholder approval of the amendments to our Articles and Bylaws proposed in this Proposal 2 would declassify our

Board. Directors elected at this Annual Meeting will be elected to three-year terms expiring at the 2029 Annual Meeting;

however, if Proposal 2 passes, each of the Directors who have been elected to terms expiring after the 2027 Annual

Meeting have irrevocably agreed to shorten their terms, resign effective as of the 2027 Annual Meeting and stand for re-

election at the 2027 Annual Meeting for a one-year term subject to CNGC nomination. To the extent that the CGNC

nominates any of the resigning Directors to stand for re-election, such resigning Director(s) along with any Director

nominees whose term was set to expire at the 2027 Annual Meeting or any other Director nominees, would stand for

election to a one-year term at the 2027 Annual Meeting. Therefore, contingent upon shareholder approval of Proposal 2 to

amend the Articles and Bylaws this year, the Company's Board would be declassified and the Director nominees at the

2027 Annual Meeting and thereafter will be elected to one-year terms expiring at the next Annual Meeting. If the office of

any Director becomes vacant by reason of death, resignation, retirement, disqualification, removal from office, increase in

the number of Directors or otherwise, a majority of the remaining Directors, although less than a quorum, at a meeting

called for that purpose, may choose a successor, who, unless removed for cause, shall hold office for the remainder of the

one year term for which they were appointed or until a successor shall be elected and qualified. As a result, beginning with

the election of Directors at the 2027 Annual Meeting, all Directors will be elected for one-year terms and the classification

of the Board will terminate.

In proposing these amendments to the Articles and Bylaws, our Board considered shareholder feedback and evolving

governance practices. Subject to shareholder approval, the Board has unanimously adopted resolutions approving and

declaring the advisability of the proposed amendments to the Articles and Bylaws.

If our shareholders approve this Proposal 2, we will file amended and restated Articles after the Annual Meeting

incorporating the revisions in <u>Appendix</u> <u>A</u>. We will also make the conforming revisions reflected in <u>Appendix</u> <u>A</u> to declassify

the Board in our Bylaws, as required by Minnesota law to get shareholder approval for such amendments to our Bylaws.

The Board believes that the amendments to our Articles and Bylaws to declassify the Board are in the best interests of the

Company and our shareholders at this time.

The Board unanimously recommends a vote "**For**" approval of amendments to our Articles and our Bylaws to declassify

the Board.

---

| | |
|:---|:---|
| **19 \| 2026 PROXY STATEMENT** | **PROPOSAL 3 - VOTE TO APPROVE AN AMENDMENT TO THE COMPANY'S ARTICLES TO ELIMINATE THE** <br>**SUPERMAJORITY VOTING REQUIREMENT IN ARTICLE XIV RELATED TO DIRECTORS** |

---

![Proposal 3.jpg](snbr-20260408_g21.jpg)

Article XIV of our existing Articles provides that it may not be altered, amended or repealed, in whole or in part, unless

authorized by the affirmative vote of the holders of not less than two-thirds of the outstanding voting power entitled to vote

(*i.e.,* a supermajority).

Shareholder approval of the amendment to our Articles proposed in this Proposal 3 would eliminate the supermajority

voting requirement in Article XIV related to amendments to the number, classification, term of office, removal, and how to

fill vacancies of Directors.

In proposing this amendment to the Articles and seeking to evolve our governance structure, our Board considered

shareholder feedback and evolving governance practices.

Our Board unanimously concluded that it is in the best interests of the Company and our shareholders at this time to

recommend that our shareholders adopt amendments to our Articles to eliminate all supermajority voting requirements

related to Directors, and replace with majority voting requirements. The Board has unanimously adopted resolutions

approving and declaring the advisability of the proposed amendment to the Articles.

If our shareholders approve this Proposal 3, we will file amended and restated Articles after the Annual Meeting

incorporating the revisions in <u>Appendix</u> <u>B</u>.

The Board unanimously recommends a vote "**For**" approval of the amendment to our Articles to eliminate the

supermajority voting requirement in Article XIV related to Directors.

---

| | |
|:---|:---|
| **20 \| 2026 PROXY STATEMENT** | **PROPOSAL 4 - VOTE TO APPROVE AN AMENDMENT TO THE COMPANY'S ARTICLES TO ELIMINATE THE** <br>**SUPERMAJORITY VOTING REQUIREMENT IN ARTICLE XV RELATED TO APPROVAL OF CERTAIN TRANSACTIONS** |

---

![Proposal 4.jpg](snbr-20260408_g22.jpg)

Article XV of our existing Articles provides that it may not be altered, amended or repealed, in whole or in part, unless

authorized by the affirmative vote of the holders of not less than two-thirds of the outstanding voting power entitled to vote.

Article XV also provides that the affirmative vote of not less than two-thirds of the outstanding voting power entitled to vote

is required for certain transactions such as various approvals (or adoptions) of any plan of merger or exchange of assets,

or issuance or delivery of stock or securities.

Shareholder approval of the amendment to our Articles in this Proposal 4 would eliminate these supermajority vote

requirements. In proposing this amendment to the Articles and seeking to evolve our governance structure, our Board

considered shareholder feedback and evolving governance practices. Our Board concluded that it is in the best interests

of the Company and our shareholders at this time to recommend that our shareholders adopt amendments to our Articles

to eliminate all supermajority voting requirements and replace with majority voting requirements, including the

requirements in Article XV related to approval of certain transactions. The Board has unanimously adopted resolutions

approving and declaring the advisability of the proposed Articles amendment.

If our shareholders approve this Proposal 4, we will file amended and restated Articles after the Annual Meeting

incorporating the revisions in <u>Appendix</u> <u>C</u>.

The Board unanimously recommends a vote "**For**" approval of the amendment of our Articles to eliminate the

supermajority voting requirements in Article XV related to certain transactions.

---

| | |
|:---|:---|
| **21\| 2026 PROXY STATEMENT** | **OUR COMPANY** |

---

![Our Company.jpg](snbr-20260408_g23.jpg)

**WHAT WE DO**

Sleep Number is the leader in personalized sleep wellness. Its mattresses are designed to evolve with each sleeper to

help them feel and perform their best. With adjustable firmness, pressure-relieving support and temperature balancing

comfort built into every mattress, Sleep Number beds adapt to customers' changing needs, night after night, year after

year. Backed by over 40 years of innovation, over a 1,000 patents and patents pending, and billions of hours of sleep data,

Sleep Number has helped more than 16 million people achieve their best sleep. The fully integrated model ensures quality,

durability, and care at every step—from design and craftsmanship to delivery and long-term support.

Sleep Number's life-changing, differentiated smart mattresses combine physical and digital innovations, integrating

unparalleled physical comfort with a highly advanced sleep wellness platform. Sleep Number's mattress portfolio offers

our signature firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep

needs of each individual; "sense and do" technology uses the sensed data to automatically adjust the bed to keep the

sleeper comfortable throughout the night. Temperature balancing technology supports the ideal climate for each sleeper

and solves a prevalent sleep challenge. Additionally, the mattresses are an exceptional value, with personalized sleep

insights delivered daily, new features regularly added to all smart beds through over-the-air updates and prices to meet

most budgets. Sleep Number mattresses provide unmatched features, benefits and comfort that can lead to improved

sleep health and wellness for both sleepers.

Sleep Number products are awarded the industry's top recognitions, including ranked #1 in customer satisfaction for

mattresses purchased in-store and online, and #1 in comfort, by J.D. Power. In addition, the company is the Official Sleep +

Wellness Partner of the NFL, marking a relationship that leverages players, team partnerships, and league-wide initiatives

to amplify brand awareness and drive consumer engagement.

**WHO WE ARE**

Sleep Number's advantaged business model is supported by our consumer innovation strategy: an individualized, digital

sleep wellness platform, a network of millions of highly engaged Smart Sleepers who are loyal brand advocates, and a

vertically integrated operating model.

And our 3,100 mission-driven team members are dedicated to Sleep Number's mission of improving lives by

individualizing sleep experiences. They passionately innovate to drive value creation, including our exclusive direct-to-

consumer selling in 600 stores and online, which meets customers whenever and wherever they choose to provide an

exceptional experience and a lifelong relationship.

Additionally, Sleep Number partners with world-leading institutions to bring the power of over 38 billion hours of

longitudinal sleep data from approximately five billion sleep sessions to sleep science and research.

---

| | |
|:---|:---|
| **22\| 2026 PROXY STATEMENT** | **OUR COMPANY** |

---

**HOW WE DO IT**

We believe our purpose of improving lives by personalizing sleep is best achieved with similarly sustainable governance,

people and environmental practices.

Ours continually evolve, but highlights include:

• We annually review and train on our Code of Business Conduct;

• Our focus on talent management is reflected in the Board making time annually to review with management our

human capital management, development and succession practices;

• Our sustainability practices are supported by a cross-functional team and informed by a materiality assessment; and

• Key environmental, social, and governance topics are shared with the full Board and standing committees annually,

quarterly or on an interim basis, as appropriate, including periodic dedicated full Board sessions covering topics such

as carbon, climate, natural resources, supply chain management, waste and toxicity, reuse and recycling, team

member engagement, health, wellbeing and belonging; the evolving nature of work; community health and impact;

compliance and internal controls; business ethics and codes of conduct; sustainable, auditable and repeatable

processes for reporting requirements; executive, Director and team member compensation; cybersecurity; and geo-

political and policy issues management.

**Code of Conduct and Ethics**

Our Code of Business Conduct and Ethics is reviewed annually with the Audit Committee and instructs team members to

comply with applicable laws, engage in ethical and safe conduct in our work environment, avoid conflicts of interests,

conduct our business with integrity and high ethical standards and safeguard our Company's assets, report potential

violations and periodically receive training and certify commitment. The Code of Business Conduct and Ethics addresses

legal and ethical issues that may be encountered by our team members during their normal course of business.

Team members are required to report any conduct that they believe in good faith violates our Code of Business Conduct

and Ethics. The Code of Business Conduct and Ethics also sets forth procedures under which team members or others

may report through our management team or, ultimately, directly to our Audit Committee (confidentially and anonymously,

if so desired) any questions or concerns regarding accounting, internal accounting controls or auditing matters. All of our

team members and Board members are required to annually certify their commitment to abide by our Code of Business

Conduct and Ethics. We regularly monitor compliance with the Code of Business Conduct and Ethics and report findings

to our Audit Committee. We also provide training in key areas covered by the Code of Business Conduct and Ethics to

help our team members to comply with their obligations.

A copy of the Code of Business Conduct and Ethics is included in our Investor Relations section of our website at

*http://ir.sleepnumber.com*. We intend to disclose any amendments to and any waivers from a provision of our Code of

Business Conduct and Ethics on our website. The information contained in or connected to our website and our Code of

Business Conduct and Ethics is not incorporated by reference into, or considered a part of, this Proxy Statement.

---

| | |
|:---|:---|
| **23\| 2026 PROXY STATEMENT** | **OUR COMPANY** |

---

**Corporate Sustainability**

Our sustainability efforts are focused on aligning and integrating environmental stewardship and social progress with our

pursuit of long-term shareholder value creation. We recently published our 2026 Corporate Sustainability Report, which

provides an update on enterprise environmental, social and governance practices and priorities. The report underscores

our continued focus on sustainability initiatives that support the resilience of our business.

• We are strengthening systems and processes that reinforce sound governance, high integrity decision-making and

transparent, consistent reporting practices.

• To attract and retain highly engaged team members, we continue to prioritize programs that promote well-being,

provide opportunities for professional development, and reward strong performance.

• Through volunteerism, financial and in-kind support, and meaningful contributions to sleep science, research and

sleep innovations, we are improving millions of lives – delivering significant value to consumers and their

communities.

• Recognizing the benefit of collaboration in achieving our goals, we work to strengthen our supplier relationships and

engage with them to increase opportunities for enhanced sustainability.

• And we are monitoring – and taking responsible actions to control – our greenhouse gas emissions, waste and other

environmental outputs, including through intentional network design, transportation optimization and innovations that

extend the useful life of product components.

A copy of the Corporate Sustainability Report is included in our Investor Relations section of our website at http://

ir.sleepnumber.com. The information contained in or connected to our website and our Corporate Sustainability Report is

not incorporated by reference into, or considered a part of, this Proxy Statement.

**Audit Committee Report**

The Audit Committee is responsible for providing independent, objective oversight with respect to our Company's

accounting and financial reporting functions, internal and external audit functions, systems of internal controls regarding

financial matters, risk assessment and risk management, information technology and information security systems,

including cybersecurity and artificial intelligence, and legal, ethical and regulatory compliance.

The Audit Committee is currently composed of three Directors, each of whom is independent as defined by the Nasdaq

listing standards and SEC Rule 10A-3. Stephen Macadam (Chair), Julie Howard, and Angel Mendez served on the Audit

Committee throughout 2025 and through the date of this report. Stephen Macadam joined the Audit Committee effective

January 1, 2025, and became Chair in September 2025. Barbara Matas and Stephen Gulis, Jr. served on the Audit

Committee through May 2025 and November 2025, respectively.

Management is responsible for our Company's financial reporting processes and internal control over financial reporting.

Deloitte & Touche LLP, our Independent Registered Public Accounting Firm, is responsible for auditing our Company's

consolidated financial statements for the 2025 fiscal year. This audit is to be conducted in accordance with the standards

of the Public Company Accounting Oversight Board (United States). The Audit Committee's responsibility is to monitor and

oversee these processes.

In connection with these responsibilities, the Audit Committee met eight times during 2025 and meetings involved

representatives of management, internal audit and the independent auditors. The Audit Committee meets periodically with

management, internal audit and the independent auditors in separate executive sessions as needed to discuss any

matters that the Audit Committee or each of these groups believe should be discussed privately.

Management represented to the Audit Committee that our Company's consolidated financial statements were prepared in

accordance with accounting principles generally accepted in the United States of America. The Audit Committee has

---

| | |
|:---|:---|
| **24 \| 2026 PROXY STATEMENT** | **OUR COMPANY** |

---

reviewed and discussed the consolidated financial statements, together with the results of management's assessment of

the Company's internal control over financial reporting, with management and the Independent Registered Public

Accounting Firm. The Audit Committee discussed with the Independent Registered Public Accounting Firm the matters

required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and the SEC.

The Independent Registered Public Accounting Firm provided the Audit Committee with written disclosures and the letter

required by applicable requirements of the Public Company Accounting Oversight Board, and the Audit Committee

discussed with the Independent Registered Public Accounting Firm that firm's independence.

Based upon the Audit Committee's discussions with management, internal audit and the Independent Registered Public

Accounting Firm and the Audit Committee's review of the representations of management and the Independent

Registered Public Accounting Firm, the Audit Committee recommended to the Board of Directors that the audited

consolidated financial statements be included in our Company's Annual Report on Form 10-K for the year ended

January 3, 2026, for filing with the Securities and Exchange Commission.

This Audit Committee Report shall not be deemed incorporated by reference by any general statement incorporating by

reference this Proxy Statement into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except

to the extent that the Company specifically incorporates this information by reference, and shall not otherwise be deemed

filed under such Acts.

*The Audit Committee of the Board of Directors*

Stephen Macadam, Chair

Julie Howard

Angel Mendez

---

| | |
|:---|:---|
| **25 \| 2026 PROXY STATEMENT** | **PROPOSAL 5 - RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** |

---

![Proposal 5.jpg](snbr-20260408_g24.jpg)

The Audit Committee is directly responsible for the appointment, compensation, retention and oversight of our

independent auditors. The Audit Committee considers the independence of our independent auditors and participates in

the selection of the independent auditor's lead engagement partner. The Audit Committee has appointed, and, as a matter

of good corporate governance, is requesting ratification by the shareholders of the appointment of, the registered public

accounting firm of Deloitte & Touche LLP (Deloitte) to serve as independent auditors for the fiscal year ending January 2,

2027. Deloitte has served as our independent auditor since 2010.

The Audit Committee considered a number of factors in determining whether to re-engage Deloitte as the Company's

independent registered public accounting firm, including the length of time the firm has served in this role, the firm's

professional qualifications and resources, the firm's past performance and the firm's capabilities in handling the breadth

and complexity of our business, as well as the potential impact of changing independent auditors.

The Board and the Audit Committee believe that the continued retention of Deloitte as the Company's independent auditor

is in the best interests of the Company and its shareholders. If shareholders do not ratify the appointment of Deloitte as

our independent auditors, the Audit Committee will reconsider whether to retain Deloitte and may determine to retain it or

another firm without resubmitting the matter to shareholders. Even if the appointment of Deloitte is ratified by

shareholders, the Audit Committee may, in its discretion, direct the appointment of a different firm of independent auditors

at any time during the year if it determines that such a change would be in the best interests of the Company and its

shareholders.

Representatives of Deloitte will be present at the Annual Meeting, will have an opportunity to make a statement if they so

desire and will be available to respond to questions from shareholders.

Why the Board recommends you support this Proposal 5:

• The Audit Committee undertakes a robust evaluation process each year to confirm the engagement of Deloitte as our

independent auditor continues to be in our shareholders' best interests;

• Deloitte has served as our independent auditor since 2010, which means the firm is well-positioned to handle the

breadth and complexity of our vertically integrated business; and

• Deloitte provides only limited services other than audit and audit-related services.

The Board recommends a vote "**For**" ratification of the appointment of Deloitte as our independent auditors for the fiscal

year ending January 2, 2027.

---

| | |
|:---|:---|
| **26\| 2026 PROXY STATEMENT** | **OUR COMPANY** |

---

**Audit and Other Fees**

The aggregate fees billed for professional services by the Independent Auditors in 2025 and 2024 were:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Audit fees | $1111858 | $923000 |
| Audit-related fees | 67152 | 58520 |
| Audit and audit-related fees | 1179010 | 981520 |
| Tax fees | 159075 | 132931 |
| All other fees |  |  |
| Total | $1338085 | $1114451 |

---

<u>Audit fees</u> in 2025 and 2024 include fees incurred for the annual audit and quarterly reviews of the Company's

consolidated financial statements and the annual audit of the Company's internal control over financial reporting for the

years ended January 3, 2026 and December 28, 2024, respectively.

<u>Audit-related fees</u> for 2025 and 2024 are related to benefit plan audit and access to an online accounting research tool.

<u>Tax fees</u> for fiscal 2025 and 2024 are primarily for tax compliance services based on time and materials.

**Pre-Approval Policies and Procedures**

Under the Sarbanes-Oxley Act of 2002 and the rules of the Securities and Exchange Commission regarding auditor

independence, the engagement of the Company's Independent Auditors to provide audit or non-audit services for the

Company must either be approved by the Audit Committee before the engagement or entered into pursuant to pre-

approval policies and procedures established by the Audit Committee. Our Audit Committee has not established any pre-

approval policies or procedures and therefore all audit or non-audit services performed for the Company by the

Independent Auditors must be approved in advance of the engagement by the Audit Committee. Under limited

circumstances, certain de minimis non-audit services may be approved by the Audit Committee retroactively. All services

provided to the Company by the Independent Auditors in 2025 were approved in advance of the engagement by the Audit

Committee and no non-audit services were approved retroactively by the Audit Committee pursuant to the exception for

certain de minimis services described above.

---

| | |
|:---|:---|
| **27 \| 2026 PROXY STATEMENT** | **OUR PAY** |

---

![Our Pay.jpg](snbr-20260408_g25.jpg)

**COMPENSATION COMMITTEE REPORT**

Dear Shareholders,

The Compensation Committee remains committed to maintaining an executive compensation program that supports the

Company's long-term strategy, strengthens accountability, and drives sustainable value creation. Over the past year, we

ensured the program reflects the Company's priorities—advancing operational execution, improving financial

performance, and supporting the next phase of the Company's transformation.

In our oversight, we focused on maintaining strong alignment between pay and performance, emphasizing metrics that

reinforce disciplined growth, cash generation, and operational improvement. We continued to ensure that a significant

portion of executive compensation is tied to measurable results, and that realized pay appropriately reflects Company

performance and shareholder experience.

The Committee also supported leadership transitions and organizational changes intended to position the Company for

future progress. Throughout these changes, we applied a consistent philosophy: compensation opportunities should be

competitive, market aligned and tied to clear expectations, while realized pay must reflect performance.

Looking ahead, we are confident that the compensation programs described in this Compensation Discussion and

Analysis (CD&A) effectively support the execution of the Company's strategic priorities, promote financial strength, and

reward progress toward long-term shareholder value creation. We appreciate your continued trust and engagement.

The Compensation Committee has reviewed and discussed the following CD&A with management, and based on this

review and discussion, the Compensation Committee recommended to the Board that the CD&A be included in this Proxy

Statement.

The Management Development and Compensation Committee

Hilary Schneider, Chair

Phillip Eyler

Julie Howard

Deborah Kilpatrick, Ph.D.

---

| | |
|:---|:---|
| **28 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

![Compensation Discussion and Analysis.jpg](snbr-20260408_g26.jpg)

**KEY PAY FACTS**

**Who Did We Pay?**

Sleep Number provides employment to approximately 3,100 team members, each of whom plays an important role in our

operations. We are legally required to focus these disclosures on the compensation of the Company's Named Executive

Officers (NEOs), even though every one of our team members contributes to our success. This Compensation Discussion

and Analysis (CD&A) describes our executive compensation program, including the objectives and elements of

compensation as well as determinations made by the Compensation Committee regarding our NEOs. In 2025, each of

these individuals qualified as one of our NEOs:

• Linda Findley, Board Member, President and Chief Executive Officer

• Shelly Ibach, former Chair, President and Chief Executive Officer

• Amy O'Keefe, Executive Vice President and Chief Financial Officer

• Robert Ryder, former interim Chief Financial Officer

• Francis Lee, former Executive Vice President and Chief Financial Officer

• Melissa Barra, Executive Vice President and Chief Product and Enterprise Strategy Officer

• Samuel Hellfeld, Executive Vice President and Chief Legal and Risk Officer and Secretary

• Christopher Krusmark, Executive Vice President and Chief Retail and People Officer

• Andrea Bloomquist, former Executive Vice President and Chief Innovation Officer

• Kevin Brown, former Executive Vice President and Chief Marketing Officer

**Why: Factors Shaping Our Pay Design and Decision Making**

The following pages outline our individual pay components and decisions made for 2025. Collectively, our pay practices

and decisions were shaped and informed considering the details below:

• Shareholder engagement and feedback;

• A belief in a strong link between NEO pay and financial and operational performance;

• A belief that a majority of NEO pay should be at risk and aligned with both near-and long-term performance;

• Peer group benchmarking;

• Advice from an independent compensation consultant;

• Adherence to pay governance best practices including stock ownership guidelines, clawback policies, double trigger

change-in-control provisions and policies against hedging, pledging, insider trading, tax gross ups, options repricing,

NEO employment contracts and dividends on unearned performance awards; and

• Integration of pay with risk management, oversight and compliance best practices.

---

| | |
|:---|:---|
| **29 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<u>Shareholder Engagement on Executive Compensation</u>

Every year, Sleep Number provides shareholders the opportunity to approve its executive compensation program on an

advisory basis. In 2025, our executive compensation program received the support of 77.63% of votes cast by

shareholders versus our prior five-year average of 84.2%. While we have regular outreach and ongoing discussions with

shareholders to learn about their perspectives and gather their feedback on a variety of topics, in the months leading up to

preparing this Proxy Statement for our 2026 Annual Meeting, we reached out to 23 of our largest shareholders collectively

representing approximately 70% of our outstanding shares. This targeted outreach was to discuss executive

compensation and corporate governance topics of interest to them. Six shareholders representing approximately 33% of

our outstanding shares accepted our invitation to speak. Six shareholders representing approximately 9% of our

outstanding shares declined our invitation, and 12 shareholders representing 28% of our outstanding shares did not

respond. The Chair of the Board, Phillip Eyler, led most of these meetings with members of the management team in

attendance.

In general, we learned that shareholders were supportive of our approach to compensation and feedback did not suggest

that we make major changes to the structure of our compensation program. Specifically, shareholders expressed strong

support for the Company's shift to use of performance based stock award units that incorporate a total shareholder return

(TSR) component as further discussed herein.

In addition to this targeted outreach ahead of the 2026 Annual Meeting, we also regularly engage with our shareholders in

the ordinary course of our investor relations activities. In total, between January 2025 and March 2026, we engaged with

shareholders representing more than 60% of our outstanding shares.

<u>Changes Made in</u> <u>2025</u>

In determining our compensation practices for fiscal year 2025, the Compensation Committee was mindful of feedback

provided by shareholders and the results of our most recent advisory vote on executive compensation, as well as the

need to execute on our business transformation to create a more durable operating model. For fiscal year 2025, Sleep

Number took the following actions:

---

| | |
|:---|:---|
| **Category** | **Description of Changes** |
| Peer Group | Our peer group was updated in 2025 to ensure it continues to <br>reflect our scale, industry and strategic direction as a sleep wellness <br>company.<br>|
| Annual Incentive Plan (AIP) | We remain committed to defined and measurable AIP goals and <br>metrics. These changes are described in more detail in the AIP <br>section.<br>|
| Equity Awards | We added a Relative Total Shareholder Return modifier to the 2025 <br>PSU awards granted to our NEOs.<br>|

---

<u>Changes Made in</u> <u>2026</u>

In 2026, the Compensation Committee continued to refine our executive compensation program to further align pay with

shareholder interests and Company priorities. For 2026 PSU grants, we will continue to use a Relative Total Shareholder

Return (TSR) modifier to reinforce alignment with shareholder outcomes. We are also enhancing our performance metrics

by incorporating Free Cash Flow (FCF) as a key PSU measure, alongside Net Sales. Free Cash Flow is an increasingly

important indicator of our performance in the current environment, as it reflects the Company's ability to convert results

into usable cash - supporting debt service and reduction, funding growth initiatives, and strengthening our overall liquidity.

The Committee believes this metric appropriately reinforces our operational discipline and value creation.

---

| | |
|:---|:---|
| **30 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<u>Company Performance</u>

---

| | |
|:---|:---|
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | **Performance metrics in our** <br>**compensation program:**<br>|
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | Long-term Incentive Plan |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | Net Sales growth |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | NOP growth |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | Relative Total Shareholder Return |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | Share price |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 |  |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 |  |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 |  |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | Annual Incentive Plan |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 | Adjusted EBITDA |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 |  |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 |  |
| Full-year financial results include:<br>•Net sales of $1.4 billion (-16% vs. 2024)<br>•Net operating loss (NOL) of $46.6 million (-303.7% vs. <br>2024)<br>•Total Operating Expense reduction of $100.4 million <br>•Adjusted EBITDA of $78.3 million (-34.6% vs. 2024)<br>•Diluted loss per share of $5.77 down from diluted loss per <br>share of $0.90 in 2024<br>•Cash used in operating activities of $3.3 million and cash <br>used in purchases of capital expenditures of $14.4 million<br>•Adjusted return on invested capital (ROIC) of -4.0%<br>•Net leverage ratio of 4.1x EBITDAR (adjusted EBITDA plus <br>consolidated rent expense) at the end of 2025 vs. covenant <br>maximum of 4.5x; $58 million of liquidity remained against <br>current credit facility at the end of 2025 |  |

---

The following are historical results on key financial metrics.

![1](snbr-20260408_g27.gif)

![13](snbr-20260408_g28.gif)

Note: For additional information on our non-GAAP financial measures, such as adjusted EBITDA and adjusted ROIC, and

their reconciliation to operating income and net income, as applicable, see "Non-GAAP Data Reconciliations" on pages 44

through 46 of our Annual Report on Form 10-K filed on March 12, 2026.

Refer to our Annual Report on Form 10-K filed on March 12, 2026, and our Corporate Sustainability Report, posted within

the Investor Relations section of our Company website, for additional information on these and other 2025 financial

measures. The information contained in our Corporate Sustainability Report is not incorporated by reference into, or

considered a part of, this Proxy Statement.

---

| | |
|:---|:---|
| **31 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<u>Pay and Performance Alignment</u>

The following is a summary of our Company Performance that determined the actual payouts earned for our 2025 Annual

Incentive Plan (AIP) and 2023 Performance Stock Units (PSUs). Across all NEOs, realizable pay decreased with declining

TSR and financial performance, demonstrating strong pay-for performance alignment. The performance and payouts for

these incentive programs are described in more detail later in this CD&A.

---

| | | |
|:---|:---|:---|
| **Element** | **Performance Achieved** | **Payout Earned** |
| **2023 PSUs** <br>(performance period <br>of fiscal years 2023 <br>through 2025)<br>| Annual growth rate achieved:<br>- 2023: net sales -10.7% and NOP -66.2%<br>- 2024: net sales -10.9% and NOP -0.3%<br>- 2025: net sales -16.1% and NOP -303.7%<br>Average difference between adjusted ROIC <br>and WACC was -413 basis points<br>| No payout was earned (compared to no payout of <br>target for the 2022 PSUs). The 2023 PSU payout <br>was an average of the percent of target earned <br>by year.<br>- 2023: 0%<br>- 2024: 0%<br>- 2025: 0%<br>The ROIC modifier did not apply since no payout <br>was earned.<br>|
| **2025 AIP** | Adjusted EBITDA for 2025 was $78.3 million, <br>which was 63% of the goal for target payout.<br>| No payout was earned. |

---

<u>Benchmarking</u>

With the assistance of independent compensation consultant Frederic W. Cook & Co., Inc. (FW Cook), the Compensation

Committee considers market data on base salary, target total cash compensation and target total direct compensation

when establishing compensation levels for executive officers. The sources for this market comparison are from peer group

pay data (most recent disclosures) and certain retail, technology or general industry surveys from third parties. For each

executive, we attempt to match as closely as possible our position to what is most comparable in our peers or the surveys.

The Compensation Committee generally seeks to align target total direct compensation opportunities with the market

median, while providing opportunity for top quartile compensation for Company performance above established goals and

below median compensation for performance below goal. Additionally, performance goals are set with consideration of

peer group and industry performance.

<u>2025 Peer Group</u>

The Compensation Committee, in consultation with independent compensation consultant FW Cook, annually reviews the

appropriateness of the size, structure, business focus and related aspects of the companies in our industry peer group.

The selected peer group consists of publicly traded companies whose net sales are within a range of one-third to three

times and market cap reasonably within our own comparable metrics, and that are involved in household and home

furnishing, appliances or retail industries with a focus on products delivered direct to consumers. The selection criteria

also consider factors such as whether the Company has products driven by innovation or services delivered by

technology.

---

| | |
|:---|:---|
| **32 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

The Compensation Committee at its meeting on September 17, 2024, approved the peer group as listed below. The peer

group was changed from the prior fiscal year to better reflect Sleep Number's size and strategic direction. This is the peer

group that was utilized in the benchmarking reviewed by the Compensation Committee for compensation actions

approved during 2025 including the actions effective in March 2025 and described in this 2026 Proxy Statement:

• Conn's, Inc. was removed due to their announced bankruptcy

• Haverty Furniture Companies, Inc.'s was added to provide additional furniture retailer representation

---

| | |
|:---|:---|
| The Aaron's Company, Inc.<br>Arlo Technologies, Inc.<br>Dolby Laboratories, Inc.<br>Ethan Allen Interiors, Inc.<br>Haverty Furniture Companies, Inc.<br>HNI Corporation<br>Inspire Medical Systems, Inc.<br>iRobot Corporation<br>| La-Z-Boy Incorporated<br>Leggett & Platt, Incorporated<br>Miller Knoll<br>Peloton Interactive, Inc.<br>RH<br>Steelcase Inc.<br>Sonos, Inc.<br>Somnigroup International Inc. (formerly Tempur Sealy <br>International, Inc.)<br>|

---

At its meeting on September 16, 2025, the Compensation Committee reviewed the peer group composition relative to the

selection criteria utilized in evaluating peer companies while considering the strategic direction of Sleep Number. The

following adjustments were made to the peer group, which was then utilized in benchmarking for compensation actions

considered in early 2026:

• The Aaron's Company, Inc. was removed as it was acquired by IQVentures in October 2024.

• Dolby Laboratories, Inc. was removed because of its market-capitalization misalignment.

• Beyond, Inc., The Lovesac Company and OneWater Marine Inc. were added.

<u>Pay Governance Best Practices</u>

In order to meet the key objectives of our executive compensation program, the Company has adopted a strong corporate

governance framework with the following practices and policies that help ensure alignment with shareholder interests.

There have been no changes to these policies or practices since the last disclosure in the 2025 Proxy Statement.

---

| | | |
|:---|:---|:---|
| **Compensation Practice** | **Sleep Number Policy or Practice** | **Sleep Number Policy or Practice** |
| **Pay for performance** | **Yes** | A significant percentage of the total direct compensation package is performance <br>based.<br>|
| **Robust stock ownership guidelines** | **Yes** | Executive officers and Directors are subject to stock ownership guidelines. |
| **Annual shareholder "Say on Pay"** | **Yes** | We value our shareholders' input on our executive compensation programs. Our <br>Board of Directors seeks an annual non-binding advisory vote from shareholders to <br>approve the executive compensation disclosed in our CD&A, tabular disclosures <br>and related narrative of this Proxy Statement.<br>|
| **Annual compensation risk** <br>**assessment**<br>| **Yes** | A risk assessment of our compensation programs is performed on an annual basis. |

---

---

| | |
|:---|:---|
| **33 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

---

| | | |
|:---|:---|:---|
| **Compensation Practice** | **Sleep Number Policy or Practice** | **Sleep Number Policy or Practice** |
| **Clawback provisions** | **Yes** | We adopted a Nasdaq-compliant Executive Clawback and Forfeiture Policy, <br>replacing our prior clawback and forfeiture policy, that requires the Compensation <br>Committee to seek recoupment, forfeiture or cancellation of certain compensation <br>of our Section 16 officers, as identified by us under Item 401(b) of Regulation S-K, <br>in the event of an accounting restatement due to the material noncompliance of the <br>Company with any financial reporting requirements under the securities law, <br>including any required accounting restatement to correct an error in previously <br>issued financial statements. There is also a clawback provision in both time-based <br>(RSU) and performance-based (PSU) LTI award agreements that allows for the <br>forfeiture and recovery of LTI granted, earned, vested or paid out if the participant <br>violates a confidentiality agreement that must be accepted as a condition of <br>receiving the LTI award.<br>|
| **Independent compensation** <br>**consultant**<br>| **Yes** | The Compensation Committee retains an independent compensation consultant to <br>advise on the executive compensation program and practices and assist in the <br>benchmarking of compensation levels.<br>|
| **Double-trigger vesting** | **Yes** | If outstanding LTI grants are assumed or substituted upon a change-in-control, the <br>vesting of the LTI grants will only be accelerated if the executive is terminated <br>without cause or terminates with good reason within two years of the change-in-<br>control (i.e., "double trigger vesting").<br>|
| **Hedging of Company stock** | **No** | Directors, executive officers, director-level and above team members, and other <br>team members designated by the Company from time to time as insiders may not <br>directly or indirectly engage in transactions intended to hedge or offset the market <br>value of Sleep Number common stock (Company securities) owned by them, <br>including, but not limited to, the use of financial instruments such as prepaid <br>variable forwards, equity swaps, collars and exchange funds. Insiders are <br>also prohibited from engaging in short sales of Company securities and <br>from trading in any form of publicly traded options, such as puts, calls or <br>other derivatives of the Company's securities.<br>|
| **Pledging of Company stock** | **No** | Directors, executive officers, director-level and above team members, and other <br>team members designated by the Company from time-to-time as insiders may not <br>directly or indirectly pledge Company securities as collateral for any obligation, <br>including purchasing Company securities on margin, holding Company securities in <br>any account which has a margin debt balance, borrowing against any account in <br>which Company securities are held or pledging Company securities as collateral for <br>a loan.<br>|
| **Tax gross-ups** | **No** | We do not provide tax gross-ups to our executive officers, other than for relocation <br>benefits that are applied consistently for all team members.<br>|
| **LTI Grant Practices and** <br>**Procedures Policy**<br>| **Yes** | We have a policy that documents the practices and procedures for making LTI <br>grants to eligible team members including executive officers. This policy specifies <br>approval procedures, timing of awards and the award formulas that determine the <br>number of options or RSUs granted.<br>|
| **Repricing of stock options** | **No** | Our equity incentive plan does not permit repricing of stock options without <br>shareholder approval or the granting of stock options with an exercise price below <br>fair market value.<br>|
| **Employment contracts** | **No** | None of our NEOs has an employment contract that provides for continued <br>employment for any period of time.<br>|

---

---

| | |
|:---|:---|
| **34 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

**PAY ELEMENTS: WHAT WE DESIGNED, TARGETED AND PAID**

**2025 Compensation Structure**

• Our NEOs' total direct compensation (TDC) is comprised of a base salary, an annual incentive (AIP or bonus) and

stock awards or long-term incentive (LTI). Each NEO also had some additional pay elements which are detailed on

the Summary Compensation Table and in the pages that follow.

• We generally seek to align TDC opportunity within a competitive range of market median.

• See "New CEO Hire Package" section beginning on page <u>[42](#i44eec75d700a4a12a1ccd8dcee0c79e2_232)</u> for details on the new hire pay package for our CEO,

Linda Findley. In addition, see "New CFO Hire Package" section beginning on page <u>[44](#i44eec75d700a4a12a1ccd8dcee0c79e2_235)</u> for details on the new hire pay

package for our CFO, Amy O'Keefe.

• 32% of our CEO's (Linda Findley) and 45% of our other NEOs' (Amy O'Keefe, Melissa Barra, Samuel Hellfeld, Chris

Krusmark) target TDC was performance-based, while 91% of our CEO's and 69% of our other NEOs' target TDC was

at-risk.

• To conserve shares utilized, the following changes were made to our LTI practices:

◦ We limited the use of Performance Stock Units (PSUs) and continued to exclude the use of Non-Qualified Stock

Options, which have a more dilutive effect on our share pool.

◦ LTI awards for our NEOs were made in 50% Performance Share Units and 50% Restricted Stock Units;

◦ We maintained our methodology for calculating the number of shares issued under the 2020 Plan. Instead of

basing the number of shares on the average closing price of the 20 days prior to the grant date ($12.11), we used

the average 2024 share price of $13.81.

• NEOs' realized pay varies significantly due to the high percentage of TDC that is at risk, as well as the changes in LTI

practices; the following pages will illustrate how Sleep Number's compensation plans are closely connected to the

Company's performance.

**Base Salary**

• The Compensation Committee determines base salaries for NEOs each year considering multiple factors, including

positioning against external benchmarks, personal performance and contributions, internal equity, succession

planning, retention objectives and budget.

• Salaries comprised 9% of our CEO's and an average of 31% of our other NEOs' TDC in 2025.

• The Compensation Committee approved the salary adjustments below effective April 14, 2025. These decisions were

based on recognizing individual performance and contributions, as well as the NEOs' pay positioning against external

benchmarks.

---

| | | |
|:---|:---|:---|
| **Name** | **Base Salary at**<br>**April 14, 2024**<br>**(Annualized)**<br>| **Base Salary at**<br>**April 14, 2025**<br>**(Annualized)**<br>|
| Shelly Ibach<sup>(1)</sup> | $1200000 | $1200000 |
| Linda Findley<sup>(2)</sup> | $— | $1200000 |
| Francis Lee<sup>(3)</sup> | $631250 | $631250 |
| Amy O'Keefe<sup>(4)</sup> | $— | $625000 |
| Andrea Bloomquist<sup>(5)</sup> | $623354 | $623354 |
| Kevin Brown<sup>(6)</sup> | $538777 | $538777 |
| Melissa Barra | $614482 | $614482 |
| Samuel Hellfeld | $549938 | $577435 |
| Christopher Krusmark<sup>(7)</sup> | $449378 | $500000 |

---

<sup>(1)</sup> Ms. Ibach role as President and Chief Executive Officer ended on April 6, 2025, but remained in a non-executive management role through May 31,

2025. Ms. Ibach continued to serve as a non-employee strategic consultant to the Company through December 31, 2025.

---

| | |
|:---|:---|
| **35 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<sup>(2)</sup> Reflects Ms. Findley's base salary upon her hire date effective April 7, 2025.

<sup>(3)</sup> Mr. Lee separated from the Company effective August 15, 2025.

<sup>(4)</sup> Reflects Ms. O'Keefe's base salary upon her hire date effective December 8, 2025.

<sup>(5)</sup> Ms. Bloomquist separated from the Company effective May 31, 2025.

<sup>(6)</sup> Mr. Brown separated from the Company effective April 16, 2025.

<sup>(7)</sup> Mr. Krusmark's base salary was updated from $449,378 to $500,000 effective April 27, 2025, and in connection with his promotion.

**Annual Incentive Plan (AIP)**

<u>Design Overview</u>

All Sleep Number team members participate in a variable pay program as part of our compensation philosophy to create

alignment between pay and performance. Our Annual Incentive Plan (AIP) provides our executive officers and

approximately 1,000 of our team members with an annual incentive opportunity contingent upon our adjusted EBITDA

performance. Our remaining team members are part of personal performance or commission-based variable pay

programs.

Adjusted EBITDA is a useful indicator of our annual financial performance and our ability to generate cash flow from

operating activities, which we believe to be an important source of our shareholder value creation. We define adjusted

EBITDA as net income plus: income tax expense, interest expense, depreciation and amortization, stock-based

compensation expense, restructuring costs, CEO transition/proxy contest costs and asset impairments (as detailed in our

quarterly and annual financial filings). For additional information on adjusted EBITDA, including a reconciliation to net

income see "Non-GAAP Data Reconciliations" on pages 44 through 46 of our Annual Report on Form 10-K filed on

March 12, 2026.

The design of our AIP has three main components that determine the amount of the payout earned by our NEOs for

Company performance: (a) base salary earned for the fiscal year, (b) the target incentive opportunity (as a % of base

salary earned), which is set each year by the Compensation Committee considering market data and the NEO's position

and (c) the percent of the target payout earned for the year (based on Company performance measured against goals for

adjusted EBITDA). It is the combination of these three components that results in the final AIP payout earned for our

NEOs.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Base Salary <br>Earned<br>| X | AIP Target<br>Incentive<br>(% of Base Salary)<br>| X | % of Target Payout<br>(earned for <br>adjusted EBITDA <br>performance vs. <br>goals)<br>| = | **AIP Annual** <br>**Payout Earned**<br>|

---

<u>Individual Target Incentive</u>

Each executive officer has a target incentive that is expressed as a percent of the actual base salary earned for the fiscal

year. The Compensation Committee reviews these targets annually to ensure that they are aligned within a competitive

range of the median target incentives and total cash opportunities of our peers and the market (*See* "2025 Peer Group" on

page <u>[31](#i44eec75d700a4a12a1ccd8dcee0c79e2_199)</u> and approach to "Benchmarking" on page <u>[31](#i44eec75d700a4a12a1ccd8dcee0c79e2_196)</u>). The 2025 AIP target incentive percentage of base salary did not

change for any NEOs.

---

| | |
|:---|:---|
| **Name** | **AIP Target Incentive for 2025** <br>**(% of actual base salary earned)**<br>|
| **Linda Findley** | 125% |
| **Other NEOs** | 70% |

---

---

| | |
|:---|:---|
| **36 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<u>2025</u> <u>Performance Goals</u>

The Compensation Committee approved the following performance goals and range of payout opportunities for the 2025

AIP. These goals and payout opportunities were set to provide a strong motivation for achievement of performance

objectives and a reasonable sharing rate of incremental adjusted EBITDA. The following is an overview of the goals and

payout levels that were approved for the 2025 AIP:

<u>EBITDA Performance:</u>

• Target - The performance goal for the target payout of 100% was set at adjusted EBITDA of $125.0 million, which was

equal to the Company's Annual Operating Plan (AOP) for 2025. This represented a 4.5% increase compared to our

2024 results.

• Maximum - The performance goal for the maximum payout of 200% was set at adjusted EBITDA of $162.0 million,

which was 29.6% above AOP and a 35.5% increase over 2024 results. The 200% payout opportunity is designed to

reward breakthrough performance.

• Threshold - The performance goal for the threshold payout of 25% was set at adjusted EBITDA of $100.0 million,

which was 20.0% below AOP and 16.4% below 2024 results. This represented an appropriate starting point for the

threshold payout and was aligned with the approach taken by many of our peers and other similarly sized companies.

---

| | | | |
|:---|:---|:---|:---|
| | **AIP Payout** <br>**Earned**<br>**(% of Target)**<br>| **Annual Adjusted** <br>**EBITDA Goals**<br>**(in millions)**<br>| **% of AOP** <br>**Achieved** <br>|
| Threshold | 25% | $100 | 80% |
| Target | 100% | $125 | 100% |
| Maximum | 200% | $162 | 130% |

---

<u>2025</u> <u>AIP Payout</u>

Our adjusted EBITDA for 2025 was $78.3 million, down 34.6% from 2024 actual and 37.4% below the Company's AOP,

which was the goal for target payout. For this level of adjusted EBITDA, no payout was earned for 2025 AIP. No

adjustments were made to our reported adjusted EBITDA results in this determination of the AIP payout for 2025.

The following table shows the full-year AIP target earned for 2025 by each NEO.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name**<sup>(7)</sup> | **2025 Base** <br>**Salary** <br>**Earned**<br>| **2025 AIP** <br>**Target** <br>**(% of Salary)**<br>| **2025 AIP** <br>**Target** <br>**Incentive** <br>**Opportunity**<br>| **2025 AIP**<br>**Actual Payout** <br>**Earned $**<br>| **2025 Actual** <br>**Payout** <br>**Earned %**<br>|
| Shelly Ibach<sup>(1)</sup> | $530769 | 140.0% | $743077 | $— | —% |
| Linda Findley<sup>(2)</sup> | $853846 | 125.0% | $1067308 | $— | —% |
| Francis Lee<sup>(3)</sup> | $412740 | 70.0% | $288918 | $— | —% |
| Robert Ryder<sup>(4)</sup> | $— | —% | $— | $— | —% |
| Amy O'Keefe<sup>(5)</sup> | $— | —% | $— | $— | —% |
| Andrea Bloomquist<sup>(6)</sup> | $275714 | 70.0% | $193000 | $— | —% |
| Kevin Brown<sup>(7)</sup> | $171994 | 70.0% | $120396 | $— | —% |
| Melissa Barra | $614482 | 70.0% | $430137 | $— | —% |
| Samuel Hellfeld | $568975 | 70.0% | $398283 | $— | —% |
| Christopher Krusmark | $482477 | 70.0% | $337734 | $— | —% |

---

<sup>(1)</sup> Ms. Ibach role as President and Chief Executive Officer ended on April 6, 2025, but remained in a non-executive management role through

May 31, 2025. Ms. Ibach continued to serve as a non-employee strategic consultant to the Company through December 31, 2025.

<sup>(2)</sup> Reflects Ms. Findley's base salary upon her hire date effective April 7, 2025.

<sup>(3)</sup> Mr. Lee separated from the Company effective August 15, 2025.

<sup>(4)</sup> As interim Chief Financial Officer, Mr. Ryder was not eligible for AIP.

<sup>(5)</sup> Ms. O'Keefe was not eligible for 2025 AIP given her hire date of December 8, 2025.

<sup>(6)</sup> Ms. Bloomquist separated from the Company effective May 31, 2025.

<sup>(7)</sup> Mr. Brown separated from the Company effective April 16, 2025.

---

| | |
|:---|:---|
| **37 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

**Long-Term Incentive Plan (LTI)**

<u>Design Overview</u>

LTI is the largest component of the total direct compensation opportunity for our executive officers. It provides a reward

opportunity that is directly aligned with the long-term interest of our shareholders. Our Performance Share Units (PSUs)

only payout value if we achieve long-term Company performance goals; and our Restricted Stock Units (RSUs) value is

aligned to our stock price appreciation. The grants have multi-year vesting requirements which also assist in the retention

of our executive team, which we believe is especially important to execute our strategy.

In 2025, Sleep Number adjusted its equity plan design for our executive officers in an effort to conserve shares available

under the plan. These changes included:

• Limiting the use of Performance Stock Units (PSUs) and eliminating the use of Non-Qualified Stock Options, which

have a more dilutive effect on the 2020 Plan;

• Adjusting our methodology for calculating the number of shares issued under the 2020 Plan. (Instead of basing the

number of shares on the average closing price of the 20 days prior to the grant date ($12.11), we used the average

2024 share price of $13.81.)

The design of our LTI includes two types of annual equity grants: Performance Stock Units (PSUs) and Restricted Stock

Units (RSUs). For 2025, our executive officers received an annual total LTI grant value that was split 50% in PSUs and

50% in RSUs. This combination balances performance- and time-based awards to appropriately reward our executive

officers for achieving long-term profitable growth and the creation of shareholder value.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Total LTI<br>Grant<br>Value | **X** | 50% | **PSUs**<br>(Target Grant Value)<br>| *PSU grants only have payout value if* <br>*Company performance goals are* <br>*achieved; RSU value is directly tied to* <br>*stock price performance* |
| Total LTI<br>Grant<br>Value |  |  |  | *PSU grants only have payout value if* <br>*Company performance goals are* <br>*achieved; RSU value is directly tied to* <br>*stock price performance* |
| Total LTI<br>Grant<br>Value | **X** | 50% | **RSUs**<br>(Grant Value)<br>| *PSU grants only have payout value if* <br>*Company performance goals are* <br>*achieved; RSU value is directly tied to* <br>*stock price performance* |

---

As a condition of accepting any LTI grant, our executive officers agree to reasonable restrictions on their activities during

and for a reasonable period of time after their respective termination of employment, including, but not limited to, and

where permitted by law, the assignment of inventions, non-competition, non-solicitation, confidentiality and an agreement

to arbitrate disputes.

<u>PSU Grants</u>

PSUs become vested on the third anniversary of the grant date, and a percent of target is earned, provided performance

exceeds established threshold goals, and paid out based on Company performance against annual growth goals over a

three-year performance period. The performance metrics for 2025 PSUs are annual growth in net sales and NOP over

fiscal years 2025, 2026 and 2027. At the end of the three-year performance period, the payout for PSUs is determined

based on the average of the payouts earned for each of the three years in the performance period, with net sales and

NOP equally weighted each year. By assessing growth achieved each year relative to long-term growth goals, our

executive officers are able to make the appropriate investments in the business during ever-changing market and

competitive environments while prioritizing long-term sustainable profitable growth.

Prior to the grant date, the Compensation Committee established annual growth goals for each of the three years,

considering the Company's long-range strategic plan and performance growth targets. Performance against these annual

growth goals will determine the percent of target payout earned for net sales and NOP for the entire performance period.

The annual measurement for either metric can yield a payout ranging from 50% to 200% of target, with no payout being

earned if performance is below the goal for a threshold payout.

---

| | |
|:---|:---|
| **38 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

New for 2025 PSUs, at the end of the three-year performance period, the payout earned under the PSUs may be adjusted

by a relative total shareholder return (TSR) modifier. The adjustment based on TSR is determined based on the schedule

below. Under no instance shall the TSR modifier adjust the award above 200% of target.

---

| | | |
|:---|:---|:---|
| **Performance Levels** | **Relative TSR Percentile** | **Relative TSR Modifier** |
| Threshold | Below 25th Percentile | 80% |
| Target | 25th - 75th Percentile | 100% |
| Maximum | Above the 75th Percentile | 120% |

---

The following chart illustrates how the overall payout for 2025 PSUs, covering the 2025 to 2027 period, will be determined.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Net Sales** | **Net Sales** | **Net Sales** | **NOP** | **NOP** | **NOP** |
| **2025** | Net sales<br>annual growth <br>each year | *% of target payout earned for* <br>*net sales each year* | **2025** | NOP<br>annual growth <br>each year | *% of target payout earned for* <br>*NOP each year* |
| **2026** | Net sales<br>annual growth <br>each year | *% of target payout earned for* <br>*net sales each year* | **2026** | NOP<br>annual growth <br>each year | *% of target payout earned for* <br>*NOP each year* |
| **2027** | Net sales<br>annual growth <br>each year | *% of target payout earned for* <br>*net sales each year* | **2027** | NOP<br>annual growth <br>each year | *% of target payout earned for* <br>*NOP each year* |
| Three-year average % of target earned for net sales | Three-year average % of target earned for net sales | Three-year average % of target earned for net sales | Three-year average % of target earned for NOP | Three-year average % of target earned for NOP | Three-year average % of target earned for NOP |

---

---

| | |
|:---|:---|
| **Overall** <br>**payout**:<br>| Average of the % of target payout earned for net sales and NOP each year (equal weighting) times the <br>target number of PSUs granted; then subject to a relative TSR modifier.<br>|

---

In an effort to conserve shares issued under the Plan, the target number of PSUs for the 2025 award was determined by

dividing the grant value (equal to 50% of the executive officer's total LTI grant value) by the average 2024 share price of

$13.81. See the footnotes to the "Summary Compensation Table" on page <u>[49](#i44eec75d700a4a12a1ccd8dcee0c79e2_265)</u> and "Grants of Plan-Based Awards" on page

<u>[51](#i44eec75d700a4a12a1ccd8dcee0c79e2_268)</u> for a description of how grant date fair value is determined for purposes of the disclosure in these tables.

<u>RSU Grants</u>

Restricted stock units vest in three equal annual installments on each of the anniversaries following the grant date.

The number of stock options granted in 2025 was determined by dividing the RSU grant value (50% of the executive

officer's total LTI grant value) by the average 2024 share price of $13.81. See the footnotes to the "Summary

Compensation Table" on page <u>[49](#i44eec75d700a4a12a1ccd8dcee0c79e2_265)</u> and "Grants of Plan-Based Awards" on page <u>[51](#i44eec75d700a4a12a1ccd8dcee0c79e2_268)</u> for a description of how grant date fair

value is determined for purposes of the disclosure in these tables.

<u>LTI Grant Values</u>

The Compensation Committee approves a total LTI grant value for each executive officer, considering the executive

officer's performance and level of responsibility, as well as the competitive positioning of the officer's targeted total direct

compensation. The Compensation Committee seeks to make annual LTI grants to provide a total direct compensation

opportunity that is within a competitive range of the market median.

The following table summarizes the annual LTI grants made to our NEOs in 2025, and the split in grant value between

PSUs (50%) and RSUs (50%). See "Grants of Plan-Based Awards" on page <u>[51](#i44eec75d700a4a12a1ccd8dcee0c79e2_268)</u> for more information on these awards. As

noted earlier, the number of PSUs and RSUs granted was based on the average 2024 share price of $13.81 rather than

basing the number of shares on the average closing price of the 20 days prior to the grant date ($12.11), which has been

our historical practice for calculating the number of shares issued under the 2020 Plan.

---

| | |
|:---|:---|
| **39 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Annual LTI Grants during 2025** <br>**(Granted March 15, 2025, except as noted below)** | **Annual LTI Grants during 2025** <br>**(Granted March 15, 2025, except as noted below)** | **Annual LTI Grants during 2025** <br>**(Granted March 15, 2025, except as noted below)** | **Annual LTI Grants during 2025** <br>**(Granted March 15, 2025, except as noted below)** |
| **Name** | **PSU**<br>**Grant Value**<br>**at Target**<br>| **RSU** <br>**Grant Value**<br>| **Total Intended** <br>**LTI Grant Value**<br>**(Shares** <br>**Determined Using** <br>**2024 Avg Share** <br>**Price of $13.81)**<br>| **Grant Date Fair** <br>**Market Value** <br>**(Based on Grant** <br>**Date Price of $7.35)**<br>|
| Linda Findley<sup>(1)</sup> | $2500000 | $7500000 | $10000000 | $3671258 |
| Francis Lee<sup>(2)</sup> | $550000 | $550000 | $1100000 | $585457 |
| Andrea Bloomquist<sup>(3)</sup> | $500000 | $500000 | $1000000 | $532228 |
| Kevin Brown<sup>(4)</sup> | $337500 | $337500 | $675000 | $359253 |
| Melissa Barra | $500000 | $500000 | $1000000 | $532228 |
| Samuel Hellfeld | $412500 | $412500 | $825000 | $439089 |
| Christopher Krusmark | $275000 | $275000 | $550000 | $292736 |

---

<sup>(1)</sup> The Compensation Committee approved a special LTI grant for Ms. Findley as part of her CEO hiring package. The LTI grant value was

$10,000,000. This grant was in the form of PSUs and RSUs weighted 25% and 75%, respectively. The date of the grant was April 15, 2025. The

average 2024 share price of $13.81 was used to align Ms. Findley's awards with other team members. The PSU award has a cliff vesting of three

years and includes the same performance metrics as the other NEOs. The RSU awards vest ratably over three years with the award becoming fully

vested three years from the date of grant subject to the terms and conditions of the applicable award agreements. The grant date fair value listed in

the table above is based on $5.07, the closing price of the Company's common stock on the Nasdaq Stock Market on April 15, 2025. See "Grants of

Plan-Based Awards" on page <u>[51](#i44eec75d700a4a12a1ccd8dcee0c79e2_268)</u> for more information on these awards.

<sup>(2)</sup> Mr. Lee separated from the Company effective August 15, 2025. Mr. Lee forfeited the LTI grants upon separation.

<sup>(3)</sup> Ms. Bloomquist separated from the Company effective May 31, 2025. Ms. Bloomquist forfeited 33,662 shares of the RSU grant and 33,665 shares

of the PSU grant upon separation. In accordance with the retirement provisions of the award agreements, 2,544 shares vested of the RSU grant

upon separation and 2,541 shares of the PSU grant remain outstanding and unvested until March 2028.

<sup>(4)</sup> Mr. Brown separated from the Company effective April 16, 2025. Mr. Brown forfeited 23,725 shares of the RSU grant and 23,726 shares of the PSU

grant upon separation. In accordance with the retirement provisions of the award agreements, 714 shares vested of the RSU grant upon separation

and 713 shares of the PSU grant remain outstanding and unvested until March 2028.

Note: The actual grant date fair value for these LTI grants as disclosed in the Summary Compensation Table varies from the amounts shown above due

to share count rounding and valuation assumptions as described in the footnotes to the "Grants of Plan-Based Awards" on page <u>[51](#i44eec75d700a4a12a1ccd8dcee0c79e2_268)</u>. Ms. Ibach did not

receive LTI grants for 2025 as she announced her retirement in October 2024, Mr. Ryder did not receive LTI grants for 2025 as he was a non-employee

of the Company and Ms. O'Keefe did not receive LTI grants for 2025 as she was hired effective December 8, 2025.

<u>2023</u> <u>PSU Payout</u>

The 2023 PSUs covering the 2023 to 2025 period, which are similar in design to the 2024 PSUs, were granted on March

15, 2023 and vested on March 15, 2026. Based on net sales and NOP annual growth over the three fiscal years (2023,

2024 and 2025), no payout was earned for the 2023 PSUs.

The following are the annual growth goals that were established for the 2023 PSU grant.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **% of** <br>**Target** <br>**Payout** <br>**Earned**<br>| **Annual** <br>**Growth in**<br>**Net Sales**<br>| **Annual** <br>**Growth in** <br>**NOP**<br>| **Average Difference**<br>**in Basis Points**<br>**Between Adjusted**<br>**ROIC and WACC**<br>| **% Reduction**<br>**in Target**<br>**Number of PSUs**<br>|
| Threshold | 50% | 3% | 4% | 300 or more | No reduction |
| Target | 100% | 5% | 8% | 200 to 299 | -5% |
| Maximum | 200% | 12% | 12% | 100 to 199 | -10% |
|  |  |  |  | 1 to 99 | -15% |
|  |  |  |  | 0 or less | -20% |

---

---

| | |
|:---|:---|
| **40 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

The following chart shows the actual performance achieved for the performance period and how the total payout for 2023

of 0% of target was determined.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Net Sales** <br>**($M)**<br>| **% Annual** <br>**Growth**<br>| **% of Target** <br>**Earned**<br>| **NOP**<br>**($M)**<br>| **% Annual** <br>**Growth**<sup>(2)</sup><br>| **% of Target**<br>**Earned**<br>| **Average %** <br>**of Target**<br>**Earned**<br>|
| **2023** | $1887 | -10.7% | **0%** | $22.9 | -66.2% | 0% | 0% |
| **2024** | $1682 | -10.9% | **0%** | $22.9 | -0.3% | 0% | 0% |
| **2025** | $1411 | -16.1% | **0%** | $(46.6) | -303.7% | 0% | 0% |
|  | **Three-year average:** | **Three-year average:** | **—%** | **Three-year average:** | **Three-year average:** | **0%** | **0.0%** |

---

**Total payout actually earned: 0% of target**

(equal weighting of average payout earned on Net Sales and NOP)

The following chart shows the calculation of the average difference between adjusted ROIC and WACC for the

performance period.

---

| | | | |
|:---|:---|:---|:---|
| | **Adjusted ROIC** | **WACC** | **Adjusted ROIC Premium in** <br>**Basis Points vs. WACC**<br>|
| **2023** | 7.8% | 9.1% | **-130** |
| **2024** | 7.6% | 7.8% | **-20** |
| **2025** | (4.1)% | 6.8% | **-1090** |
|  | **Three-year average:** | **Three-year average:** | **-413** |

---

ROIC modifier was not applied to this payout due to no payouts being earned. The three-year average discount of 413

basis points would have reduced the payout by 20%.

**<u>Long-Term Retention Awards</u>**

On March 12, 2025, concurrent with the appointment of the Company's new CEO, the Compensation Committee

approved cash-based retention awards for members of the executive management team in amounts ranging from

$300,000 to $800,000 in view of the Company's retention profile and prevailing market practices for executive retention

during a CEO transition. The awards were structured in cash to preserve shares available under the Plan and vest in

equal installments on the first and second anniversaries of the awards subject to continued employment and other terms

such that they are forfeited if the continued service requirement is not satisfied. Ms. Barra and Mr. Hellfeld each received

awards valued at $800,000, Mr. Lee, Ms. Bloomquist and Mr. Krusmark each received awards valued at $600,000, and

Mr. Brown received an award valued at $300,000. Mr. Lee, Ms. Bloomquist and Mr. Brown's awards were forfeited

because they did not met the continued employment requirement.

**Benefits and Perquisites**

<u>Benefits</u>

Our executive officers participate in the benefit programs provided to our benefit eligible team members. This includes

Company provided medical, dental, basic life, short-term disability, long-term disability and a matched 401(k) plan. Our

NEOs participate in the 401(k) plan on the same basis as all other team members. There is no supplemental matching

program, excess plan or other executive retirement program. The value of the 401(k) matching contribution made by the

Company for our NEOs is included in "All Other Compensation" as disclosed in the "Summary Compensation Table" on

page <u>[49](#i44eec75d700a4a12a1ccd8dcee0c79e2_265)</u>. Effective October 10, 2025, the Company suspended the 401(k) matching contribution due to current business

performance.

<u>Non-Qualified Deferred Compensation Plan</u>

As described in more detail on page <u>[54](#i44eec75d700a4a12a1ccd8dcee0c79e2_277)</u><u>,</u> our executive officers, along with other leaders, may elect to defer a portion of

their salary, AIP payout and PSU/RSU payout under this non-qualified deferred compensation plan. The Company does

not make any contributions to this plan on behalf of participants. The plan offers a range of investment options for the

---

| | |
|:---|:---|
| **41 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

tracking of an investment return on the deferrals, and participants can elect how their deferrals will be distributed in the

future.

<u>Executive Benefits and Perquisites</u>

Consistent with our commitment to emphasize pay for performance in our mix of total compensation, our executive

officers receive very few executive benefits and perquisites. The Company provides two perquisites to our executive

officers – financial counseling and an annual executive physical exam. The annual limit for financial counseling was

$20,000 for our CEO and $10,000 for our other NEOs. The Company pays for the cost after insurance coverage of an

annual executive physical exam. Amounts reimbursed for financial counseling or the executive physical exam are fully

taxable to the executive, and there is no "gross up" by the Company to cover these taxes for the executive. Additionally,

the Compensation Committee approved the payment of certain one-time security enhancement costs and ongoing

security monitoring expenses for Ms. Ibach when she was CEO that were recommended as part of a security study

conducted by an independent third-party security consultant. The total amount paid by the Company in 2025 that was

included in the "All Other Compensation" column of the "Summary Compensation Table" on page <u>[49](#i44eec75d700a4a12a1ccd8dcee0c79e2_265)</u> was $25,574, which

represents security monitoring costs for Ms. Ibach. Ms. Findley did not incur any security costs in fiscal year 2025.

<u>Employment Agreements</u>

We do not have employment agreements with any of our executive officers that provide for continued employment for any

period of time.

<u>Severance Plan</u>

Our executive officers and other key leaders of the Company participate in the Sleep Number Executive Severance Pay

Plan. This plan provides for severance pay, prorated incentive payment and other benefits such as outplacement and

limited COBRA reimbursement in the event of involuntary termination of employment not for cause or termination for good

reason, including for events following a change-in-control, as those terms are defined in the plan. This plan is described in

more detail in the compensation table in the section labeled "Potential Payments Upon Termination or Change in Control"

starting on page <u>[55](#i44eec75d700a4a12a1ccd8dcee0c79e2_280)</u>.

**Compensation Related to CEO Transition**

<u>CEO Transition and Advisory Agreement</u>

As previously disclosed, on October 24, 2024 we entered into a Transition and Advisory Agreement with Ms. Ibach to

facilitate a smooth leadership transition and ensure that the Company continues to benefit from Ms. Ibach's relationships

with key partners and suppliers and institutional knowledge. Pursuant to the agreement, Ms. Ibach retired as Chair at the

2025 Annual Meeting and thereafter served as a strategic advisor to the Board of Directors through the end of 2025.

As further described in a Form 8-K filed by Sleep Number on October 30, 2024, in exchange for Ms. Ibach remaining as

an advisor with the Company, Ms. Ibach's outstanding performance adjusted restricted stock unit ("PSU") and stock option

awards issued under our 2020 Equity Incentive Plan, as amended, ("2020 Plan") were treated in accordance with the

retirement provision of the award agreements, which provided for the treatment of such awards in the event of Ms. Ibach's

retirement at or beyond age 60 with five or more years of service with Sleep Number; provided, however, the

Compensation Committee waived the requirement, as applicable, that Ms. Ibach provides written notice of her intention to

retire one year before her actual retirement date. Under such retirement treatment, Ms. Ibach's outstanding PSU and

stock option awards became fully vested upon her separation of employment from Sleep Number, and options will remain

exercisable for three years after her separation of employment from Sleep Number, subject to a maximum exercise period

of 10 years from the original grant date of the option awards. Ms. Ibach's outstanding RSU awards issued under the 2020

Plan became fully vested upon her separation of employment from Sleep Number and were treated in accordance with

the RSU award agreements provided that we waived the requirement that Ms. Ibach remain in continuous employment or

service with Sleep Number during the regular vesting period set forth in the RSU award agreements.

---

| | |
|:---|:---|
| **42 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

In fiscal 2024, the Summary Compensation Table reflected the grant or modification date fair value of awards modified

under Ms. Ibach's Transition and Advisory Agreement, computed in accordance with FASB ASC Topic 718, in fiscal year

2024. See "Compensation related to CEO Transition" on pages 46 and 47 of our Definitive Proxy Statement filed on April

18, 2025 for additional information.

<u>New CEO Hire Package</u>

In connection with Linda Findley's appointment as CEO on April 7, 2025, the Company entered into an offer letter with Ms.

Findley that documents, among other things, her compensation and employment terms. After the letter was executed, but

prior to Ms. Findley's start date and the grant date under her equity inducement awards, we reported our financial results

for 2024 and provided details of our financial outlook. The Company's stock price declined significantly on and after the

date of that report. Because Ms. Findley's inducement grant of equity was to be based, in some circumstances, on the

stock price on the grant date (which was subsequent to the stock price decline), Ms. Findley, the Compensation

Committee and independent Directors, recognized that the inducement grant as originally structured would create more

dilution than they anticipated at the time the offer letter was executed.

The Company and Ms. Findley reached an agreement to restructure the inducement grant, in the interests of

shareholders, by using a notional share price based on the average closing price in 2024 to calculate the number of

shares to be granted, adding additional performance metrics to the vesting conditions and as a multiplier on some of the

equity awards and providing for a cash sign-on bonus, a portion of which Ms. Findley requested to use to purchase the

Company's stock in the open market subject to our Insider Trading Policy.

The Compensation Committee, together with the other independent Directors, spent a significant amount of time

evaluating and preparing Ms. Findley's compensation package with the Compensation Committee's independent

compensation consultant. In approving the final terms of Ms. Findley's compensation package, including the amendments

to the initial compensation structure, they considered, among other things:

• Sleep Number's critical need for a qualified leader to continue the business transformation;

• Ms. Findley's experience and track record of performance and achievement in her previous roles;

• Ms. Findley's total target direct compensation and benefits in her previous role;

• Sleep Number's peer group, and the total compensation opportunity for CEOs of companies with whom the Company

competes for talent;

• Our recent stock price decline; and

• The alignment of Ms. Findley's compensation package with the Company's pay for performance philosophy.

Based on such considerations, the Compensation Committee and the other independent Directors ultimately approved a

compensation package for Ms. Findley as summarized below. Notably, the Compensation Committee determined not to

increase her total direct compensation for 2026.

---

| | | |
|:---|:---|:---|
| **Compensation Element** | **Description** | **Rationale** |
| Base Salary | Annual base salary of $1,200,000 | Provides a predictable level of income |
| Annual Incentive Award | 125% of base salary (target); 25% of target <br>(threshold); 200% of target (maximum)<sup>(1)</sup> <br>| Ties upside earning opportunity to <br>Company and individual performance <br>results<br>|
| Annual Long-Term Incentive <br>Award<br>| Annual equity awards with a target value of <br>$5,000,000, with normal annual grants <br>commencing in 2026. The current mix of the annual <br>award is comprised of performance stock units <br>(50%) and time vested restricted stock units (50%). <br>| Aligns Ms. Findley's interests with <br>those of our shareholders and <br>motivates and rewards exceptional <br>performance.<br>|

---

---

| | |
|:---|:---|
| **43 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

---

| | | |
|:---|:---|:---|
| **Compensation Element** | **Description** | **Rationale** |
| Inducement Equity Grant – <br>Time-Based RSUs with <br>Performance Modifier<br>| One-time RSU with Performance Modifier award of <br>362,057 shares.<br>•Award vests ratably over 3 years<br>•The final number of shares vesting may be <br>modified based on the average closing share <br>price for the 20-days prior to the vesting, with <br>100% vesting if the average share price is at or <br>below $13.81, 125% vesting if the average <br>share price is $30.00 and 200% vesting if the <br>average share price is greater than or equal to <br>$50.00. Payouts will be interpolated between <br>the points noted above.<br>| Aligns Ms. Findley's interests with <br>those of our shareholders and <br>motivates and rewards exceptional <br>performance.<br>Aligns Ms. Findley's awards with that <br>of all other team members and the <br>Directors by basing the number of <br>shares granted on the share price of <br>$13.81, the average closing price in <br>2024.<br>Necessary to attract and retain a <br>qualified leader like Ms. Findley. |
| Inducement Equity Grant – <br>Performance Share Units<br>| 2025 PSU award of 181,028 shares.<br>•Award cliff vests in 3 years.<br>•Performance metrics include Net Sales and <br>Net Operating Profit in fiscal years 2025, 2026, <br>and 2027.<br>•The final number of shares vesting may be <br>modified based on the Company's relative Total <br>Shareholder Return (rTSR) versus the S&P <br>1500 Specialty Retail Index such that the <br>award may be increased by 20% if the <br>Company's rTSR is within the top 25<sup>th</sup> <br>percentile of the index, and may be decreased <br>by 20% if the Company's rTSR falls within the <br>bottom 25<sup>th</sup> percentile of the index. No <br>modification would occur if the Company's <br>rTSR performance is between the 25<sup>th</sup> and 75<sup>th</sup> <br>percentile.<br>| Aligns Ms. Findley's interests with <br>those of our shareholders and <br>motivates and rewards exceptional <br>performance.<br>Aligns Ms. Findley's awards with that <br>of all other team members and the <br>Directors by basing the number of <br>shares granted on the share price of <br>$13.81, the average closing price in <br>2024.<br>Necessary to attract and retain a <br>qualified leader like Ms. Findley. |
| Inducement Equity Grant – <br>Time-Based RSUs<br>| 2025 RSU award of 181,029 shares.<br>•Award vests ratably over 3 years.<br>| Aligns Ms. Findley's interests with <br>those of our shareholders and <br>motivates and rewards exceptional <br>performance.<br>Aligns Ms. Findley's awards with that <br>of all other team members and the <br>Directors by basing the number of <br>shares granted on the share price of <br>$13.81, the average closing price in <br>2024.<br>Necessary to attract and retain a <br>qualified leader like Ms. Findley. |
| Inducement Cash Award | Sign-on cash bonus of $2,500,000 to be paid in <br>three installments: first installment of $1,250,000 <br>on April 15, 2025, the second installment of <br>$625,000 on April 15, 2026, and the third <br>installment of $625,000 on April 15, 2027; Ms. <br>Findley will use the after-tax proceeds from the first <br>installment to buy, or enter into a trading plan to <br>buy, common stock in the open market in the <br>Company's next open trading window, subject to <br>the Insider Trading Policy.<br>Ms. Findley purchased 104,520 shares of the <br>Company's common stock at prices between $7.01 <br>and $7.58 in May 2025.<br>| Aligns Ms. Findley's interests with <br>those of shareholders by requiring <br>Ms. Findley to use the after-tax <br>proceeds from the first installment to <br>buy, or enter into a trading plan to <br>buy, shares of the Company's <br>common stock in the open market.<br>Necessary to attract and retain a <br>qualified leader like Ms. Findley.<br>|
| Benefits and Perquisites | Company-provided medical dental, basic life, short-<br>term disability, long-term disability, matched 401(k) <br>plan, non-qualified deferred compensation plan, <br>financial counseling, executive physical and <br>relocation assistance.<br>| Benefits are substantially similar to <br>what are provided to other company <br>employees<br>Necessary to attract and retain a <br>qualified leader like Ms. Findley.<br>|

---

<sup>(1)</sup> No payout was earned for 2025 AIP. See "Annual Incentive Plan (AIP): 2025 AIP Payout" on page <u>[36](#i44eec75d700a4a12a1ccd8dcee0c79e2_223)</u> for additional details.

---

| | |
|:---|:---|
| **44 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<u>Interim CFO Appointment</u>

On July 18, 2025, the Company appointed Robert P. Ryder as the interim Chief Financial Officer (CFO) of the Company.

The Company paid a weekly fee of $58,750 as compensation for Mr. Ryder's interim services, as well as reimbursement

of Mr. Ryder's reasonable and authorized travel expenses related to performance of the services. Mr. Ryder's interim CFO

services ended December 8, 2025, and he continued to serve in an advisory role until December 12, 2025.

<u>New CFO Hire Package</u>

On November 28, 2025, the Company appointed Amy K. O'Keefe as the Executive Vice President and CFO of the

Company effective December 8, 2025. Ms. O'Keefe's compensation package is summarized below:

---

| | |
|:---|:---|
| **Compensation Element** | **Description** |
| Base Salary | Annual base salary of $625,000 |
| Annual Incentive Award | 70% of base salary (target); 25% of target (threshold); 200% of target (maximum) <br>beginning in fiscal 2026<br>|
| Annual Long-Term Incentive <br>Award<br>| Annual equity awards with a target value of $1,200,000, with normal annual grants <br>commencing in March 2027. The current mix of the annual award is comprised of <br>performance stock units (50%) and time vested restricted stock units (50%). <br>|
| Inducement Equity Grant – <br>Time-Based RSUs<br>| One-time RSU award with a value of $400,000 (69,742 shares) granted on December 15, <br>2025.<br>•Award vests ratably over 3 years<br>|
| Inducement Equity Grant – <br>Performance Share Units<br>| PSU award with a value of $800,000 (89,286 shares) granted on March 16, 2026<br>•Award cliff vests in 3 years.<br>•Performance metrics include Net Sales and Net Operating Profit in fiscal years 2026, <br>2027 and 2028.<br>•The final number of shares vesting may be modified based on the Company's relative <br>Total Shareholder Return (rTSR) versus the S&P 1500 Specialty Retail Index such that <br>the award may be increased by 20% if the Company's rTSR is within the top 25<sup>th</sup> <br>percentile of the index, and may be decreased by 20% if the Company's rTSR falls <br>within the bottom 25<sup>th</sup> percentile of the index. No modification would occur if the <br>Company's rTSR performance is between the 25<sup>th</sup> and 75<sup>th</sup> percentile.<br>|
| Inducement Equity Grant – <br>Time-Based RSUs<br>| RSU award with a value of $600,000 (66,965 shares) granted on March 16, 2026<br>•Award vests ratably over 3 years.<br>|
| Relocation Expense | One-time relocation payment of $150,000 plus an additional amount based on a 40% tax <br>rate to help cover applicable taxes for a total payment of $250,000 subject to tax <br>withholding.<br>|
| Benefits and Perquisites | Company-provided medical dental, basic life, short-term disability, long-term disability, <br>matched 401(k) plan, non-qualified deferred compensation plan, financial counseling, <br>executive physical and relocation assistance.<br>|

---

---

| | |
|:---|:---|
| **45 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

**COMPENSATION OVERSIGHT AND PROCESSES**

**Compensation Philosophy and Approach**

Our executive compensation program is designed to support our long-term strategic orientation. It is competitive, heavily

weighted toward performance-based incentive programs and allows for appropriate risk taking and investments in the

business as we execute our strategy. Our incentive programs reward our executive officers for superior performance to

deliver sustainable, profitable growth. The incentive opportunities are tied to multiple financial metrics that support our

business strategy and are aligned with stakeholder interests.

Our executive compensation program is designed to:

• Attract, motivate and retain a talented management team to achieve superior Company performance that is

sustainable over time;

• Provide a market competitive total compensation opportunity that is predominantly performance based and at risk;

• Reward executives for achieving financial performance goals and creating shareholder value; and

• Reinforce our philosophy of pay for performance with opportunities to earn market competitive compensation.

<u>Tax Considerations</u> 

Section 162(m) of the Internal Revenue Code generally places a $1 million limit on the amount a publicly held Company

can deduct in any tax year on compensation paid to each "covered employee" which includes our NEOs. While the

Compensation Committee considers tax deductibility as one of many factors in determining executive compensation, the

Compensation Committee will award or modify compensation that it determines to be consistent with the goals of our

executive compensation program even if such compensation is not tax deductible by the Company.

We currently expect that we will continue to structure our executive compensation program consistent with our pay for

performance philosophy so that a significant portion of total executive compensation is linked to Sleep Number's

performance.

<u>Compensation Committee and Governance</u>

The Compensation Committee is comprised entirely of independent, non-employee Directors. The key responsibilities of

the Compensation Committee as outlined in its charter include:

• Review and approve the Company's compensation philosophy;

• Establish executive compensation structure and programs designed to motivate and reward superior Company

performance;

• Lead the Board of Directors' annual process to evaluate the performance of the CEO;

• Determine the composition and value of compensation for the CEO and other executive officers including base

salaries, annual cash incentive awards, long-term equity-based awards, benefits and perquisites;

• Establish, administer, amend and terminate executive compensation and major team member benefit programs;

• Periodically review the Company's succession and management development plans for the CEO and other executive

officers;

• Periodically review the Company's objectives and programs for talent management, including initiatives focused on

wellbeing and diversity, equity and inclusion;

• Assess management development progress and talent depth, organizational strategy and succession planning for key

leadership positions in the context of the Company's strategic, operational and financial growth objectives; and

• Establish structure and amount of non-employee Director compensation.

---

| | |
|:---|:---|
| **46 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

To the extent determined by the Compensation Committee, and subject to the requirements of applicable law, the

Compensation Committee may delegate duties and responsibilities to one or more members of the Compensation

Committee or others.

The Compensation Committee usually meets five to six times per year, in person or virtually to conduct normal committee

business. Our CEO and certain members of our management team and the Compensation Committee's independent

compensation consultant may be invited to attend all or a portion of a Committee meeting, depending on the nature of the

agenda. The Compensation Committee meets in executive session, as needed, without members of management

present. In addition to these normal meetings, in 2025 the Compensation Committee held several additional ad hoc

meetings relating to CEO succession planning.

Our CEO nor any other member of our management team votes on any matters before the Compensation

Committee. The Compensation Committee, however, solicits the views of our CEO on compensation matters, other than

her own, and particularly with respect to the compensation of members of the management team reporting to the

CEO. The Compensation Committee also solicits the views of other members of senior management and the Company's

Human Resources leaders on topics related to key compensation elements and broad-based team member benefit plans.

<u>Role of Independent Compensation Consultant</u>

Under its charter, the Compensation Committee has the authority to retain and consult with independent advisors to assist

in fulfilling their responsibilities and duties. To maintain the independence of these advisors, use by the Company of any of

these advisors for work other than that expressly commissioned by the Compensation Committee must be approved in

advance by the Compensation Committee.

Since fiscal 2013, the Compensation Committee has retained FW Cook as its independent compensation consultant. At

the Compensation Committee's request each year, FW Cook certifies that it continues to be an independent advisor and

discloses information in a letter to the Compensation Committee that demonstrates this independence. The Compensation

Committee assessed this certification and disclosure information and concluded that no conflict of interest or

independence concerns exist in the engagement of FW Cook as the Compensation Committee's independent

compensation consultant. In the course of its engagement, the independent compensation consultant:

• Provides on-going assessment of each of the principal elements of the Company's executive compensation program;

• Advises the Compensation Committee on the design of both the annual cash incentive plan and the long-term equity

incentive program;

• Works with the Compensation Committee and representatives of senior management to assess and refine the

Company's peer group for ongoing comparative analysis purposes;

• Provides the Compensation Committee with updates related to regulatory and legislative matters;

• Reviews market data, trends and analyses based on proxy data for our peers and other data sources to inform

executive compensation levels and design; and

• Provides advice and guidance to the Compensation Committee on pay actions for executives.

<u>CEO Assessment Process</u>

The Compensation Committee evaluates the CEO's performance by soliciting input from all members of the Board. The

Board also assesses the CEO's performance against objectives incorporating key strategic and operational factors,

including growth, profitability, innovation, advancement of strategic initiatives, leadership, organizational development,

integrity and stakeholder relations. The CEO performance feedback from all independent Board members is consolidated

into a report which is the basis of a full Board discussion in Executive Session led by the Chair of the Compensation

Committee. The Board's assessment of CEO performance is a major consideration in determining any compensation

adjustments for the coming year.

---

| | |
|:---|:---|
| **47 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<u>Compensation Risk Assessment</u>

Based on an annual risk assessment, the Company has determined that none of its compensation policies, practices or

programs is reasonably likely to have a material adverse effect on the Company. The results of this risk assessment were

shared with the Compensation Committee.

<u>Insider Trading Policy</u>

We have adopted an Insider Trading Policy that applies to our Directors, officers and all team members who have access

to material, nonpublic information regarding Sleep Number. As described in the policy, filed as Exhibit 19.1 to the

Company's Annual Report on Form 10-K filed on March 12, 2026, the policy is reasonably designed to promote

compliance with insider trading laws, rules and regulations, and Nasdaq listing standards.

<u>Grant of Certain Equity Awards</u>

Similar to 2024, in 2025 we adjusted our equity plan design for our executive officers in an effort to conserve shares

available under the plan. During the last completed fiscal year no options, SARs or similar option-like instruments were

awarded to our executive officers or any other team member. In the past when we have granted option awards, we

granted those options annually on March 15 which is generally within two weeks of when we publicly announce our

financial results for the fourth quarter and full fiscal year. Our interim equity grants during the year (for example, to newly

hired or promoted team members) occurs on the 15th of the month (or the next business day) following their hire or

promotion date.

<u>Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic</u> 

<u>Information</u> 

During fiscal 2025, we did not grant any stock options or similar awards as part of our equity compensation program. Our

fiscal 2025 equity compensation program for executive officers consisted of a mix of PSU and RSU awards. With respect

to the timing equity awards, it is our policy to make annual executive equity grants on March 15. Our practice with respect

to the timing of annual non-employee Director equity grants is the date of the Annual Meeting. If stock options or similar

awards are granted in the future, we intend to avoid granting stock options or similar awards in anticipation of the release

of material nonpublic information that is likely to result in changes to the price of our common stock, such as a significant

positive or negative earnings announcement, and not time the public release of such information based on stock option

grant dates. We have not intentionally timed any prior option, SARs or similar option-like equity awards to coincide with

the release of material non-public information.

<u>Grant Practices Specific to Stock Options</u>

We do not currently grant stock options as part of our equity compensation programs. If stock options were to be granted

in the future, the Company would not grant such options in anticipation of the release of material nonpublic information

that is likely to result in changes to the price of our common stock. In addition, we generally do not grant stock options at

any time during the four business days prior to or the one business day following the filing of our periodic reports or the

filing or furnishing of a Form 8-K that discloses material nonpublic information. These restrictions do not apply to RSUs,

PSUs, or other types of equity awards that do not include an exercise price related to the market price of our common

stock on the date of grant. During fiscal year 2025, (i) none of our NEOs were awarded stock options with an effective

grant date during any period beginning four business days before the filing or furnishing of a Form 10-Q, Form 10-K, or

Form 8-K that disclosed material nonpublic information, and ending one business day after the filing or furnishing of such

reports, and (ii) we did not time the disclosure of material nonpublic information for the purpose of affecting the value of

executive compensation.

<u>Stock Ownership Guidelines</u>

Encouraging stock ownership among our executive officers is critical in aligning their interests with those of our

shareholders. The Company has a stock ownership guideline policy in place for executive officers as well as for

---

| | |
|:---|:---|
| **48 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

Directors. Under the policy, all executive officers and non-employee Directors are expected to achieve the ownership

guideline within five years of first becoming an executive officer or being initially elected to the Board.

According to the policy, the stock ownership value for executive officers includes: (a) shares owned outright, (b) shares

held in the Profit Sharing and 401(k) Plan or the Executive Deferral Plan, (c) after-tax intrinsic value of vested and

outstanding stock options, and (d) after-tax value of outstanding PSUs (prorated to the extent that any year of the

performance period has been completed and the payout for that year is known). For non-employee Directors, the stock

ownership value includes: (a) shares owned outright, (b) shares deferred in lieu of Director fees, (c) shares deferred from

vested RSU awards, and (d) unvested and outstanding RSU awards.

Until the guideline is met, executive officers are required to hold 50% of the net shares from the vesting or payout of any

LTI grant or from the exercise of stock options. For non-employee Directors, they are not permitted to sell any shares

except to the extent required to pay the exercise price, transaction costs and taxes applicable to the exercise of stock

options or vesting of RSUs. As of the end of fiscal year 2025, the table below summarizes the current ownership levels

compared to the ownership guideline.

---

| | | |
|:---|:---|:---|
| | **Ownership Guideline** | **Current Ownership**<sup>(1)</sup> |
| CEO | 5 x annual base salary | **3.4 x** |
| Average of NEOs (other than CEO) | 3 x annual base salary | **1.0 x** |
| Average of Non-employee Directors | 5 x annual cash retainer | **4.9 x** |

---

<sup>(1)</sup> Current ownership as determined under the stock ownership guideline policy and based on a closing share price on January 3, 2026, of $8.59.

As the table shows, current ownership levels are below guidelines for NEOs. This is attributed to the decline in share price

in 2024 and 2025. Under our Stock Ownership Guidelines, the CEO has five years to meet the guidelines; Ms. Findley has

not yet met the five times ownership requirements due to her recent hire. Total shares owned outright by each NEO

increased in 2025 (not counting what is considered ownership for vested stock options or the earned portion of

outstanding PSUs).

---

| | |
|:---|:---|
| **49 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

**KEY TABLES AND GRAPHS**

**Summary Compensation Table**

The following table contains compensation information for the last three fiscal years relating to the NEOs. Note that the

AIP awards earned for each fiscal year are reported under the heading "Non-Equity Incentive Plan Compensation." The

values shown under the headings "Stock Awards" and "Option Awards" are the grant date fair values of the awards

received in each fiscal year. This does not represent what was earned or paid out for these awards due to performance.

The details of our NEOs' compensation are discussed in the Compensation Discussion and Analysis beginning on

page <u>[28](#i44eec75d700a4a12a1ccd8dcee0c79e2_178)</u>.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name**<br>**And Principal**<br>**Position**<br>| **Year** | **Salary**<br>**($)**<br>| **Bonus**<br>**($)**<br>| **Stock**<br>**Awards**<sup>(1)(2)</sup><br>**($)**<br>| **Option**<br>**Awards**<sup>(1)(3)</sup><br>**($)**<br>| **Non-**<br>**Equity**<br>**Incentive Plan** <br>**Compensation**<sup>(4)</sup><br>**($)**<br>| **All Other**<br>**Compensation**<sup>(5)</sup><br>**($)**<br>| **Total**<br>**($)**<br>|
| Linda A. Findley<br>President and CEO<sup>(6)</sup> | 2025 | $853846 | 1250000 | $4104519 | $— | $— | $25209 | $6233574 |
| Linda A. Findley<br>President and CEO<sup>(6)</sup> |  |  |  |  |  |  |  |  |
| Shelly R. Ibach<br>Former President and CEO<sup>(7)</sup> | 2025 | $530769 | $— | $— | $— | $— | $1115497 | $1646266 |
| Shelly R. Ibach<br>Former President and CEO<sup>(7)</sup> | 2024 | $1200000 | $— | $3357129 | $983001 | $1004640 | $38639 | $6583409 |
| Shelly R. Ibach<br>Former President and CEO<sup>(7)</sup> | 2023 | $1200000 | $— | $3444144 | $1165494 | $420000 | $119553 | $6349191 |
| Francis K. Lee<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Former EVP and CFO<sup>(8)</sup> | 2025 | $412740 | $— | $602583 | $— | $— | $1098834 | $2114157 |
| Francis K. Lee<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Former EVP and CFO<sup>(8)</sup> | 2024 | $629327 | $— | $656286 | $— | $263436 | $22298 | $1571347 |
| Francis K. Lee<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Former EVP and CFO<sup>(8)</sup> | 2023 | $228365 | $300000 | $1431245 | $1194801 | $— | $10488 | $3164899 |
| Robert P. Ryder<br>Former Interim CFO<sup>(9)</sup> | 2025 | $— | $— | $— | $— | $— | $1264562 | $1264562 |
| Robert P. Ryder<br>Former Interim CFO<sup>(9)</sup> |  |  |  |  |  |  |  |  |
| Amy K. O'Keefe<br>EVP and CFO<sup>(10)</sup> | 2025 | $24038 | $— | $570490 | $— | $— | $60 | $594588 |
| Amy K. O'Keefe<br>EVP and CFO<sup>(10)</sup> |  |  |  |  |  |  |  |  |
| Andrea Bloomquist<br>Former EVP and Chief <br>Innovation Officer<sup>(11)</sup> | 2025 | $275714 | $— | $547797 | $— | $— | $1085369 | $1908880 |
| Andrea Bloomquist<br>Former EVP and Chief <br>Innovation Officer<sup>(11)</sup> | 2024 | $618130 | $— | $546910 | $— | $258749 | $18201 | $1441990 |
| Andrea Bloomquist<br>Former EVP and Chief <br>Innovation Officer<sup>(11)</sup> | 2023 | $599712 | $— | $823038 | $278483 | $103783 | $18468 | $1823484 |
| Kevin K. Brown<br>Former EVP and Chief <br>Marketing Officer<sup>(12)</sup><br>| 2025 | $171994 | $— | $369762 | $— | $— | $937306 | $1479062 |
| Melissa Barra<br>EVP and Chief Sales and <br>Services Officer | 2025 | $614482 | $— | $547797 | $— | $— | $30032 | $1192311 |
| Melissa Barra<br>EVP and Chief Sales and <br>Services Officer | 2024 | $608530 | $— | $546910 | $— | $254731 | $26240 | $1436411 |
| Melissa Barra<br>EVP and Chief Sales and <br>Services Officer | 2023 | $589858 | $— | $823038 | $278483 | $102301 | $24889 | $1818569 |
| Samuel R. Hellfeld<br>EVP and Chief Legal and <br>Risk Officer<sup>(13)</sup> | 2025 | $568975 | $150000 | $451933 | $— | $— | $20407 | $1191315 |
| Samuel R. Hellfeld<br>EVP and Chief Legal and <br>Risk Officer<sup>(13)</sup> | 2024 | $542265 | $— | $519552 | $— | $226992 | $19484 | $1308293 |
| Samuel R. Hellfeld<br>EVP and Chief Legal and <br>Risk Officer<sup>(13)</sup> | 2023 | $519231 | $— | $685817 | $232112 | $89856 | $20243 | $1547259 |
| Christopher D. Krusmark<br>EVP and Chief Retail and <br>People Officer | 2025 | $482477 | $— | $301299 | $— | $— | $23239 | $807015 |
| Christopher D. Krusmark<br>EVP and Chief Retail and <br>People Officer | 2024 | $443107 | $— | $300799 | $— | $185485 | $19969 | $949360 |
| Christopher D. Krusmark<br>EVP and Chief Retail and <br>People Officer | 2023 | $425192 | $70000 | $590343 | $149579 | $73742 | $17014 | $1325870 |

---

<sup>(1)</sup> Reflects the aggregate grant date fair value of equity awards granted or modified during fiscal years 2025, 2024 and 2023, computed in accordance

with FASB ASC Topic 718. See Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended

January 3, 2026, for a discussion of the relevant assumptions used in calculating these amounts.

<sup>(2)</sup> The "Stock Awards" column includes Performance Stock Unit (PSU) and Restricted Stock Unit (RSU) awards granted during fiscal years 2025, 2024

and 2023. The amounts included for PSU awards represent the grant date fair value assuming the achievement of the performance goals for a target

payout. If the PSU awards granted during fiscal year 2025 had been calculated assuming that the maximum payout had been earned, the grant date

fair value of these PSU awards would have been as follows: for Ms. Findley, $1,944,241 (target of $972,120); for Mr. Lee, $619,708 (target of

$309,854); for Ms. Bloomquist, $563,365 (target of $281,683); for Mr. Brown, $380,271 (target of $190,135); for Ms. Barra, $563,365 (target of

$281,683); for Mr. Hellfeld, $464,777 (target of $232,389) and for Mr. Krusmark, $309,862 (target of $154,931). Also included in this column is the

grant date fair value of RSU awards granted during fiscal year 2025, as disclosed in the "Grants of Plan-Based Awards" table.

<sup>(3)</sup> No new stock option awards were granted in fiscal year 2025.

<sup>(4)</sup> Represents annual incentive compensation earned under the AIP. See the discussion in the Compensation Discussion and Analysis under the heading

"Annual Incentive Plan (AIP)" on page <u>[35](#i44eec75d700a4a12a1ccd8dcee0c79e2_211)</u>.

---

| | |
|:---|:---|
| **50 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<sup>(5)</sup> The all other compensation amounts for fiscal 2025 included the following:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Severance** | **Consulting** | **Life Insurance** <br>**Premiums**<br>| **Company** <br>**Matching** <br>**Contributions** <br>**to 401(k) Plan**<br>| **Perquisites**<sup>(a)</sup> | **Security Costs** | **Total** |
| Linda Findley | $— | $— | $1715 | $5538 | $17956 | $— | $25209 |
| Shelly Ibach | $— | $1050000 | $4220 | $14000 | $21703 | $25574 | $1115497 |
| Francis Lee | $1073125 | $— | $989 | $14000 | $10720 | $— | $1098834 |
| Robert Ryder | $— | $1264562 | $— | $— | $— | $— | $1264562 |
| Amy O'Keefe | $— | $— | $— | $— | $60 | $— | $60 |
| Andrea Bloomquist | $1059702 | $— | $1367 | $14000 | $10300 | $— | $1085369 |
| Kevin Brown | $915919 | $— | $873 | $14000 | $6514 | $— | $937306 |
| Melissa Barra  | $— | $— | $1559 | $14000 | $14473 | $— | $30032 |
| Samuel Hellfeld | $— | $— | $935 | $14000 | $5472 | $— | $20407 |
| Christopher Krusmark | $— | $— | $779 | $14000 | $7200 | $— | $21979 |

---

<sup>(a)</sup>Amounts reported represent Company paid amounts for tax preparation and financial planning expenses, executive physical expenses, technology

allowance expenses and incremental travel costs paid by the Company for spouses of our executive officers in connection with certain off-site,

business related travel.

<sup>(6)</sup> Ms. Findley assumed the role of President and Chief Executive Officer on April 7, 2025.

<sup>(7)</sup> Ms. Ibach role as President and Chief Executive Officer ended on April 6, 2025, but remained in a non-executive management role through May 31,

2025. Ms. Ibach continued to serve as a non-employee strategic consultant to the Company through December 31, 2025.

<sup>(8)</sup> Mr. Lee assumed the role of Executive Vice President and Chief Financial Officer on August 14, 2023. Mr. Lee departed as Chief Financial Officer

effective July 21, 2025, but continued to serve in an advisory role to the Company through August 15, 2025.

<sup>(9)</sup> Mr. Ryder assumed the role of Interim Chief Financial Officer from July 21, 2025 through December 8, 2025, but continued to serve in an advisory role

to the Company through December 12, 2025.

<sup>(10)</sup> Ms. O'Keefe assumed the role of Executive Vice President and Chief Financial Officer on December 8, 2025.

<sup>(11)</sup> Ms. Bloomquist departed as Executive Vice President and Chief Innovation Officer on May 31, 2025.

<sup>(12)</sup> Mr. Brown was not an NEO in 2023 or 2024 and departed as Executive Vice President and Chief Marketing Officer on April 16, 2025.

<sup>(13)</sup> Mr. Hellfeld received a discretionary bonus of $150,000 in fiscal year 2025.

---

| | |
|:---|:---|
| **51 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

**Grants of Plan-Based Awards**

The following table summarizes for each of the NEOs the non-equity incentive award opportunity under the AIP for fiscal

year 2025 and the equity awards made during the fiscal year 2025.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Estimated Future Payouts**<br>**Under Non-Equity Incentive**<br>**Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts**<br>**Under Non-Equity Incentive**<br>**Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts**<br>**Under Non-Equity Incentive**<br>**Plan Awards**<sup>(1)</sup> | **Estimated Future Payouts**<br>**Under Equity Incentive**<br>**Plan Awards** | **Estimated Future Payouts**<br>**Under Equity Incentive**<br>**Plan Awards** | **Estimated Future Payouts**<br>**Under Equity Incentive**<br>**Plan Awards** | **All**<br>**Other**<br>**Stock**<br>**Awards:**<br>**Number**<br>**of Shares**<br>**of Stock**<br>**or Units**<br>**(#)** | **All**<br>**Other**<br>**Option**<br>**Awards:**<br>**Number**<br>**of**<br>**Securities**<br>**Under-**<br>**lying**<br>**Options**<br>**(#)** | **Exercise**<br>**or Base**<br>**Price of**<br>**Option**<br>**Awards**<br>**($/Sh)** | **Grant**<br>**Date**<br>**Fair**<br>**Value of**<br>**Stock and**<br>**Option**<br>**Awards**<br>**($)**<sup>(7)</sup> |
| **Name** | **Thresh-**<br>**old**<br>**($)**<br>| **Target**<br>**($)**<br>| **Maxi-**<br>**mum**<br>**($)**<br>| **Thresh-**<br>**old**<br>**(#)**<br>| **Target**<br>**(#)**<br>| **Maxi-**<br>**mum**<br>**(#)**<br>| **All**<br>**Other**<br>**Stock**<br>**Awards:**<br>**Number**<br>**of Shares**<br>**of Stock**<br>**or Units**<br>**(#)** | **All**<br>**Other**<br>**Option**<br>**Awards:**<br>**Number**<br>**of**<br>**Securities**<br>**Under-**<br>**lying**<br>**Options**<br>**(#)** | **Exercise**<br>**or Base**<br>**Price of**<br>**Option**<br>**Awards**<br>**($/Sh)** | **Grant**<br>**Date**<br>**Fair**<br>**Value of**<br>**Stock and**<br>**Option**<br>**Awards**<br>**($)**<sup>(7)</sup> |
| Linda <br>Findley | $375000 | $1500000 | $3000000 |  |  |  |  |  |  |  |
| Linda <br>Findley<br>4/15/25<sup>(2)</sup> |  |  |  | 15080 | 181028 | 362056 |  |  |  | $972120 |
| Linda <br>Findley<br>4/15/25<sup>(3)</sup> |  |  |  |  |  |  | 181029 |  |  | $917817 |
| Linda <br>Findley<br>4/15/25<sup>(4)</sup> |  |  |  |  |  |  | 362057 |  |  | $2214582 |
| Francis<br>Lee | $110469 | $441875 | $883750 |  |  |  |  |  |  |  |
| Francis<br>Lee<br>3/15/25<sup>(5)</sup> |  |  |  | 3318 | 39827 | 79654 |  |  |  | $309854 |
| Francis<br>Lee<br>3/15/25<sup>(6)</sup> |  |  |  |  |  |  | 39827 |  |  | $292728 |
| Amy | $— | $— | $— |  |  |  |  |  |  |  |
| O'Keefe<br>12/15/25<sup>(8)</sup> |  |  |  |  |  |  | 69742 |  |  | $221802 |
| Andrea <br>Bloomquist | $109087 | $436348 | $872696 |  |  |  |  |  |  |  |
| Andrea <br>Bloomquist<br>3/15/25<sup>(5)</sup> |  |  |  | 3016 | 36206 | 72412 |  |  |  | $281683 |
| Andrea <br>Bloomquist<br>3/15/25<sup>(6)</sup> |  |  |  |  |  |  | 36206 |  |  | $266144 |
| Kevin<br>Brown | $94286 | $337143 | $754286 |  |  |  |  |  |  |  |
| Kevin<br>Brown<br>3/15/25<sup>(5)</sup> |  |  |  | 2036 | 24439 | 48878 |  |  |  | $190135 |
| Kevin<br>Brown<br>3/15/25<sup>(6)</sup> |  |  |  |  |  |  | 24439 |  |  | $179627 |
| Melissa <br>Barra | $107534 | $430137 | $860275 |  |  |  |  |  |  |  |
| Melissa <br>Barra<br>3/15/25<sup>(5)</sup> |  |  |  | 3016 | 36206 | 72412 |  |  |  | $281683 |
| Melissa <br>Barra<br>3/15/25<sup>(6)</sup> |  |  |  |  |  |  | 36206 |  |  | $266114 |
| Samuel <br>Hellfeld | $101051 | $404205 | $808409 |  |  |  |  |  |  |  |
| Samuel <br>Hellfeld<br>3/15/25<sup>(5)</sup> |  |  |  | 2488 | 29870 | 59740 |  |  |  | $232389 |
| Samuel <br>Hellfeld<br>3/15/25<sup>(6)</sup> |  |  |  |  |  |  | 29870 |  |  | $219545 |
| Christopher <br>Krusmark | $87500 | $350000 | $700000 |  |  |  |  |  |  |  |
| Christopher <br>Krusmark<br>3/15/25<sup>(5)</sup> |  |  |  | 1659 | 19914 | 39828 |  |  |  | $154931 |
| Christopher <br>Krusmark<br>3/15/25<sup>(6)</sup> |  |  |  |  |  |  | 19914 |  |  | $146368 |

---

<sup>(1)</sup> This represents the cash annual incentive opportunity for 2025 under the AIP. The actual amounts earned under this plan for 2025 are reported in the

Non-Equity Incentive Plan Compensation column of the Summary Compensation Table. If the minimum performance level for payment of the

threshold amount is not achieved, then no incentive would be payable under the plan. The performance level for payment of the maximum amount

requires maximum EBITDA performance. See discussion in the Compensation Discussion and Analysis under the heading "Annual Incentive Plan

(AIP)" on page <u>[35](#i44eec75d700a4a12a1ccd8dcee0c79e2_211)</u>.

<sup>(2)</sup> This represents an inducement PSU award Ms. Findley received upon hire and is described in greater detail in the Compensation Discussion and

Analysis under the heading, "Long-Term Incentive Plan (LTI)." The target number of PSUs will be adjusted based on Company performance against

annual growth goals over a three-year performance period covering fiscal years 2025, 2026 and 2027. The PSUs are also subject to a relative total

shareholder return modifier covering the full three-year performance cycle, which may increase or decrease actual payouts under the PSUs by plus or

minus 20%. PSUs are also subject to a three-year vesting requirement from the grant date. If any dividends are paid on our common stock, the

holders of the PSUs would receive dividends at the same rate as paid to other shareholders if and when the PSU award is earned and becomes fully

vested.

<sup>(3)</sup> This represents an inducement RSU award Ms. Findley received upon hire and is described in greater detail in the Compensation Discussion and

Analysis under the heading, "Long-Term Incentive Plan (LTI)." These RSUs vest one-third each year on each of the first three anniversaries of the date

of grant, subject to continuing employment through the applicable vesting date.

<sup>(4)</sup> This represents an inducement RSU award Ms. Findley received upon hire. These RSUs vest one-third each year on each of first three anniversaries

of the data of grant, with a stock performance modifier, subject to continuing employment through the applicable vesting date.

<sup>(5)</sup> This represents PSU awards described in greater detail in the Compensation Discussion and Analysis under the heading, "Long-Term Incentive Plan

(LTI)." The target number of PSUs will be adjusted based on Company performance against annual growth goals over a three-year performance

period covering fiscal years 2025, 2026 and 2027. The PSUs are also subject to a relative total shareholder return modifier covering the full three-year

performance cycle, which may increase or decrease actual payouts under the PSUs by plus or minus 20%. PSUs are also subject to a three-year

vesting requirement from the grant date. If any dividends are paid on our common stock, the holders of the PSUs would receive dividends at the same

rate as paid to other shareholders if and when the PSU award is earned and becomes fully vested.

<sup>(6)</sup> This represents RSU awards described in greater detail in the Compensation Discussion and Analysis under the heading, "Long-Term Incentive Plan

(LTI)." These RSUs vest one-third each year on each of the first three anniversaries of the date of grant, subject to continuing employment through the

applicable vesting date.

---

| | |
|:---|:---|
| **52 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<sup>(7)</sup> Reflects the grant date fair value computed in accordance with FASB ASC Topic 718. The value for the March 15, 2025 PSU awards reflects the target

award value.

<sup>(8)</sup> This represents an inducement RSU award for Ms. O'Keefe for appoint to role of Executive Vice President and Chief Financial Officer on December 8,

2025. These RSUs vest one-third each year on each of the first three anniversaries of the date of grant, subject to continuing employment through the

applicable vesting date.

**Outstanding Equity Awards at Fiscal Year-End**

The following table summarizes the total outstanding equity awards for each of the NEOs as of January 3, 2026.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Number of** <br>**Securities** <br>**Underlying** <br>**Unexercised** <br>**Options**<br>**(#)** <br>**Exercisable**<br>| **Number of** <br>**Securities** <br>**Underlying** <br>**Unexercised** <br>**Options (#)** <br>**Unexercisable**<br>| **Option** <br>**Exercise** <br>**Price**<br>**($)**<br>| **Option** <br>**Expiration** <br>**Date**<br>| **Number of** <br>**Shares or** <br>**Units of** <br>**Stock That** <br>**Have Not** <br>**Vested**<br>**(#)**<br>| **Market** <br>**Value of** <br>**Shares or** <br>**Units of** <br>**Stock That** <br>**Have Not** <br>**Vested**<br>**($)**<sup>(9)</sup><br>| **Equity** <br>**Incentive** <br>**Plan** <br>**Awards:** <br>**Number of** <br>**Unearned** <br>**Shares,** <br>**Units or** <br>**Other Rights** <br>**That Have** <br>**Not Vested**<br>**(#)**<br>| **Equity** <br>**Incentive** <br>**Plan** <br>**Awards:** <br>**Market or** <br>**Payout** <br>**Value of** <br>**Unearned** <br>**Shares,** <br>**Units or** <br>**Other Rights** <br>**That Have** <br>**Not Vested**<br>**($)**<sup>(9)</sup><br>|
| Linda Findley |  |  |  |  | 362057<sup>(1)</sup> | $3110070 |  |  |
|  |  |  |  |  | 181029<sup>(2)</sup> | $1555039 |  |  |
|  |  |  |  |  |  |  | 181028<sup>(3)</sup> | $1555039 |
| Shelly Ibach | 36575 |  | $18.81 | 3/22/2026 |  |  |  |  |
|  | 53720 |  | $23.61 | 3/21/2027 |  |  |  |  |
|  | 51095 |  | $34.35 | 3/21/2028 |  |  |  |  |
|  | 40405 |  | $47.00 | 5/28/2028 |  |  |  |  |
|  | 10045 |  | $43.91 | 5/28/2028 |  |  |  |  |
|  | 67325 |  | $35.68 | 5/28/2028 |  |  |  |  |
|  | 21880 |  | $146.97 | 5/28/2028 |  |  |  |  |
|  | 40550 |  | $61.66 | 5/28/2028 |  |  |  |  |
|  | 4340 |  | $41.95 | 5/28/2028 |  |  |  |  |
|  | 68490 |  | $28.41 | 5/28/2028 |  |  |  |  |
|  |  |  |  |  |  |  | 90946<sup>(4)</sup> | $781226 |
| Amy O'Keefe |  |  |  |  | 69742<sup>(8)</sup> | $599084 |  |  |
| Andrea Bloomquist | 4346 |  | $47.00 | 5/31/2026 |  |  |  |  |
|  | 10260 |  | $35.68 | 5/31/2026 |  |  |  |  |
|  | 3585 |  | $146.97 | 5/31/2026 |  |  |  |  |
|  | 8110 |  | $61.66 | 5/31/2026 |  |  |  |  |
|  | 12065 |  | $28.41 | 5/31/2026 |  |  |  |  |
|  |  |  |  |  |  |  | 8158<sup>(4)</sup> | $70077 |
|  |  |  |  |  |  |  | 2541<sup>(3)</sup> | $21827 |
| Kevin Brown | 7665 |  | $34.35 | 4/16/2026 |  |  |  |  |
|  | 5870 |  | $47.00 | 4/16/2026 |  |  |  |  |
|  | 8980 |  | $35.68 | 4/16/2026 |  |  |  |  |
|  | 2645 |  | $146.97 | 4/16/2026 |  |  |  |  |
|  | 6180 |  | $61.66 | 4/16/2026 |  |  |  |  |
|  | 7595 |  | $28.41 | 4/16/2026 |  |  |  |  |
|  |  |  |  |  |  |  | 4946<sup>(4)</sup> | $42486 |
|  |  |  |  |  |  |  | 713<sup>(3)</sup> | $6125 |

---

---

| | |
|:---|:---|
| **53 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Number of** <br>**Securities** <br>**Underlying** <br>**Unexercised** <br>**Options**<br>**(#)** <br>**Exercisable**<br>| **Number of** <br>**Securities** <br>**Underlying** <br>**Unexercised** <br>**Options (#)** <br>**Unexercisable**<br>| **Option** <br>**Exercise** <br>**Price**<br>**($)**<br>| **Option** <br>**Expiration** <br>**Date**<br>| **Number of** <br>**Shares or** <br>**Units of** <br>**Stock That** <br>**Have Not** <br>**Vested**<br>**(#)**<br>| **Market** <br>**Value of** <br>**Shares or** <br>**Units of** <br>**Stock That** <br>**Have Not** <br>**Vested**<br>**($)**<sup>(9)</sup><br>| **Equity** <br>**Incentive** <br>**Plan** <br>**Awards:** <br>**Number of** <br>**Unearned** <br>**Shares,** <br>**Units or** <br>**Other Rights** <br>**That Have** <br>**Not Vested**<br>**(#)**<br>| **Equity** <br>**Incentive** <br>**Plan** <br>**Awards:** <br>**Market or** <br>**Payout** <br>**Value of** <br>**Unearned** <br>**Shares,** <br>**Units or** <br>**Other Rights** <br>**That Have** <br>**Not Vested**<br>**($)**<sup>(9)</sup><br>|
| Melissa Barra | 2128 |  | $34.35 | 3/21/2028 |  |  |  |  |
|  | 4563 |  | $47.00 | 3/29/2029 |  |  |  |  |
|  | 9940 |  | $35.68 | 3/15/2030 |  |  |  |  |
|  | 3490 |  | $146.97 | 3/15/2031 |  |  |  |  |
|  | 8110 |  | $61.66 | 3/15/2032 |  |  |  |  |
|  | 10910 | 5455<sup>(5)</sup> | $28.41 | 3/15/2033 |  |  |  |  |
|  |  |  |  |  | 13474<sup>(6)</sup> | $115742 |  |  |
|  |  |  |  |  |  |  | 20211<sup>(4)</sup> | $173612 |
|  |  |  |  |  | 36206<sup>(7)</sup> | $311010 |  |  |
|  |  |  |  |  |  |  | 36206<sup>(3)</sup> | $311010 |
| Samuel Hellfeld | 2615 |  | $18.81 | 3/22/2026 |  |  |  |  |
|  | 1955 |  | $23.61 | 3/21/2027 |  |  |  |  |
|  | 1535 |  | $34.35 | 3/21/2028 |  |  |  |  |
|  | 3420 |  | $36.81 | 9/20/2028 |  |  |  |  |
|  | 4565 |  | $47.00 | 3/29/2029 |  |  |  |  |
|  | 5130 |  | $35.68 | 3/15/2030 |  |  |  |  |
|  | 2265 |  | $146.97 | 3/15/2031 |  |  |  |  |
|  | 6180 |  | $61.66 | 3/15/2032 |  |  |  |  |
|  | 9093 | 4547<sup>(5)</sup> | $28.41 | 3/15/2033 |  |  |  |  |
|  |  |  |  |  | 14484<sup>(6)</sup> | $124418 |  |  |
|  |  |  |  |  |  |  | 16674<sup>(4)</sup> | $143230 |
|  |  |  |  |  | 29870<sup>(7)</sup> | $256583 |  |  |
|  |  |  |  |  |  |  | 28870<sup>(3)</sup> | $247993 |
| Christopher Krusmark | 1630 |  | 47.00 | 3/29/2029 |  |  |  |  |
|  | 3850 |  | 35.68 | 3/15/2030 |  |  |  |  |
|  | 2075 |  | 146.97 | 3/15/2031 |  |  |  |  |
|  | 5025 |  | 61.66 | 3/15/2032 |  |  |  |  |
|  | 5860 | 2.930<sup>(5)</sup> | 28.41 | 3/15/2033 |  |  |  |  |
|  |  |  |  |  | 7410<sup>6)</sup> | $63652 |  |  |
|  |  |  |  |  |  |  | 11116<sup>(4)</sup> | $95486 |
|  |  |  |  |  | 19914<sup>(7)</sup> | $171061 |  |  |
|  |  |  |  |  |  |  | 19914<sup>(3)</sup> | $171061 |

---

<sup>(1)</sup> These RSU awards were granted on April 15, 2025 with a stock performance modifier and vest one-third each year on each of the first three

anniversaries of the date of grant, subject to continuing employment through the applicable vesting date.

<sup>(2)</sup> These RSU awards were granted on April 15, 2025 and vest one-third each year on each of the first three anniversaries of the date of grant, subject to

continuing employment through the applicable vesting date.

<sup>(3)</sup> These PSU awards were granted on March 15, 2025 and will become vested on March 15, 2028, subject to achieving performance criteria, total

shareholder return modifier and continuing employment through the vesting date. The number of shares shown above reflects the target award

level. The performance period for this award covers fiscal years 2025, 2026 and 2027.

<sup>(4)</sup> These PSU awards were granted on March 15, 2024 and will become vested on March 15, 2027, subject to achieving performance criteria and

continuing employment through the vesting date. The number of shares shown above reflects the target award level. The performance period for this

award covers fiscal years 2024, 2025 and 2026.

<sup>(5)</sup> These stock options were granted on March 15, 2023 and vest one-third each year on each of the first three anniversaries of the date of grant, subject

to continuing employment through the applicable vesting date.

<sup>(6)</sup> These RSU awards were granted on March 15, 2024 and vest one-third each year on the first three anniversaries of the date of grant, subject to

continuing employment through the applicable vesting date.

<sup>(7)</sup> These RSU awards were granted on March 15, 2025 and vest one-third each year on the first three anniversaries of the date of grant, subject to

continuing employment through the applicable vesting date.

---

| | |
|:---|:---|
| **54 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<sup>(8)</sup> These RSU awards were granted on December 15, 2025 and vest one-third each year on the first three anniversaries of the date of grant, subject to

continuing employment through the applicable vesting date.

<sup>(9)</sup> Calculated by multiplying unvested stock awards by $8.59, the closing price of the Company's common stock on the Nasdaq Stock Market on January

2, 2026, the last trading day of fiscal year 2025.

**Option Exercises and Stock Vested**

The following table summarizes the stock options that were exercised and the stock awards that became vested for each

of the NEOs during the fiscal year ended January 3, 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Number of**<br>**Shares Acquired**<br>**on Exercise**<br>**(#)**<br>| **Value Realized**<br>**on Exercise**<br>**($)**<sup>(1)</sup><br>| **Number of**<br>**Shares Acquired**<br>**on Vesting**<br>**(#)**<br>| **Value**<br>**Realized**<br>**on Vesting**<br>**($)**<sup>(9)</sup><br>|
| Linda Findley |  |  |  | $— |
| Shelly Ibach |  |  | 178955<sup>(2)</sup> | $1518547 |
| Francis Lee |  |  | 16315<sup>(3)</sup> | $147321 |
| Rob Ryder |  |  |  |  |
| Amy O'Keefe |  |  |  |  |
| Andrea Bloomquist |  |  | 10702<sup>(4)</sup> | $92180 |
| Kevin Brown |  |  | 5660<sup>(5)</sup> | $39066 |
| Melissa Barra |  |  | 6737<sup>(6)</sup> | $49517 |
| Samuel Hellfeld |  |  | 9562<sup>(7)</sup> | $70281 |
| Christopher Krusmark |  |  | 8934<sup>(8)</sup> | $72586 |

---

<sup>(1)</sup> The value realized on the exercise of stock options for purposes of this table is based on the difference between the fair market value of our common

stock on the date of exercise and the exercise price of the stock option.

<sup>(2)</sup> The amount shown represents the vesting of RSU awards granted on March 15, 2024, which vested 30,316 shares on March 15, 2025 and 60,630

shares on May 31, 2025. In addition, 88,009 shares related to a PSU award granted on March 21, 2018 vested on March 21, 2025. This PSU was

previously deferred for four years after the original vest date.

<sup>(3)</sup> The amount shown represents the vesting of RSU awards granted March 15, 2024, which vested 8,085 shares on March 15, 2025; and RSU awards

granted August 15, 2023, which vested 8,230 shares on August 15, 2025.

<sup>(4)</sup> The amount shown represents the vesting of RSU awards granted March 15, 2024, which vested 6,737 shares on March 15, 2025 and 1,421 shares

on May 31, 2025; and RSU awards granted March 15, 2025, which vested 2,544 shares on May 31, 2025.

<sup>(5)</sup> The amount shown represents the vesting of RSU awards granted March 15, 2024, which vested 4,548 shares on March 15, 2025 and 398 shares on

April 16, 2025; and RSU awards granted March 15, 2025, which vested 714 shares on April 16, 2025.

<sup>(6)</sup> The amount shown represents the vesting of RSU awards granted March 15, 2024, which vested 6,737 shares on March 15, 2025.

<sup>(7)</sup> The amount shown represents the vesting of RSU awards granted March 15, 2022, which vested 2,320 shares on March 15, 2025; and RSU awards

granted March 15, 2024, which vested 7,242 shares on March 15, 2025.

<sup>(8)</sup> The amount shown represents the vesting of RSU awards granted March 15, 2022, which vested 2,320 shares on March 15, 2025; RSU granted

March 15, 2024, which vested 3,706 shares on March 15, 2025; and RSU awards granted September 5, 2023, which vested 2,908 shares on

September 5, 2025.

<sup>(9)</sup> The value realized for purposes of this table is based on the fair market value of our common stock on the date of vesting.

**Non-Qualified Deferred Compensation**

NEOs are eligible to participate in the Sleep Number Executive Deferral Plan (Deferral Plan), a non-qualified deferred

compensation plan. The Deferral Plan allows executives to defer payment of up to 50% of their base salary, 75% of their

AIP payout and 100% of their payout from PSUs or other stock awards. At the time that executives make their deferral

election, they choose whether their deferrals will be paid out in a lump sum or up to ten annual installments following a

specified future date or their termination of employment. For salary or AIP deferrals, executives choose how to allocate

their deferrals across a range of notional investment alternatives that are similar to the investment fund options in the

Company's 401(k) Plan. The executive's deferral account is credited with the earnings as if there was a deemed

investment in the notional investment alternatives offered for the Deferral Plan. For deferrals of PSUs or other stock

awards, the amounts deferred are tracked in deferred share units and distributions are settled in shares of common stock.

The following table summarizes for each NEO their contributions, earnings and balance for the Deferral Plan for the fiscal

year ended January 3, 2026. Note that the Company does not make any contributions to the Deferral Plan on behalf of

participants.

---

| | |
|:---|:---|
| **55 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Executive** <br>**Contributions in** <br>**Last Fiscal Year**<br>**($)**<br>| **Registrant** <br>**Contributions in** <br>**Last Fiscal Year**<br>**($)**<br>| **Aggregate** <br>**Earnings** <br>**(Losses) in Last** <br>**Fiscal Year**<sup>(1)</sup><br>**($)**<br>| **Aggregate** <br>**Withdrawals/**<br>**Distributions**<br>**($)**<br>| **Aggregate** <br>**Balance at Last** <br>**Fiscal Year-**<br>**End**<sup>(2)</sup><br>**($)**<br>|
| Linda Findley | $— | $— | $— | $— | $— |
| Shelly Ibach | $— | $— | $502142 | $(1734800) | $10021204 |
| Amy O'Keefe | $— | $— | $— | $— | $— |
| Francis Lee | $— | $— | $— | $— | $— |
| Andrea Bloomquist | $— | $— | $(185) | $(344986) | $— |
| Kevin Brown | $— | $— | $— | $— | $— |
| Melissa Barra  | $— | $— | $— | $— | $— |
| Samuel Hellfeld | $— | $— | $— | $— | $— |
| Christopher Krusmark | $— | $— | $— | $— | $— |

---

<sup>(1)</sup> These amounts represent the total aggregate notional earnings for fiscal year 2025 for the executive's deferral account under the Deferral Plan. These

are notional earnings based on how the executive has elected to direct their salary or AIP deferrals to various investment alternatives, and the actual

market return of that investment alternative for the year. For PSU deferrals, earnings represent the change in market value of the deferred share units

held in the executive's deferral account.

<sup>(2)</sup> This is the aggregate market value of the executive's deferral account under the Deferral Plan as of the end of fiscal year 2025.

**Potential Payments Upon Termination or Change in Control**

This section describes the potential payments that would be made to the NEOs under various employment termination

scenarios as if they occurred at the end of fiscal year 2025 (as of January 3, 2026). The values shown in the table are

calculated as of this date based on certain estimates or assumptions as described in the footnotes. The actual amounts

received may differ materially from those shown in the table. The table does not include amounts already vested that the

executive would receive if he or she left the Company for any reason, such as the fully vested balance of an executive's

deferral account, gains from outstanding options that are exercisable, or payments and benefits that are provided on a

non-discriminatory basis to salaried team members generally upon termination.

All Sleep Number team members, including all executive officers, are "at will" team members, meaning that the team

member or the Company may terminate the employment relationship with or without cause and with or without notice, at

any time at the option of either the team member or the Company. Executive officers do not have employment

agreements and do not have any contractual or other right to employment for any term or period of time. In addition,

executive officers are only eligible for the severance pay and other benefits as provided under the Company's Executive

Severance Pay Plan as shown in the table and described in the footnotes.

The table below shows information about the acceleration of option or stock awards in the event of a change in control as

defined under the Company's 2020 Equity Incentive Plan, as amended (the 2020 Plan). The 2020 Plan contains a

"double-trigger" change in control provision. Under this provision, if outstanding option or stock awards are assumed or

substituted following a change in control, vesting of the option or stock awards is only accelerated in the event of

involuntary termination not for cause or resignation for good reason of the team member, as those terms are defined

under the 2020 Plan. This is provided that the team member's termination of employment occurs within two years of the

change in control.

Vesting of stock option, PSU and RSU awards may also be accelerated in the event a NEO qualifies for retirement

treatment under the terms of the award agreements and the 2020 Plan. If an executive is at least age 55 and has five or

more years of service at retirement, the vesting will be accelerated on a pro-rata portion of their option or stock award

based on the portion of the vesting period that was actually worked through the date of retirement. If an executive is at

least age 60 and has five or more years of service at retirement, there is a full acceleration of vesting of stock option or

PSU awards provided that the executive gives a one-year notice of their intention to retire for awards granted prior to

2024, and a three month notice of their intention to retire for awards granted in 2024; there is not full acceleration of

vesting for RSU awards.

---

| | |
|:---|:---|
| **56 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

Pursuant to applicable SEC regulations, since Ms. Ibach, Mr. Lee, Ms. Bloomquist and Mr. Brown separated from the

Company prior to December 31, 2025, the table below shows potential payments to them only under the actual triggering

event that occurred in connection with their departures and does not include the other potential triggering events that were

no longer a possibility as of December 31, 2025.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Triggering Events** | **Triggering Events** | **Triggering Events** | **Triggering Events** | **Triggering Events** |
| <br>**Name** | <br>**Type of Payment** | **Voluntary**<br>**Termination**<br>**($)**<br>| **For Cause**<br>**Termination**<br>**($)**<br>| **Involuntary**<br>**Termination**<br>**(No Change in**<br>**Control)**<br>**($)**<br>| **Involuntary**<br>**Termination**<br>**(Following**<br>**Change in**<br>**Control)**<sup>(1)</sup><br> **($)**<br>| **Death or**<br>**Disability**<br>**($)**<br>|
| Linda Findley | Cash Severance<sup>(2)</sup> |  |  | $5418000 | $8118000 |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(4)</sup> |  |  |  | $6220139 | $6220139 |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $29297 | $29297 |  |
|  | Total | $— |  | $5447297 | $14367436 | $6220139 |
| Shelly Ibach<sup>(6)</sup> | Cash Severance<sup>(2)</sup> |  |  |  |  |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(6)</sup> | $1305091 |  |  |  |  |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  |  |  |  |
|  | Total | $1305091 |  |  |  |  |
| Francis Lee<sup>(6)</sup> | Cash Severance<sup>(2)</sup> |  |  | $1073125 |  |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(6)</sup> |  |  |  |  |  |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $19093 |  |  |
|  | Total |  |  | $1092218 |  |  |
| Amy O'Keefe | Cash Severance<sup>(2)</sup> |  |  | $1075000 | $2137500 |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(4)</sup> |  |  |  | $599084 | $599084 |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $7507 | $7507 |  |
|  | Total |  |  | $1082507 | $2744091 | $599084 |
| Andrea Bloomquist<sup>(6)</sup> | Cash Severance<sup>(2)</sup> |  |  | $1059702 |  |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(6)</sup> |  |  | $128554 |  |  |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  |  |  |  |
|  | Total |  |  | $1188256 |  |  |
| Kevin Brown<sup>(6)</sup> | Cash Severance<sup>(2)</sup> |  |  | $915919 |  |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(6)</sup> |  |  | $25979 |  |  |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $19093 | $— |  |
|  | Total |  |  | $960991 | $— |  |
| Melissa Barra | Cash Severance<sup>(2)</sup> |  |  | $1057119 | $2101739 |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(4)</sup> |  |  |  | $853563 | $853563 |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $14749 | $14749 |  |
|  | Total |  |  | $1071868 | $2970051 | $853563 |
| Samuel Hellfeld | Cash Severance<sup>(2)</sup> |  |  | $994140 | $1975779 |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(4)</sup> |  |  |  | $733122 | $733122 |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $20842 | $20842 |  |
|  | Total |  |  | $1014982 | $2729743 | $733122 |
| Christopher Krusmark | Cash Severance<sup>(2)</sup> |  |  | $862500 | $1712500 |  |
|  | Option Award Acceleration<sup>(3)</sup> |  |  |  |  |  |
|  | Stock Award Acceleration<sup>(4)</sup> |  |  |  | $469469 | $469469 |
|  | Benefit Reimbursement<sup>(5)</sup> |  |  | $7507 | $7507 |  |
|  | Total |  |  | $870007 | $2189476 | $469469 |

---

---

| | |
|:---|:---|
| **57 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

<sup>(1)</sup> The amounts payable to the NEOs upon a change in control may be subject to reduction under Sections 280G and 4999 of the Internal Revenue

Code.

<sup>(2)</sup> Our NEOs are participants in the Company's Executive Severance Pay Plan. Under this plan, a participant is eligible for severance pay and other

benefits in the event of involuntary termination not for cause or resignation for good reason (qualifying termination), as those terms are defined under

the plan. There is no severance pay benefit for voluntary termination or involuntary termination for cause. As a condition of receiving any severance

pay under the plan, the executive must agree to a general release of claims against the Company. The amount of the severance pay payable for a

qualifying termination is a multiple of the sum of the executive's annual base salary plus the target annual incentive award under AIP, as of the date of

termination. If the qualifying termination occurs within a period starting six months before a change in control event and ending two years after a

change in control event, the multiple would be as follows: In order to receive the additional severance pay for qualifying terminations after a change in

control, the executive must agree to refrain from certain restricted activities for an extended period of two years after termination of employment. The

plan defines restricted activities to include certain competitive and solicitation activities. Severance pay benefits are paid in a lump sum following

termination of employment. The cash severance amounts shown above were calculated using annual base salary and target annual incentive for AIP

in effect for each executive as of the end of fiscal 2025. Also under the plan, participants are eligible for outplacement services. The maximum value of

this benefit is included in the cash severance amounts shown above. The plan does provide for a pro-rata annual incentive award for the period of the

year that the participant was actively employed. The calculations for this table are as of the end of the fiscal year, which is when participants in the AIP

become eligible for the full incentive award earned for that fiscal year. As a result, the table does not include any value for a pro-rata annual incentive.

<sup>(3)</sup> The value of the acceleration of the vesting of unvested stock options held by a NEO is based on the difference between: (a) the fair market value of

our common stock as of January 2, 2026 ($8.59), or date of termination, and (b) the per share exercise price of the options held by the executive,

provided (a) is higher than (b). The range of exercise prices of unvested stock options held by our NEO as of January 3, 2026 was $18.81 to $146.97.

No amounts are included in the table above for stock options because the respective exercise prices are all above $8.59 or fair market value of our

common stock as of the date of termination. For voluntary termination when an executive is eligible for retirement treatment (age 55 and five or more

years of service), the number of unvested stock options is prorated in valuing the acceleration of vesting.

<sup>(4)</sup> The value of the acceleration of the vesting of stock awards held by a NEO is based on: (a) the number of unvested PSUs or RSUs held by the

executive as of January 3, 2026, multiplied by (b) the fair market value of our common stock on January 2, 2026 ($8.59). PSUs whose performance

period had been completed as of January 3, 2026 are reflected based on the actual payout earned. All other PSUs are reflected at the lesser of target

or the maximum payout achievement possible. For voluntary termination when an executive is eligible for retirement treatment (age 55 and five or

more years of service), the number of unvested RSUs is prorated in valuing the acceleration of vesting.

<sup>(5)</sup> For a qualifying termination under the Executive Severance Pay Plan, a NEO is eligible to receive a reimbursement equal to the difference in cost

between the monthly COBRA premium and the monthly cost for the medical and dental plan coverage while an active team member. The

reimbursement is for as long as the executive is covered by COBRA but for a period not to exceed two years for Ms. Findley and one year for all other

NEOs.

<sup>(6)</sup> The chart above illustrates the actual incremental benefits received by the NEO in connection with the termination of their employment. Ms. Ibach and

Ms. Bloomquist separated from the Company effective May 31, 2025; Mr. Lee separated from the Company effective August 15, 2025; and Mr. Brown

separated from the Company effective April 16, 2025. The value of the acceleration of stock awards is based on (a) the number of accelerated RSUs

multiplied by the market fair value of our common stock as of the termination date plus (b) the number of accelerated PSUs multiplied by the market

fair value of our common stock as of the termination date. PSUs whose performance period had been completed as of January 3, 2026 are reflected

based on the actual payout earned. All other PSUs are reflected at the lesser of target or the maximum payout achievement.

**OTHER INFORMATION**

**CEO Pay Ratio**

As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are

providing the following information about the relationship of the annual total compensation of our team members and the

annual total compensation of our CEO. For fiscal year 2025, we determined on January 3, 2026 that the annual total

compensation of the team member identified as the median was $57,989 compared to last year's median of $59,362.

Based on this information, the 2025 ratio of the annual total compensation of our CEO, as reported in the Total column of

the Summary Compensation Table as $6,233,574, to the median annual total compensation of all team members,

excluding our CEO, was estimated to be 107 to 1.

The following is a summary of the methodology and assumptions used in determining the median annual total

compensation of our team members for 2025:

• We used our total active team member population as of the end of fiscal year 2025;

• For purposes of measuring total CEO compensation, the annualized compensation of our current CEO, Linda Findley,

was used;

• For measuring total compensation of our team members, we included base wages, incentive compensation,

commissions, over-time, paid time off and holiday pay that was actually paid to each team member during fiscal year

2025; and

• For team members included in the population that were hired during fiscal year 2025, we annualized their actual total

compensation to consider that they worked for only a portion of the year.

---

| | |
|:---|:---|
| **58 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

It should be noted that under the SEC's rules and guidance, there are numerous ways to determine the compensation of a

company's median employee, including the employee population sampled, the elements of total compensation included,

any assumptions made and the use of statistical sampling. In addition, no two companies have identical employee

populations or compensation programs. As such, our pay ratio may not be comparable to the pay ratio reported by other

companies.

**Pay Versus Performance**

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, we are providing the

following information comparing for the last three fiscal years calculated compensation values for disclosure purposes,

financial performance of the Company and total shareholder returns. The table shows a calculated value for the

Compensation Actually Paid (CAP) as required by SEC rules for the CEO and other NEOs. These amounts do not reflect

the actual compensation earned by or paid to the CEO or other NEOs for these fiscal years. For information regarding the

compensation decisions made by our Committee, please see the sections of the Compensation Discussion and Analysis

of the proxy statements for the fiscal years covered in the table below.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year**  | **Summary** <br>**Compensation** <br>**Table Total for** <br>**Ms. Findley**<sup>(1) (3)</sup> | **Compensation**<br>**Actually Paid**<br>**to Ms. Findley**<sup>(4)</sup> | **Summary** <br>**Compensation** <br>**Table Total for** <br>**Ms. Ibach**<sup>(2)(3)</sup> | **Compensation**<br>**Actually Paid**<br>**to Ms. Ibach**<sup>(4)</sup> | **Average**<br>**Summary**<br>**Compensation**<br>**Table Total for**<br>**Other** <br>**NEOs**<sup>(3)(5)</sup> | **Average** <br>**Compensatio**<br>**n Actually** <br>**Paid to Other** <br>**NEOs**<sup>(4)(5)</sup> | **Value of Initial Fixed** <br>**$100 Investment Based** <br>**On:**<sup>(6)</sup> | **Value of Initial Fixed** <br>**$100 Investment Based** <br>**On:**<sup>(6)</sup> | **Net (Loss)** <br>**Income**<br>**($ millions)**<sup>(7)</sup> | **Net Sales** <br>**Growth**<sup>(8)</sup> |
| **Year**  | **Summary** <br>**Compensation** <br>**Table Total for** <br>**Ms. Findley**<sup>(1) (3)</sup> | **Compensation**<br>**Actually Paid**<br>**to Ms. Findley**<sup>(4)</sup> | **Summary** <br>**Compensation** <br>**Table Total for** <br>**Ms. Ibach**<sup>(2)(3)</sup> | **Compensation**<br>**Actually Paid**<br>**to Ms. Ibach**<sup>(4)</sup> | **Average**<br>**Summary**<br>**Compensation**<br>**Table Total for**<br>**Other** <br>**NEOs**<sup>(3)(5)</sup> | **Average** <br>**Compensatio**<br>**n Actually** <br>**Paid to Other** <br>**NEOs**<sup>(4)(5)</sup> | **Sleep** <br>**Number** <br>**Total** <br>**Sharehol**<br>**der** <br>**Return**<br>| **S&P 400** <br>**Specialty** <br>**Stores** <br>**Index** <br>**Total** <br>**Shareholde**<br>**r Return**<br>| **Net (Loss)** <br>**Income**<br>**($ millions)**<sup>(7)</sup> | **Net Sales** <br>**Growth**<sup>(8)</sup> |
| **2025** | $6233574 | $9350716 | $1646266 | $(222340) | $1318986 | $731658 | $10 | $159 | $(132.0) | (16.1)% |
| **2024** | $— | $— | $6583409 | $4658822 | $1439510 | $1220875 | $31 | $195 | $(20.3) | (10.9)% |
| **2023** | $— | $— | $6349191 | $2797599 | $1824602 | $1097590 | $30 | $199 | $(15.3) | (10.7)% |
| **2022** | $— | $— | $6702614 | $(12847068) | $1592120 | $(1323910) | $52 | $162 | $36.6 | (3.2)% |
| **2021** | $— | $— | $9599571 | $15233052 | $2028184 | $2806197 | $154 | $173 | $153.7 | 17.7% |

---

<sup>(1)</sup> Ms. Findley has served as the Company's President and CEO since April 7, 2025.

<sup>(2)</sup> Ms. Ibach role as President and Chief Executive Officer ended on April 6, 2025, but remained in a non-executive management role through May 31,

2025. Ms. Ibach continued to serve as a non-employee strategic consultant to the Company through December 31, 2025.

<sup>(3)</sup> The amounts are reported in the Total column of the Summary Compensation Table for the CEO and for an average of the other NEOs for each fiscal

year.

<sup>(4)</sup> This is a calculation of CAP for each fiscal year as determined in accordance with SEC rules. See table below for a reconciliation of the estimated

value for CAP to the amounts reported in the Total column of the Summary Compensation Table on page <u>[49](#i44eec75d700a4a12a1ccd8dcee0c79e2_265)</u>.

<sup>(5)</sup> The average for 2025 includes Mr. Lee, Mr. Ryder, Ms. O'Keefe, Ms. Bloomquist, Mr. Brown, Ms. Barra, Mr. Hellfeld and Mr. Krusmark. The average

for 2024 includes Mr. Lee, Ms. Bloomquist, Ms. Barra and Mr. Hellfeld as the other NEOs. The average for 2023 includes Mr. David Callen, Mr.

Krusmark, Mr. Lee, Ms. Bloomquist, Ms. Barra and Mr. Hellfeld as other NEOs. The average for 2022 includes Mr. Callen, Ms. Bloomquist, Ms. Barra

and Mr. Hellfeld as other NEOs. The average for 2021 includes Mr. Callen, Ms. Bloomquist, Ms. Barra and Mr. Saklad as other NEOs.

<sup>(6)</sup> For the relevant fiscal year, this represents the cumulative Total Shareholder Return (TSR) by measuring what the value of a $100 investment at the

start of fiscal 2021 would be at the end of fiscal years 2021, 2022, 2023, 2024 and 2025. The S&P 400 Specialty Store Index TSR is the total return

assuming reinvestment of dividends and is included in the Comparative Stock Performance chart reported in our Annual Report on Form 10-K for the

fiscal years 2021, 2022, 2023, 2024 and 2025.

<sup>(7)</sup> This is net income as reported in the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal years 2021, 2022,

2023, 2024 and 2025.

<sup>(8)</sup> This is the annual growth in net sales as reported in the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal

years 2021, 2022, 2023, 2024 and 2025. This is the Company-selected measure for this disclosure.

The following table is a reconciliation of the estimated value for CAP to the amounts reported in the Total column of the

Summary Compensation Table for the fiscal years 2021, 2022, 2023, 2024 and 2025.

---

| | |
|:---|:---|
| **59 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Summary** <br>**Compensation** <br>**Table Total**<br>| **Deduct:** <br>**Amounts** <br>**Reported in** <br>**the Summary** <br>**Compensation** <br>**Table for** <br>**Stock and** <br>**Option** <br>**Awards**<br>| **Add: Value of** <br>**Awards** <br>**Granted** <br>**During the** <br>**Year,** <br>**Outstanding** <br>**and Unvested** <br>**at Year-end**<br>| **Add: Change** <br>**in Value of** <br>**Awards** <br>**Granted in** <br>**Any Prior** <br>**Year,** <br>**Outstanding** <br>**and Unvested** <br>**at Year-End**<br>| **Add: Value of** <br>**Awards** <br>**Granted and** <br>**Vested in the** <br>**Same Year** <br>| **Add: Change** <br>**in Value of** <br>**Awards** <br>**Granted in** <br>**Any Prior** <br>**Year, Vested** <br>**During the** <br>**Year**<br>| **Add: Change in** <br>**Value of** <br>**Awards that** <br>**Failed to Meet** <br>**Applicable** <br>**Vesting** <br>**Conditions** <br>**During the Year**<br>| **Estimated** <br>**Compensation** <br>**Actually Paid** <br>**(CAP)**<sup>(1)</sup><br>|
| **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** | **CEO - Ms. Findley** |
| 2025 | $6233574 | $(4104519) | $7221661 | $— | $— | $— | $— | $9350716 |
| **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** | **CEO - Ms. Ibach** |
| 2025 | $1646266 | $— | $(1085678) | $— | $— | $(782928) | $— | $(222340) |
| 2024 | $6583409 | $(4340130) | $3287427 | $(794372) | $— | $(77512) | $— | $4658822 |
| 2023 | $6349191 | $(4609638) | $1965546 | $(1212687) | $— | $305187 | $— | $2797599 |
| 2022 | $6702614 | $(5419385) | $1280493 | $(12212135) | $— | $(3198655) | $— | $(12847068) |
| 2021 | $9599571 | $(6440343) | $4245801 | $(1037718) | $— | $8865741 | $— | $15233052 |
| **Average for Other NEOs** | **Average for Other NEOs** |  |  |  |  |  |  |  |
| 2025 | $1318986 | $(423958) | $277170 | $(110559) | $3855 | $(92129) | $(241707) | $731658 |
| 2024 | $1439510 | $(567415) | $534511 | $(165733) | $— | $(19998) | $— | $1220875 |
| 2023 | $1824602 | $(1081157) | $483831 | $(165585) | $— | $35899 | $— | $1097590 |
| 2022 | $1592120 | $(1019287) | $238188 | $(1773616) | $— | $(361315) | $— | $(1323910) |
| 2021 | $2028184 | $(1058309) | $714143 | $(134889) | $— | $1257068 | $— | $2806197 |

---

<sup>(1)</sup> In determining the estimated CAP, stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of

grant. Adjustments have been made using stock option fair values as of each measurement date using the stock price as of the measurement date

and updated assumptions (i.e., term, volatility, risk free rates) as of the measurement date. Performance Stock Unit (PSU) grant date fair values are

calculated using the stock price as of date of grant assuming target performance or a Monte Carlo valuation for those awards with a shareholder

return modifier. Adjustments have been made using the stock price and performance accrual modifier as of year-end and as of each vesting date.

Time-vested Restricted Stock Unit (RSU) grant date fair values are calculated using the stock price as of date of grant or a Monte Carlo valuation for

those awards with a shareholder return modifier. Adjustments have been made using the stock price as of year-end and as of each vesting date.

As noted above, the estimate of CAP reflects adjusted values to unvested and vested equity awards during the years

shown in the table based on year-end stock prices, various accounting valuation assumptions, and projected performance

modifiers but does not reflect actual amounts paid out for those awards. CAP generally fluctuates due to stock price

achievement and varying levels of projected and actual achievement of performance goals (as reflected in the significant

decrease to 2022 CAP). For a discussion of how our Committee assessed Company performance and made pay

decisions each year for our NEOs, see the Compensation Discussion and Analysis in this Proxy Statement and in the

proxy statements for 2021, 2022, 2023, and 2024.

---

| | |
|:---|:---|
| **60 \| 2026 PROXY STATEMENT** | **COMPENSATION DISCUSSION AND ANALYSIS** |

---

Below are graphs comparing the estimated CAP values for our CEO and other NEOs to: (1) TSR for Sleep Number and

the S&P 400 Specialty Stores Index, (2) net income and (3) annual net sales growth.

![5153](snbr-20260408_g29.gif)

![5155](snbr-20260408_g30.gif)

![5158](snbr-20260408_g31.gif)

As described in various sections of our Compensation Discussion and Analysis, the following are key performance

measures that determine the incentive compensation earned by the CEO and other NEOs for Company performance. By

design, our executive compensation mix is heavily weighted toward incentive compensation which is all performance-

based and only earned with achievement of financial goals for AIP and PSUs or appreciation of our share price for stock

options.

---

| | |
|:---|:---|
| **Metric** | **How This Metric Influences Pay** |
| Net Sales Growth | This is one of two key measures in our PSU design. Half of the PSU payout opportunity is tied <br>to our achievement of annual growth goals for net sales over a three year period.<br>|
| NOP Growth | This is one of two key measures in our PSU design. Half of the PSU payout opportunity is tied <br>to our achievement of annual growth goals for NOP over a three year period.<br>|
| Adjusted ROIC | There is an ROIC modifier in our PSU design for 2023 and 2024. This potential reduction in the <br>number of target PSUs applies if the average difference between Adjusted ROIC and WACC is <br>below a certain threshold.<br>|
| Adjusted EBITDA | This is the only measure in our AIP design. The AIP payout opportunity is tied to our <br>achievement of fiscal year goals for Adjusted EBITDA.<br>|
| Relative Total <br>Shareholder Return<br>| There is a relative total shareholder return in our PSU design for 2025. This potential reduction <br>in the number of target PSUs applies if the actual relative total shareholder return falls below a <br>certain threshold.<br>|
| Share Price | Stock options require share price appreciation above the exercise price in order to have any <br>value. The value of PSUs earned and paid out also depends on share price.<br>|

---

---

| | |
|:---|:---|
| **61 \| 2026 PROXY STATEMENT** | **PROPOSAL 6 - ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION** |

---

![Proposal 6.jpg](snbr-20260408_g32.jpg)

**Background**

Consistent with the views expressed by shareholders at our 2023 Annual Meeting when we last asked our shareholders to

cast an advisory vote as to whether future advisory votes on executive compensation, or "say-on-pay" votes, should occur

every year, every two years or every three years, the Board has determined to hold an advisory vote to approve executive

compensation annually. The next advisory vote on the frequency of our "say-on-pay" vote will be put to our shareholders

at our 2029 Annual Meeting.

This advisory resolution, commonly referred to as "say-on-pay," is being provided to our shareholders as required

pursuant to Section 14A of the Securities Exchange Act and is non-binding on the Company and the Board. However, the

Board and the Compensation Committee value the opinions of our shareholders and will carefully consider the outcome of

the vote when making future compensation decisions. The next "say-on-pay" vote will be held at our 2027 Annual Meeting.

As described more fully in the Compensation Discussion and Analysis (CD&A) section of this Proxy Statement, our

compensation programs are structured to align the interests of our executive officers with the interests of our

shareholders. They are designed to attract, motivate and retain, a talented management team to achieve superior results.

Shareholders are urged to read the CD&A, which discusses in-depth how our executive compensation programs are

aligned with our performance and the creation of shareholder value.

**Board Recommendation**

The Board unanimously recommends a vote "**For**" approval of, on a non-binding basis, the compensation of the

Company's named executive officers as described in the CD&A, tabular disclosures and other executive compensation

narrative provided in this Proxy Statement for the Company's 2026 Annual Meeting.

**Vote Required**

The affirmative vote of the holders of a majority of the shares of common stock present and entitled to vote directly or by

proxy on this matter at the Annual Meeting, and at least a majority of the minimum number of shares necessary for a

quorum, is necessary for approval of the foregoing resolution. Unless a contrary choice is specified, proxies solicited by

the Board will be voted "**For**" approval of, on a non-binding basis, the compensation of the Company's named executive

officers as described in this Proxy Statement.

---

| | |
|:---|:---|
| **62 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

![Proposal 7.jpg](snbr-20260408_g33.jpg)

**Introduction**

On May 13, 2020, our shareholders approved the Sleep Number Corporation 2020 Equity Incentive Plan (as thereafter

amended, the "2020 Plan") at our 2020 Annual Meeting. The 2020 Plan permits the Compensation Committee, or a

subcommittee thereof, to grant to eligible team members, non-employee Directors and consultants of Sleep Number (each

a participant) non-statutory and incentive stock options, stock appreciation rights (also known as SARs), restricted stock

awards, restricted stock units, deferred stock units, annual performance cash awards and other cash-based awards and

other stock-based awards. On May 21, 2024, our shareholders approved Amendment No. 1 to the 2020 Plan to increase

the number of authorized shares by 1,500,000. On May 28, 2025, our shareholders approved Amendment No. 2 to the

2020 Plan to increase the number of authorized shares by an additional 500,000. Subject to both adjustments, the

maximum number of shares of our common stock authorized for issuance under the 2020 Plan is 5,240,000 shares.

The purpose of the 2020 Plan is to advance the interests of the Company and its shareholders by enabling the Company

and its subsidiaries to (i) attract, motivate and retain a talented management team to achieve superior results, (ii) provide

market competitive equity incentive opportunities that are linked to the growth and profitability of the Company and

increases in shareholder value, and (iii) align the interests of key executives, team members and Directors with those of

our shareholders.

Our equity compensation program provides our team members with an incentive to deliver our long-term strategic

objectives and achieve superior results. We believe equity is a critical tool for attracting, retaining and rewarding our team,

and aligning their interests with those of our shareholders over the long-term. We believe that providing at-risk, equity-

based compensation is a fundamental component of our compensation program, is essential to creating compensation

opportunities that are competitive relative to market levels and aligns incentives with our shareholders' interests in a

manner that promotes long-term performance.

**Background to this Proposal 7**

Four years of sustained macroeconomic challenges and a historic industry recession has resulted in a prolonged stock

price decline. Given the decline in our stock price, our modeling in the last two years indicated we would not have enough

shares available under the 2020 Plan to make our standard annual equity grants using our historical practices in 2025. To

address this issue, the Company took actions to reduce share usage in 2024 and 2025, and proposed an amendment to

the 2020 Plan to provide enough additional shares to issue 2025 annual grants. On May 21, 2024, shareholders approved

the addition of 1,500,000 shares to the 2020 Plan. On May 28, 2025, shareholders again approved the addition of 500,000

shares to the 2020 Plan. The Company recently discovered it had not been accurately accounting for the number of

shares in the 2020 Plan, including with respect to recycled shares that fluctuate annually. For that reason, the Company

had approximately 500,000 more shares than it anticipated it would have when doing its calculations leading up to the

May 28, 2025 Annual Meeting and shareholder vote. Nonetheless, with the depressed share value, an equity grant to a

consultant as announced in January 2026, and the ongoing need to use equity to attract, retain and reward our team, the

Company is still in need of requesting additional shares.

With industry demand continuing to decline in 2025, and the Company's share price remaining depressed, the Company

was again in the position of needing to take steps to limit share usage for our annual 2025 grants and conserve equity in

light of our current situation. These steps included:

• Limiting the use of Performance Stock Units (PSUs) and continuing the elimination of Non-Qualified Stock Options,

which have a more dilutive effect on the 2020 Plan;

---

| | |
|:---|:---|
| **63 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

• Limiting the number of team members that receive equity grants; and

• Eliminating the ability of our non-employee Directors to receive their cash retainer payments in stock.

While these actions were necessary to enable us to continue to use equity awards to compensate our team members in

2025, they are not long-term solutions. As of March 17, 2026, after our annual grants, including the conservation

measures described above, we are left with approximately 583,000 shares available under the 2020 Plan. We do not

believe that this is sufficient to provide competitive equity-based compensation to our team members beyond 2026.

To address this issue, and to enable the Company to retain critical talent as we execute the important task of transforming

our operating model for greater financial resiliency and positioning the business for accelerating growth as the mattress

industry recovers, on March 11, 2026, the Compensation Committee adopted an amendment to the 2020 Plan to increase

the number of shares of our common stock available for issuance by an additional 750,000 shares (the Plan Amendment).

The Plan Amendment is subject to the approval of shareholders. **We are asking shareholders to approve the Plan** 

**Amendment so that we can effectively maintain the vital equity component of our compensation program going** 

**forward.**

Our Board believes that equity compensation plays an important role in the Company's success by motivating and

engaging our executives, team members and non-employee Directors and allowing them to participate in shareholder

value creation through their ownership interest in the Company. **The Board therefore recommends that you vote to** 

**approve the Plan Amendment.**

If our shareholders approve the Plan Amendment, the Plan Amendment will become effective as of the date of

shareholder approval. If our shareholders to not approve the Plan Amendment, the 2020 Plan, as currently in effect, will

remain in effect until it terminates in accordance with its terms.

**Key Vote Considerations**

Without sufficient shares to grant to our team members, we would be forced to rely on other forms of compensation,

including cash. The retention value of non-stock-based awards may not be sufficient to retain key talent. As a result, we

may need to deliver long-term incentive awards in the form of cash, which would reduce our financial flexibility and impact

our ability to pay down debt, which is a top priority in 2026. Cash-based awards are also suboptimal because they are

limited in their ability to align team member interests with shareholder interests over the long-term.

Our Board recommends you vote to approve the Plan Amendment because the Board believes an increase in the number

of shares available for issuance under the 2020 Plan is in the best interests of our Company and our shareholders for the

following reasons:

• <u>We have been responsible stewards of shareholder equity.</u> In response to our current situation, we have taken

targeted steps over the last two years to significantly reduce share usage and operate within the constraints of the

2020 Plan with respect to the number of shares available.

• <u>The Plan Amendment will advance Company and shareholder interests by allowing us to attract, motivate, and retain</u> 

<u>key talent.</u> Having a talented and motivated management team is essential to executing our business strategies and

achieving superior results. Stock-based incentive compensation has been an important component of the total direct

compensation opportunity for our management team. It helps us provide a market competitive compensation

opportunity that is predominantly performance-based and at risk.

• <u>Our ability to award equity is essential to our ability to retain team members during an important time.</u> The 2020 Plan

is a broad-based plan under which the Company grants awards to NEOs, non-employee Directors and many current

and prospective team members. The market for talent in our industry is competitive, and it is critical that we retain our

---

| | |
|:---|:---|
| **64 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

team members as we execute an important and complex transformation. Any impairment to our ability to attract and

retain talent could limit our ability to realize the benefits of this initiative.

• <u>The Plan Amendment is consistent with our pay-for-performance compensation philosophy</u>. We believe that stock-

based incentive compensation rewards our management team for superior performance in delivering sustainable and

profitable growth. It is performance-based, fully at-risk, and only has value if the Company performance meets or

exceeds predetermined financial goals, or if shareholder value increases. This reinforces our pay for performance

culture.

• <u>The Plan Amendment will enable us to continue aligning the interests of our executives with those of our</u> 

<u>shareholders.</u> We have designed our stock-based incentive compensation so that our management team is motivated

to achieve financial performance goals and increase shareholder value. This creates a strong alignment between our

rewards and shareholder interests. Also, with our stock ownership guidelines, the ownership levels of our common

stock that are maintained by our non-employee Directors and executives foster further alignment with the interests of

our shareholders.

• <u>The Plan Amendment protects shareholder interests and embraces sound stock-based compensation practices.</u> As

described in more detail below under the heading "Summary of Sound Governance Features of the 2020 Plan," the

2020 Plan includes a number of features that are consistent with protecting the interests of our shareholders and

sound corporate governance practices.

**Summary of Sound Governance Features of the 2020 Plan**

The Board and the Compensation Committee believe that the 2020 Plan contains several features that are consistent with

protecting the interests of our shareholders and sound corporate governance practices, including the following:

• No "evergreen" provision;

• No liberal share "recycling" for stock options or SARs;

• No reloads;

• Stock option exercise prices and SAR grant prices will not be lower than the fair market value on the grant date;

• No re-pricing or exchange of "underwater" options or SARs without shareholder approval;

• Stock options and SARs are not entitled to dividend equivalent rights;

• No dividends or dividend equivalents will be paid out on unvested awards;

• Shareholder approval is required for material revisions to the 2020 Plan;

• "Clawback" provisions; and

• "Double-Trigger" vesting in change in control.

**Equity Compensation Plan Information and Share Usage Information**

In determining the number of shares of common stock by which to increase the 2020 Plan, the Board and the

Compensation Committee considered a number of factors, which are discussed further below, including:

• Shares currently available under the 2020 Plan and total outstanding equity awards;

• Historical equity and award granting practice, including share usage (commonly referred to as "burn rate"); and

• Overhang and dilution.

---

| | |
|:---|:---|
| **65 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

<u>Shares Currently Available and Total Outstanding Equity Awards</u>

---

| | |
|:---|:---|
| **(all data as of March 17, 2025)** | |
| New Shares Requested | 750000 |
| Shares Remaining Available for Issuance Under 2020 Plan | 582858 |
| Common Shares Outstanding | 23042873 |
| Stock Options/SARs Outstanding | 721214 |
| Weighted-Average Exercise Price of Outstanding Stock Options/SARs | $42.07 |
| Weighted-Average Remaining Term of Outstanding Stock Options/SARS | 2.7 |
| Total Stock-Settled Full-Value Awards Outstanding | 4189251 |

---

<u>Share Usage</u>

In determining the number of shares of common stock by which to increase the 2020 Plan, the Board and the

Compensation Committee considered the historical number of equity awards granted under the 2020 Plan. The following

table sets forth information regarding stock-settled, time-vested equity awards granted, and performance-based equity

awards earned, over each of the last three fiscal years:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** | **3-Year** <br>**Average** |
| Stock Options/Stock Appreciation Rights <br>(SARs) Granted<br>|  |  | 305000 | **3-Year** <br>**Average** |
| Stock-Settled Time-Vested Restricted <br>Shares/Units Granted<br>| 1233000 | 674000 | 304000 | **3-Year** <br>**Average** |
| Stock-Settled Performance-Based Shares/<br>Units Vested<br>| 5000 | 45000 | 201000 | **3-Year** <br>**Average** |
| Weighted-Average Basic Common Shares <br>Outstanding<br>| 22883000 | 22606000 | 22429000 | **3-Year** <br>**Average** |
| **Share Usage Rate** | 5.4% | 3.2% | 3.6% | 4.1% |

---

Based on historical and anticipated granting practices, we expect the additional shares authorized for issuance by the

Plan Amendment to cover awards through our 2026 annual grant. Expectations regarding future share usage could be

impacted by a number of factors such as award type mix, hiring and promotion activity at the executive level, the rate at

which shares are returned to the share reserve under permitted addbacks, the future performance of our stock price, the

consequences of acquiring other companies and other factors. While we believe that the assumptions we used are

reasonable, future share usage may differ from current expectations.

<u>Overhang</u>

The following table sets forth certain information with respect to the Company's equity compensation plans:

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 17,** <br>**2026**<br>| **January 3,** <br>**2026**<br>|
| Stock Options/SARs Outstanding | 721214 | 758815 |
| Weighted-Average Exercise Price of Outstanding Stock Options/SARs | $42.07 | $42.47 |
| Weighted-Average Remaining Term of Outstanding Stock Options/SARS | 2.7 years | 2.7 years |
| Total Stock-Settled Full-Value Awards Outstanding | 4189251 | 2247617 |
| Share reserve under the 2020 Plan | 5240000 | 5240000 |
| Proposed Amended Share reserve under the 2020 Plan | 5990000 | 5990000 |

---

---

| | |
|:---|:---|
| **66 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

<u>Dilution and Expected Duration</u>

Our Board recognizes the impact of dilution on our shareholders and has evaluated the Plan Amendment carefully in the

context of the need to motivate, retain and ensure that our leadership team and key team members remain focused on our

strategic priorities. The total fully-diluted overhang as of March 17, 2026 and January 3, 2026, assuming that the entire

share reserve is granted in stock options, SARs, or full-value awards would be 19.3% and 22.0%, respectively. In this

context, fully-diluted overhang is calculated as the sum of grants outstanding and shares available for future awards

(numerator) divided by the sum of the numerator and basic common shares outstanding, with all data effective as of

March 17, 2026 and January 3, 2026. Our Board believes that the increase included in the Plan Amendment represents a

reasonable amount of potential equity dilution to accommodate our long-term strategic and growth priorities.

**Summary of the 2020 Plan Features**

Below is a summary of the major features of the 2020 Plan, assuming approval of the Plan Amendment. Other than

increasing the shares of common stock available for issuance, the Plan Amendment does not modify the terms of the

2020 Plan. The summary is qualified in its entirety by reference to the full text of the 2020 Plan, a copy of which may be

obtained upon request to Investor Relations at 1001 Third Avenue South, Minneapolis, Minnesota, 55404 or by telephone

at 763-551-7498. A copy of the Plan Amendment has also been filed electronically with the SEC as <u>Appendix</u> <u>D</u> to this

Proxy Statement, available through the SEC's website at www.sec.gov.

<u>Purpose</u>

The purpose of the 2020 Plan is to advance the interests of the Company and its shareholders by enabling the Company

and its subsidiaries to (i) attract, retain, and motivate our management team for achievement of Company results and

creation of shareholder value, (ii) provide stock-based incentive compensation opportunities that are linked to the growth

and profitability of the Company and increases in shareholder value, and (iii) provide opportunities for equity ownership

that align the interests of key team members and Board members with those of our shareholders.

<u>Plan Administration</u>

The 2020 Plan will be administered by the Compensation Committee, or by a subcommittee thereof, or any other

committee designated by the Board in accordance with the 2020 Plan. All members of the Compensation Committee

administering the 2020 Plan will be "non-employee Directors" within the meaning of Rule 16b-3 under the Exchange Act

and "independent" under the Nasdaq listing rules, the rules and regulations of the SEC and other applicable laws.

Under the terms of the 2020 Plan, subject to certain limitations, the Compensation Committee has the authority to, among

other things:

• Select eligible participants to whom awards are granted;

• Determine the types, amounts and terms of awards to be granted and when;

• Determine the provisions of such awards, including the applicable performance measures, if any, and the duration,

restrictions and conditions of such awards;

• Interpret the 2020 Plan and any instrument evidencing an award under the 2020 Plan and establish rules and

regulations pertaining to its administration;

• Determine fair market value in accordance with the 2020 Plan;

• Subject to shareholder approval requirements for some amendments, determine whether and under what

circumstances and terms to amend the 2020 Plan or any outstanding award agreement;

• Adopt subplans or special provisions applicable to awards regulated by the laws of jurisdictions other than the United

States;

• Authorize any person to execute on behalf of the Company an award agreement or other instrument required to effect

a grant;

---

| | |
|:---|:---|
| **67 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

• Determine whether awards will be settled in shares of common stock, cash or in any combination thereof;

• Determine whether an award will be eligible for dividend equivalent rights;

• Impose restrictions, conditions or limitations on resales and subsequent transfers; and

• Make any other determination and take any other action that the Compensation Committee deems necessary or

desirable for administration of the 2020 Plan.

<u>Delegation</u>

To the extent permitted by applicable law, the Compensation Committee may delegate to one or more of its members or to

one or more officers of the Company such administrative duties or powers, as it may deem advisable. The Compensation

Committee may authorize one or more Directors or officers of the Company to designate team members, other than

officers, Directors or 10% shareholders of the Company, to receive awards under the plan and determine the size of any

such awards, subject to certain limitations.

<u>No Re-pricing or Exchange</u>

Except in connection with a change in control, the Compensation Committee may not, except as described below under

the heading "Adjustments," without prior approval of our shareholders, seek to effect any re-pricing of any previously

granted option or SAR by: (i) amending or modifying the terms of the option or SAR to lower the exercise price, (ii)

canceling an underwater option or SAR in exchange for (A) cash, (B) replacement options or SARs having a lower

exercise price or (C) other awards, or (iii) repurchasing the underwater options or SARs and granting new awards under

the 2020 Plan. An option or SAR will be deemed to be "underwater" at any time when the fair market value of the common

stock is less than the exercise price of the option or SAR.

<u>Shares Authorized</u>

Subject to adjustment, the maximum number of shares of our common stock authorized for issuance under the 2020 Plan,

assuming the Plan Amendment is approved, is 5,990,000 shares less one share for every share subject to an award

granted under the Prior Plan between December 28, 2019, and the date of shareholder approval of the 2020 Plan. No

more than 5,990,000 shares may be granted as incentive stock options.

If (i) any shares subject to an award are forfeited, an award expires or an award is settled for cash (in whole or in part) or

(ii) after December 28, 2019 any shares subject to an award under the Prior Plan is forfeited, expires or settled for cash (in

whole or in part), then in each such case the shares subject to such award will, to the extent of such forfeiture, expiration

or cash settlement, be added to the shares available for awards under the 2020 Plan. As noted above, the Company had

not fully accounted for certain recycled shares in prior years, but as disclosed above, this has now been rectified. In the

event that withholding tax liabilities arising from an award (other than an option or SAR) or, after December 28, 2019, an

award under the Prior Plan (other than an option or SAR) is satisfied by the tendering of shares (either actually or by

attestation) or by the withholding of shares by the Company, the shares so tendered or withheld will be added to the

shares available for awards under the 2020 Plan. However, the following shares will not be added to the shares

authorized for grant under the 2020 Plan: (i) shares tendered by a participant or withheld by the Company in payment of

the exercise price of an option under the 2020 Plan or the Prior Plan, (ii) shares tendered by a participant or withheld by

the Company to satisfy any tax withholding obligation with respect to options or SARs under the 2020 Plan or the Prior

Plan, (iii) shares subject to a SAR under the 2020 Plan or the Prior Plan that are not issued in connection with its stock

settlement on exercise thereof and (iv) shares reacquired by the Company on the open market or otherwise using cash

proceeds from the exercise of options under the 2020 Plan or the Prior Plan.

<u>Limits on Non-Employee Director Awards</u>

Awards granted during a single fiscal year to any non-employee Director, taken together with any cash fees paid during

the fiscal year to the non-employee Director, in respect of the Director's service as a member of the Board during such

year, shall not exceed $500,000 in total value. The independent members of the Board may make exceptions to this limit

---

| | |
|:---|:---|
| **68 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

for a non-executive chair of the Board, provided that the non-employee Director receiving such additional compensation

may not participate in the decision to award such compensation.

<u>Minimum Vesting Requirement</u>

Awards granted under the 2020 Plan (other than annual performance cash awards and other cash-based awards) shall

vest no earlier than the first anniversary of the date on which the award is granted; provided, that the following awards

shall not be subject to the foregoing minimum vesting requirement: any (i) substitute awards granted in connection with

awards that are assumed, converted or substituted pursuant to a merger, acquisition or similar transaction entered into by

the Company or any of its subsidiaries in accordance with Section 20 of the 2020 Plan, (ii) shares delivered in lieu of fully

vested cash obligations, (iii) awards to non-employee Directors that vest on the earlier of the one-year anniversary of the

grant date and the next Annual Meeting of shareholders of the Company which is at least 50 weeks after the immediately

preceding year's Annual Meeting and (iv) any additional awards the Compensation Committee may grant, up to a

maximum of 5% of the available share reserve authorized for issuance under the 2020 Plan; and, provided, further, that

the foregoing restriction does not apply to the Compensation Committee's discretion to provide for accelerated

exercisability or vesting of any award, including in cases of retirement, death, disability or a change in control, in the terms

of the award agreement or otherwise.

<u>Adjustments</u>

In the event of any reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend,

stock split, combination of shares, rights offering, divestiture or extraordinary dividend (including a spin off) or other similar

change in the corporate structure or shares of the Company, the Compensation Committee will make the appropriate

adjustment. These adjustments may be to the number and kind of securities and property that may be available for

issuance under the 2020 Plan or the terms and conditions of any outstanding awards, including any performance goals or

criteria with respect thereto. In order to prevent dilution or enlargement of the rights of participants, the Compensation

Committee may also adjust the number, kind, and exercise price of securities or other property subject to outstanding

awards.

<u>Participation</u>

Awards may be granted to team members, non-employee Directors and consultants of the Company or any of its

subsidiaries. A "consultant" is one who renders services that are not in connection with the offer and sale of our securities

in a capital raising transaction and does not directly or indirectly promote or maintain a market for our securities. As of

March 13, 2026, approximately 270 team members and six non-employee Directors would have been eligible to

participate in the 2020 Plan.

<u>Types of Awards</u>

The 2020 Plan will permit us to grant non-statutory and incentive stock options, SARs, restricted stock awards, restricted

stock units, deferred stock units, annual performance cash awards, other cash-based awards and other stock-based

awards. Awards may be granted either alone or in addition to or in tandem with any other type of award.

<u>Non-Statutory and Incentive Stock Options</u>

Stock options entitle the holder to purchase a specified number of shares of our common stock at a specified price, which

is called the exercise price, subject to the terms and conditions of the stock option grant. The 2020 Plan permits the grant

of both non-statutory and incentive stock options, though incentive stock options may be granted only to team members.

Each stock option granted under the 2020 Plan must be evidenced by an award agreement that specifies the exercise

price, the term, the number of shares underlying the stock option, the vesting and any other conditions. Except for

substitute awards grated under Section 20 of the 2020 Plan, the exercise price of each stock option granted under the

2020 Plan must be at least 100% of the fair market value of a share of our common stock as of the date the award is

granted to a participant. Fair market value is the closing price of our common stock, as reported on the Nasdaq. The

closing price of our common stock, as reported on the Nasdaq, on March 13, 2026, was $3.45 per share. The

---

| | |
|:---|:---|
| **69 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

Compensation Committee will fix the terms and conditions of each stock option, subject to certain restrictions. The

Compensation Committee will fix the term of each stock option, but stock options granted under the 2020 Plan will not be

exercisable more than 10 years after the date the stock option is granted. Stock options may be exercised, in whole or in

part, by payment in full of the exercise price in cash or its equivalent. In the discretion of the Compensation Committee,

payment may also be made by the delivery of common stock already owned by the participant prior to such delivery or to

be issued upon the exercise of the option being exercised, by broker-assisted cashless exercise, by "net exercise," or by a

combination of such methods; or such other method as may be permitted by the Compensation Committee. In the case of

a "net exercise" of a stock option, we will not require payment of the exercise price or any required tax withholding

obligations related to the exercise, but will reduce the number of shares issued upon the exercise by the largest number of

whole shares that has a fair market value that does not exceed the aggregate exercise price for the shares underlying the

stock option and any required tax withholding obligations.

<u>Stock Appreciation Rights</u>

A stock appreciation right, or SAR, is a right granted to receive payment of cash, stock or a combination of both, equal to

the difference between the fair market value of shares of our common stock and the exercise price of such shares. Each

SAR granted must be evidenced by an award agreement that specifies the exercise price, the term, and such other

provisions as the Compensation Committee may determine. Except for substitute awards granted under Section 20 of the

2020 Plan, the exercise price of a SAR must be at least 100% of the fair market value of our common stock on the date of

grant. The Compensation Committee will fix the term of each SAR, but SARs granted under the 2020 Plan will not be

exercisable more than 10 years after the date the SAR is granted.

<u>Restricted Stock Awards, Restricted Stock Units and Deferred Stock Units</u>

Restricted stock awards, restricted stock units and/or deferred stock units may be granted under the 2020 Plan. A

restricted stock award is an award of common stock that is subject to restrictions on transfer and risk of forfeiture upon

certain events, typically including termination of service. Restricted stock units are similar to restricted stock awards,

except that no shares are actually awarded to the participant on the grant date. A deferred stock unit is a right that allows

a participant to receive shares of our common stock at a future time as determined by the Compensation Committee or

the participant, subject to certain guidelines. The Compensation Committee shall determine, and set forth in an award

agreement, the period of restriction, the number of shares of restricted stock awards or the number of restricted stock

units granted, and other such conditions or restrictions, including, in the case of a performance award, any performance

goals upon which the performance award is subject and any performance period during which any performance goals

must be achieved. Participants holding shares of restricted stock awards may be granted voting rights with respect to their

shares, but participants holding restricted stock units and/or deferred stock units will not have voting rights with respect to

their restricted stock units and/or deferred stock units. After all conditions and restrictions applicable to restricted stock

awards, restricted stock units and/or deferred stock units have been satisfied or have lapsed (including the satisfaction of

any applicable tax withholding obligations), shares of restricted stock awards will become freely transferable (except as

otherwise provided in the 2020 Plan), and restricted stock units will be paid in cash, shares of our common stock, or some

combination of cash and shares of our common stock as determined by the Compensation Committee. The

Compensation Committee may provide that a restricted stock award is conditioned upon the participant making or

refraining from making an election with respect to the award under Section 83(b) of the IRC.

<u>Annual Performance Cash Awards</u>

Annual performance cash awards may be granted under the 2020 Plan in such amounts and upon such terms as the

Compensation Committee may determine, based on the achievement of specified performance goals for annual periods

or other time periods, as determined by the Compensation Committee.

---

| | |
|:---|:---|
| **70 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

<u>Non-Employee Director Awards</u>

The Compensation Committee at any time and from time to time may grant to non-employee Directors non-statutory stock

options, SARs or full value awards. Any such awards may be granted singly, in combination or in tandem, and may be

granted pursuant to such terms, conditions and limitations as the Compensation Committee may establish in its sole

discretion consistent with the provisions of the 2020 Plan.

The 2020 Plan permits non-employee Directors to elect to receive shares of our common stock in lieu of their Director

fees otherwise payable in cash. The election to receive our common stock in lieu of cash must be made in the calendar

quarter preceding the date any such fees are payable. The number of shares to be issued is determined by dividing the

dollar amount of reserved fees by the fair market value of our common stock on the date such fees would otherwise have

been payable.

<u>Other Cash-Based Awards and Other Stock-Based Awards</u>

Cash-based awards that are not annual performance cash awards may be granted to participants in such amounts and

upon such terms as the Compensation Committee may determine. These other cash-based awards will be paid in cash

only. Other stock-based awards (including the grant or offer for sale of unrestricted shares of our common stock or the

payment in cash or otherwise of amounts based on the value of shares of our common stock) may be granted in such

amounts and subject to such terms and conditions (including performance goals) as determined by the Compensation

Committee. These other stock-based awards shall be expressed in terms of shares of our common stock or units based

on shares of our common stock, as determined by the Compensation Committee. Other stock-based awards will be paid

in cash or shares of our common stock, as determined by the Compensation Committee.

<u>Performance Measure Elements</u>

The performance goals upon which the payment or vesting of a performance award depends may include, without

limitation, one or more of the following performance measure elements:

• Sales and revenue measure elements, including gross revenue or sales, sales allowances, net revenue or net sales,

invoiced revenue or sales, collected revenue or sales, revenues from new products and bad debts;

• Expense measurement elements, including direct material costs, direct labor costs, indirect labor costs, direct

manufacturing costs, indirect manufacturing costs, cost of goods sold, sales, general and administrative expenses,

operating expenses, non-cash expenses, tax expense, non-operating expenses and total expenses;

• Profitability and productivity measure elements, including gross margin, net operating income, EBITDA (earnings

before interest, taxes, depreciation and amortization), EBIT (earnings before interest and taxes), NOPAT (net

operating income after taxes), net income, net cash flow and net cash flow from operations;

• Asset utilization and effectiveness measure elements, including cash, excess cash, accounts receivable, inventory

(work-in-progress or finished goods), current assets, working capital, total capital, fixed assets, total assets, standard

hours, plant utilization, purchase price variance and manufacturing overhead variance;

• Debt and equity measure elements, including accounts payable, current accrued liabilities, total current liabilities, total

debt, debt principal payments, net current borrowings, total long-term debt, credit rating, retained earnings, total

preferred equity, total common equity and total equity;

• Shareholder and return measure elements, including earnings per share (diluted and fully diluted), stock price,

dividends, shares repurchased, total return to shareholders, debt coverage ratios, return on assets, return on equity,

return on invested capital and economic profit (for example, economic value added);

• Customer and market measure elements, including dealer/channel size/scope, dealer/channel performance/

effectiveness, order fill rate, customer satisfaction, customer service/care, brand awareness and perception, market

share, warranty rates, product quality and channel inventory; and

---

| | |
|:---|:---|
| **71 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

• Organizational and team member measure elements, including headcount, team member performance, team member

productivity, standard hours, team member engagement/satisfaction, team member turnover and team member

diversity.

The Compensation Committee may amend or modify the vesting criteria (including any performance goals, performance

measures or performance periods) of any outstanding awards based in whole or in part on the financial performance of

the Company (or any subsidiary or division, business unit or other sub-unit thereof) in recognition of unusual or

nonrecurring events affecting the Company or the financial statements of the Company or of changes in applicable laws,

regulations or accounting principles, whenever the Compensation Committee determines that such adjustments are

appropriate in order to prevent unintended dilution or enlargement of the benefits or potential benefits intended to be

made available under the 2020 Plan.

<u>Dividend Equivalents</u>

With the exception of stock options and SARs, awards under the 2020 Plan may, in the Compensation Committee's

discretion, earn dividend equivalents with respect to the cash or stock dividends or other distributions that would have

been paid on the shares of our common stock covered by such award had such shares been issued and outstanding on

the dividend payment date. Such dividend equivalents will be converted to cash or additional shares of our common stock

by such formula and at such time and subject to such limitations as determined by the Compensation Committee, and

only paid out once the award becomes vested.

<u>Termination of Service</u>

Unless otherwise expressly set forth in an individual agreement, the Compensation Committee will have the sole

discretion to determine and set forth in an award agreement the effect that the termination of a participant's employment

or other service with the Company and all subsidiaries may have on any award.

<u>Modification of Rights upon Termination</u>

Upon a participant's termination of employment or other service with the Company or any subsidiary, the Compensation

Committee may, in its sole discretion (which may be exercised at any time on or after the grant date, including following

such termination) cause stock options or SARs (or any part thereof) held by such participant as of the effective date of

such termination to terminate, become or continue to become exercisable or remain exercisable following such

termination of employment or service, and restricted stock, restricted stock units, deferred stock units, performance

awards, annual performance cash awards, non-employee Director awards, other cash-based awards and other stock-

based awards held by such participant as of the effective date of such termination to terminate, vest or become free of

restrictions and conditions to payment, as the case may be, following such termination of employment or service, in each

case in the manner determined by the Compensation Committee; provided, however, that no stock option or SAR may

remain exercisable beyond its expiration date.

<u>Determination of Termination</u>

The change in a participant's status from a team member to a consultant will be deemed a termination unless the

Compensation Committee determines otherwise, in its sole discretion. The change in a participant's status from a

consultant to a team member or from that of a team member to that of a Director will not be deemed a termination of the

participant's service as a consultant or team member, respectively. Unless the Compensation Committee determines

otherwise, a participant's termination date will be deemed to be the date recorded on personnel or other records of the

Company or any subsidiary. If the payment of an award that is subject to Section 409A of the IRC is triggered by

termination of a participant's employment or other service, the termination must also constitute a "separation from service"

within the meaning of Section 409A of the IRC, and any change in employment status that constitutes a "separation from

service" under Section 409A of the IRC will be treated as a termination of employment or service, as the case may be.

<u>Forfeiture and Recoupment</u>

---

| | |
|:---|:---|
| **72 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

If a participant is determined by the Compensation Committee to have taken any action while providing services to the

Company or after termination of such services, that would constitute "cause" or an "adverse action," as such terms are

defined in the 2020 Plan, all rights of the participant under the 2020 Plan and any agreements evidencing an award then

held by the participant will terminate and be forfeited. The Compensation Committee has the authority to rescind the

exercise, vesting, issuance or payment in respect of any awards of the participant that were exercised, vested, issued or

paid, and require the participant to pay to the Company, within ten days of receipt of notice, any amount received or the

amount gained as a result of any such rescinded exercise, vesting, issuance or payment. The Company may defer the

exercise of any stock option or SAR for up to six months after receipt of notice of exercise in order for the Compensation

Committee to determine whether "cause" or "adverse action" exists. The Company is entitled to withhold and deduct future

wages to collect any amount due. In addition, if the Company is required to prepare an accounting restatement due to

material noncompliance, as a result of misconduct, with any financial reporting requirement under the securities laws, then

any participant who is one of the individuals subject to automatic forfeiture under Section 304 of the Sarbanes-Oxley Act

of 2002 will reimburse the Company for the amount of any award received by such individual under the 2020 Plan during

the 12-month period following the first public issuance or filing with the Securities and Exchange Commission, as the case

may be, of the financial document embodying such financial reporting requirement. The Company may also seek to

recover any award made as required by the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection

Act or any other clawback, forfeiture or recoupment provision required by applicable law or under the requirements of any

stock exchange or market upon which our common stock is then listed or traded. In addition, all awards under the 2020

Plan will be subject to forfeiture and other penalties pursuant to any standalone clawback or forfeiture policy of the

Company, as in effect from time to time, including the Sleep Number Corporation Clawback and Forfeiture Policy, and

such forfeiture and/or penalty conditions or provisions as determined by the Compensation Committee and set forth in the

applicable award agreement.

<u>Change in Control and Acceleration of Vesting</u>

Generally, a change in control means the occurrence of any one of the following events:

• During any 24 month period, individuals who, as of the beginning of such period, constitute the Board cease for any

reason to constitute at least a majority of the Board, subject to certain exceptions;

• Any person is or becomes a "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or

indirectly, of securities of the Company representing 35% or more of the combined voting power of the Company's

then outstanding securities eligible to vote for the election of the Board, subject to certain exceptions;

• The consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction

involving the Company or any of its subsidiaries that requires the approval of the Company's shareholders, unless

certain criteria are met; or

• The consummation of a sale of all or substantially all of the Company's assets or the approval by shareholders of the

Company of a plan of complete liquidation or dissolution of the Company.

Notwithstanding the foregoing, such a change in control shall not be deemed to occur solely because any person acquires

beneficial ownership of more than 35% of the Company's voting securities as a result of the acquisition of Company voting

securities by the Company which reduces the number of our voting securities outstanding. However, if after such

acquisition by the Company such person becomes the beneficial owner of additional voting securities of the Company that

increases the percentage of our outstanding voting securities beneficially owned by such person, a change in control of

the Company shall then occur.

---

| | |
|:---|:---|
| **73 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

Without limiting the authority of the Compensation Committee to adjust awards as discussed under the headings "Plan

Administration" and "Adjustments," if a change in control of the Company occurs, then, unless otherwise provided in the

Award Agreement, if the Company is not the surviving corporation or the acquiring corporation does not assume the

outstanding awards or substitute equivalent awards, then:

• All outstanding stock options and SARs will become immediately exercisable in full and will remain exercisable for the

remainder of their terms, regardless of whether the participant to whom such stock options or SARs have been

granted remains in employment or service with the Company or any subsidiary;

• All restrictions and vesting requirements applicable to any award based solely on the continued service of the

participant will terminate; and

• All awards, the vesting or payment of which are based on performance goals, will vest as though such performance

goals were fully achieved at target and will become immediately payable.

However, no award that provides for a deferral of compensation within the meaning of Section 409A of the Internal

Revenue Code of 1986, as amended (IRC) will be cashed out upon the occurrence of a change in control unless the event

or circumstances constituting the change in control also constitute a "change in the ownership" of the Company, a "change

in the effective control" of the Company or a "change in the ownership of a substantial portion of the assets" of the

Company, in each case as determined under Section 409A of the IRC. The treatment of any other awards in the event of a

change in control will be as determined by the Compensation Committee in connection with the grant thereof, as reflected

in the applicable award agreement. The Compensation Committee is given the power under the 2020 Plan to alternatively

provide that upon a change in control, any or all outstanding stock-based awards will be canceled and terminated and the

holders will receive a payment of cash or stock equal to the difference, if any, between the consideration received by

shareholders in respect of a share of common stock in connection with the change in control and the purchase price per

share, if any, under the award, multiplied by the number of shares subject to such award, provided that if such product is

zero or less, or the award is not exercisable, the award may be canceled and terminated without payment for such award.

If a participant's employment or other service with the Company is terminated without "cause" or "adverse action" (as such

terms are defined in the 2020 Plan) within two years following a change in control, and the Company is the surviving

corporation following such change in control, or the acquiror assumes the outstanding awards or substitutes equivalent

equity awards relating to the securities of such acquiror or its affiliates for such awards, then:

• All outstanding options and SARs will become immediately exercisable in full and will remain exercisable for the

remainder of their terms, regardless of whether the participant to whom such options or SARs have been granted

remains in employment or service with the Company;

• All restrictions and vesting requirements applicable to any award based solely on the continued service of the

participant will terminate; and

• All awards, the vesting or payment of which is based on performance goals, will vest as though such performance

goals were fully achieved at target and will become immediately payable.

However, no award that provides for a deferral of compensation within the meaning of Section 409A of the IRC will be

cashed out upon the occurrence of a change in control unless the event or circumstances constituting the change in

control also constitute a "change in the ownership" of the Company, a "change in the effective control" of the Company or

a "change in the ownership of a substantial portion of the assets" of the Company, in each case as determined under

Section 409A of the IRC. The treatment of any other awards in the event of a change in control will be as determined by

the Compensation Committee in connection with the grant thereof, as reflected in the applicable award agreement.

<u>Substituted Awards</u>

The Compensation Committee may grant awards under the 2020 Plan in substitution for stock and stock-based awards

held by team members of another entity who become team members of the Company or a subsidiary as a result of a

---

| | |
|:---|:---|
| **74 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

merger or consolidation of the former employing entity with the Company or a subsidiary or the acquisition by the

Company or a subsidiary of property or stock of the former employing corporation. The Compensation Committee may

direct that the substitute awards be granted on such terms and conditions as the Compensation Committee considers

appropriate in the circumstances, subject to compliance with the rules under Sections 409A, 422 and 424 of the IRC, as

and where applicable.

<u>Term, Termination and Amendment</u>

Unless sooner terminated by the Board, the 2020 Plan will terminate at midnight on May 12, 2030. No award will be

granted after termination of the 2020 Plan, but awards outstanding upon termination of the 2020 Plan will remain

outstanding in accordance with their applicable terms and conditions and the terms and conditions of the 2020 Plan.

Subject to certain exceptions, the Board has the authority to terminate and the Compensation Committee has the authority

to amend the 2020 Plan or any outstanding award agreement at any time and from time to time, provided that certain

amendments to the 2020 Plan will not become effective without shareholder approval, as set forth below. No termination,

suspension or amendment of the 2020 Plan may materially adversely affect any outstanding award without the consent of

the affected participant.

No amendments to the 2020 Plan will be effective without approval of the Company's shareholders if: (a) shareholder

approval of the amendment is then required pursuant to Section 422 of the IRC, the rules of the primary stock exchange

on which the common stock is then traded, applicable U.S. state and federal laws or regulations and the applicable laws

of any foreign country or jurisdiction where awards are, or will be, granted under the 2020 Plan or (b) such amendment

would: (i) modify the restrictions on re-pricing, (ii) materially increase benefits accruing to participants, (iii) subject to

certain adjustments, increase the aggregate number of shares of common stock issued or issuable under the 2020 Plan,

(iv) modify the eligibility requirements for participants in the 2020 Plan or (v) reduce the minimum exercise price as set

forth in the 2020 Plan.

<u>Plan Benefits</u>

It is not presently possible to determine the benefits or amounts that will be received by or allocated to participants under

the 2020 Plan or that would have been received by or allocated to participants for the last completed fiscal year if the 2020

Plan had then been in effect because awards under the 2020 Plan will be made at the discretion of the Compensation

Committee.

---

| | |
|:---|:---|
| **75 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

<u>Awards Previously Granted Under 2020 Plan</u>

The following table sets forth the total number of shares of our common stock subject to awards that have been granted

(even if not currently outstanding) under the 2020 Plan as of March 13, 2026:

---

| | | | |
|:---|:---|:---|:---|
| **Name and Position** | **Number of** <br>**Shares** <br>**Underlying** <br>**Stock Options**<br>| **Target** <br>**Number of** <br>**PSUs**<br>| **Number of** <br>**Shares** <br>**Underlying** <br>**RSUs**<br>|
| Linda Findley, President and CEO<sup>(1)</sup> |  |  |  |
| Shelly Ibach, former President and CEO | 135260 | 312656 | 90946 |
| Francis Lee, former EVP and CFO | 72005 | 91855 | 88770 |
| Robert Ryder, former Interim CFO |  |  |  |
| Amy O'Keefe, EVP and CFO<sup>(2)</sup> |  |  |  |
| Andrea Bloomquist, former EVP and Chief Innovation Officer | 28060 | 102932 | 56417 |
| Kevin Brown, former EVP and Chief Marketing Officer | 19735 | 70631 | 38081 |
| Melissa Barra, EVP, Chief Sales and Services Officer | 27965 | 102787 | 56417 |
| Samuel Hellfeld, EVP, Chief Legal and Risk Officer | 22085 | 83349 | 53916 |
| Christopher Krusmark, EVP and Chief Retail and People Officer | 15890 | 57240 | 41720 |
| Current Executive Group | 326530 | 830560 | 473594 |
| Non-Employee Director Group | 63996 |  | 241626 |
| All Other Employee and Consultant Group | 143380 | 325927 | 2523936 |

---

<sup>(1)</sup> Ms. Findley assumed the role of President and Chief Executive Officer on April 7, 2025. As an incentive to join the Company, Ms. Findley received

inducement grants. See "Pay Elements: Benefits and Perquisites - New CEO Hire Package " on page <u>[42](#i44eec75d700a4a12a1ccd8dcee0c79e2_232)</u> for further details.

<sup>(2)</sup> Ms. O'Keefe assumed the role of Executive Vice President and Chief Financial Officer on December 8, 2025. As an incentive to join the Company, Ms.

O'Keefe received inducement grants of 69,742 shares of a restricted stock unit granted on December 15, 2025. See "Pay Elements: Benefits and

Perquisites - New CFO Hire Package " on page <u>[44](#i44eec75d700a4a12a1ccd8dcee0c79e2_235)</u> for further details.

**Federal Income Tax Information**

The following is a general summary, as of the date of this Proxy Statement, of the federal income tax consequences to

participants and the Company of transactions under the 2020 Plan. This summary is intended for the information of

shareholders considering how to vote at the 2026 Annual Meeting and not as tax guidance to participants in the 2020

Plan, as the consequences may vary with the types of grants made, the identity of the participant, including the

participant's individual tax situation, and the method of payment or settlement. The summary does not address the effects

of other federal taxes or taxes imposed under state, local or foreign tax laws. Participants are encouraged to seek the

advice of a qualified tax advisor regarding the tax consequences of participation in the 2020 Plan.

<u>Incentive Stock Options</u>

With respect to statutory stock options, which are more commonly referred to as incentive stock options, generally, the

participant is not taxed, and we are not entitled to a deduction, on either the grant or the exercise of an incentive stock

option so long as the requirements of Section 422 of the IRC continue to be met (the participant may, however, need to

determine whether there are any alternative minimum tax (AMT) implications upon exercise). If the participant meets the

employment requirements and does not dispose of the shares of our common stock acquired upon exercise of an

incentive stock option until at least one year after date of the exercise of the stock option and at least two years after the

date the stock option was granted, gain or loss realized on sale of the shares will be treated as long-term capital gain or

loss. If the shares of our common stock are disposed of before those periods expire, which is called a disqualifying

disposition, the participant will be required to recognize ordinary income in an amount equal to the lesser of (i) the excess,

if any, of the fair market value of our common stock on the date of exercise over the exercise price or (ii) if the disposition

is a taxable sale or exchange, the amount of gain realized. Upon a disqualifying disposition, we will generally be entitled,

in the same tax year, to a deduction equal to the amount of ordinary income recognized by the participant, assuming that

a deduction is allowed under Section 162(m) of the IRC.

---

| | |
|:---|:---|
| **76 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

<u>Non-Statutory Stock Options</u>

The grant of a stock option that does not qualify for treatment as an incentive stock option, which is generally referred to

as a non-statutory stock option, is generally not a taxable event for the participant. Upon exercise of the stock option, the

participant will generally be required to recognize ordinary income in an amount equal to the excess of the fair market

value of our common stock acquired upon exercise (determined as of the date of exercise) over the exercise price of the

stock option, and we will be entitled to a deduction in an equal amount in the same tax year, assuming that a deduction is

allowed under Section 162(m) of the IRC. At the time of a subsequent sale or disposition of shares obtained upon exercise

of a non-statutory stock option, any gain or loss will be a capital gain or loss, which will be either a long-term or short-term

capital gain or loss, depending on how long the shares have been held.

<u>Stock Appreciation Rights (SARs)</u>

The grant of a SAR will not cause the participant to recognize ordinary income or entitle us to a deduction for federal

income tax purposes. Upon the exercise of a SAR, the participant will recognize ordinary income in the amount of the

cash or the value of shares payable to the participant (before reduction for any withholding taxes), and we will receive a

corresponding deduction in an amount equal to the ordinary income recognized by the participant, assuming that a

deduction is allowed under Section 162(m) of the IRC.

<u>Restricted Stock, Restricted Stock Units, Deferred Stock Units and Other Stock-Based Awards</u>

The federal income tax consequences with respect to restricted stock, restricted stock units, deferred stock units and

other stock unit and stock-based awards depend on the facts and circumstances of each award, including, in particular,

the nature of any restrictions imposed with respect to the awards. In general, if an award granted to the participant is

subject to a "substantial risk of forfeiture" (e.g., the award is conditioned upon the future performance of substantial

services by the participant) and is nontransferable, a taxable event occurs when the risk of forfeiture ceases or the awards

become transferable, whichever first occurs. At such time, the participant will recognize ordinary income to the extent of

the excess of the fair market value of the stock on such date over the participant's cost for such stock (if any), and the

same amount is deductible by us, assuming that a deduction is allowed under Section 162(m) of the IRC. Under certain

circumstances, the participant, by making an election under Section 83(b) of the IRC within thirty days of the grant date of

an award, can accelerate federal income tax recognition with respect to an award of stock that is subject to a substantial

risk of forfeiture and transferability restrictions, in which event the ordinary income amount and our deduction will be

measured and timed as of the grant date of the award. If the award granted to the participant is not subject to a substantial

risk of forfeiture or transferability restrictions, the participant will recognize ordinary income with respect to the award to

the extent of the excess of the fair market value of the stock at the time of grant over the participant's cost, if any, and the

same amount is deductible by us, assuming that a deduction is allowed under Section 162(m) of the IRC. If a stock unit

award or other stock-based award is granted but no stock is actually issued to the participant at the time the award is

granted, the participant will recognize ordinary income at the time the participant receives stock free of any substantial risk

of forfeiture (or receives cash in lieu of such stock) and the amount of such income will be equal to the fair market value of

the stock at such time over the participant's cost, if any, and the same amount is then deductible by us, assuming that a

deduction is allowed under Section 162(m) of the IRC.

<u>Annual Performance Cash Awards and Other Cash-Based Awards</u>

Annual performance cash awards and other cash-based awards will be taxable as ordinary income to the participant in the

amount of the cash received by the participant (before reduction for any withholding taxes), and we will receive a

corresponding deduction in an amount equal to the ordinary income recognized by the participant, assuming that a

deduction is allowed under Section 162(m) of the IRC.

<u>Withholding Obligations</u>

We are entitled to withhold and deduct from future wages of the participant, to make other arrangements for the collection

of, or to require the recipient to pay to us, an amount necessary for us to satisfy the recipient's federal, state or local tax

---

| | |
|:---|:---|
| **77 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

withholding obligations with respect to awards granted under the 2020 Plan. Withholding for taxes may be calculated

based on the maximum applicable tax rate for the participant's jurisdiction or such other rate that will not trigger a negative

accounting impact on the Company. The Compensation Committee may permit a participant to satisfy a tax withholding

obligation by withholding shares of common stock underlying an award, tendering previously acquired shares, delivery of

a broker exercise notice or a combination of these methods.

<u>Code Section 409A</u>

A participant may be subject to a 20% penalty tax, in addition to ordinary income tax, at the time the grant becomes

vested, plus an interest penalty tax, if the grant constitutes deferred compensation under Section 409A of the IRC and the

requirements of Section 409A of the IRC, including any exceptions thereto, are not satisfied.

<u>Code Section 162(m)</u>

Pursuant to Section 162(m) of the IRC, the annual compensation paid to an individual who is a "covered employee" is not

deductible by us to the extent it exceeds $1 million. The Tax Cuts and Jobs Act, signed into law on December 22, 2017,

amended Section 162(m), effective for tax years beginning after December 31, 2017, (i) to expand the definition of a

"covered employee" to include any person who was the CEO or the Chief Financial Officer (CFO) at any time during the

year and the three most highly compensated officers (other than the CEO and CFO) who were employed at any time

during the year whether or not the compensation is reported in the Summary Compensation Table included in our Proxy

Statement; (ii) to treat any individual who is considered a covered employee at any time during a tax year beginning after

December 31, 2016 as remaining a covered employee permanently; and (iii) to eliminate the performance-based

compensation exception to the $1 million deduction limit (with a transition provision continuing the performance-based

exception for certain compensation covered by a written binding contract in existence on November 2, 2017).

<u>Excise Tax on Excess Parachute Payments</u>

Unless otherwise provided in a separate agreement between a participant and the Company, if, with respect to a

participant, the acceleration of the vesting of an award or the payment of cash in exchange for all or part of an award,

together with any other payments that such participant has the right to receive from the Company, would constitute an

"excess parachute payment" under Section 280G of the IRC, then the payments to such participant will be reduced to the

largest amount as will result in no portion of such payments being subject to the excise tax imposed by Section 4999 of

the IRC. Such reduction, however, will only be made if the aggregate amount of the payments after such reduction

exceeds the difference between the amount of such payments absent such reduction minus the aggregate amount of the

excise tax imposed under Section 4999 of the IRC attributable to any such excess parachute payments. If such provisions

are applicable and if a team member will be subject to a 20% excise tax on any "excess parachute payment" pursuant to

Section 4999 of the IRC, we will be denied a deduction with respect to such excess parachute payment pursuant to

Section 280G of the IRC.

---

| | |
|:---|:---|
| **78 \| 2026 PROXY STATEMENT** | **PROPOSAL 7 - VOTE ON AMENDMENT TO THE SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN, AS AMENDED** |

---

**Equity Compensation Plan Information**

---

| | | | |
|:---|:---|:---|:---|
| **Plan Category** | **Number of securities** <br>**to be issued upon** <br>**exercise of** <br>**outstanding options,** <br>**warrants and rights**<sup>(1)</sup> <br><sup>(a)</sup><br>| **Weighted average** <br>**exercise price of** <br>**outstanding options,** <br>**warrants and rights**<sup>(3)</sup><br><sup>(b)</sup><br>| **Number of** <br>**securities** <br>**remaining available** <br>**for future issuance** <br>**under equity** <br>**compensation plans** <br>**(excluding** <br>**securities reflected** <br>**in column (a))**<sup>(4) (c)</sup><br>|
| Equity compensation plans approved by <br>security holders<br>| 3007357<br><sup>(2)</sup> | $42.47 | 3436823 |
| Equity compensation plans not approved by <br>security holders<br>|  | Not applicable |  |
| Total | 3007357 | $42.47 | 3436823 |

---

<sup>(1)</sup> Includes the 2020 Plan and the Sleep Number Corporation 2010 Omnibus Incentive Plan.

<sup>(2)</sup> This amount includes 1,122,642 restricted stock units, 1,106,148 performance-based stock units and 18,927 phantom shares. Performance-based

stock units are shown at target. The actual number of shares to be issued under performance-based stock unit awards depends on Company

performance against goals.

<sup>(3)</sup> The weighted average exercise price does not take into account the unvested restricted stock units, performance-based stock units or phantom

shares, which have no exercise price.

<sup>(4)</sup> This represents the number of shares of common stock available for issuance under the 2020 Plan.

**Board Recommendation**

The Board unanimously recommends that the shareholders vote "**For**" approval of the amendment to the Sleep Number

Corporation 2020 Equity Incentive Plan, as amended, to increase the number of shares authorized for issuance by

750,000 shares.

**Vote Required**

The affirmative vote of the holders of a majority of the shares of common stock present and entitled to vote in person or by

proxy on this matter at the Annual Meeting, and at least a majority of the minimum number of votes necessary for a

quorum, is necessary for approval of the Plan Amendment. Unless a contrary choice is specified, proxies solicited by the

Board will be voted "**For**" approval of the Plan Amendment.

---

| | |
|:---|:---|
| **79 \| 2026 PROXY STATEMENT** | **OUR SHAREHOLDERS** |

---

![Our Shareholders.jpg](snbr-20260408_g34.jpg)

**STOCK OWNERSHIP OF MANAGEMENT AND CERTAIN BENEFICIAL OWNERS**

The following table shows the beneficial ownership of Sleep Number common stock as of February 28, 2026 (unless

another date is indicated) by: (a) each Director, each nominee for Director recommended by our Board and each

executive officer named in the Summary Compensation Table on page <u>[49](#i44eec75d700a4a12a1ccd8dcee0c79e2_265)</u> of this Proxy Statement, (b) all Directors and

executive officers as a group and (c) each person known by us to be the Beneficial Owner of more than 5% of Sleep

Number common stock.

---

| | | | |
|:---|:---|:---|:---|
| **Title of Class** | **Name and Address of Beneficial Owner**<sup>(1)</sup> | **Amount and** <br>**Nature of** <br>**Beneficial** <br>**Ownership**<sup>(2)(3)</sup><br>| **Percent of Class** |
| **Named Executive Officers and Directors:** | **Named Executive Officers and Directors:** | | |
| Common Stock | Melissa Barra | 131665 | \* |
| Common Stock | Andrea L. Bloomquist | 131414 | \* |
| Common Stock | Kevin K. Brown | 41437 | \* |
| Common Stock | Phillip M. Eyler<sup>(4)</sup> | 16957 | \* |
| Common Stock | Linda A. Findley | 285549 | 1.2% |
| Common Stock | Stephen L. Gulis, Jr<sup>(4)</sup> | 93772 | \* |
| Common Stock | Samuel R. Hellfeld | 96509 | \* |
| Common Stock | Julie M. Howard<sup>(4)</sup> | 41385 | \* |
| Common Stock | Shelly R. Ibach | 836711 | 3.6% |
| Common Stock | Deborah L. Kilpatrick, Ph.D.<sup>(4)</sup> | 41204 | \* |
| Common Stock | Christopher K. Krusmark | 57416 | \* |
| Common Stock | Brenda J. Lauderback<sup>(4)</sup> | 69331 | \* |
| Common Stock | Francis K. Lee | 18874 | \* |
| Common Stock | Stephen E. Macadam<sup>(4)</sup> | 111318 | \* |
| Common Stock | Barbara R. Matas<sup>(4)</sup> | 60561 | \* |
| Common Stock | Angel L. Mendez<sup>(4)</sup> | 16957 | \* |
| Common Stock | Amy K. O'Keefe |  | \* |
| Common Stock | Robert P. Ryder | 15000 | \* |
| Common Stock | Hilary A. Schneider | 12102 | \* |
| Common Stock | All current Directors and executive officers as a group (14 <br>persons)<sup>(5)</sup><br>| 850417 | 3.6% |
| **5% Shareholders:** | **5% Shareholders:** |  |  |
| Common Stock | Stadium Capital Management LLC<sup>(6)</sup><br>199 Elm Street<br>New Canaan, CT 06840<br>| 2616459 | 11.4% |
| Common Stock | M Partners Fund LP<sup>(7)</sup><br>24 Shipyard Drive, Suite 102<br>Hingham, MA 02043<br>| 2263729 | 9.9% |
| Common Stock | FMR LLC<sup>(8)</sup><br>245 Summer Street<br>Boston, MA 02210<br>| 2129876 | 9.3% |
| Common Stock | BlackRock, Inc.<sup>(9)</sup><br>55 East 52<sup>nd</sup> Street<br>New York, New York 10055<br>| 1455050 | 6.4% |

---

---

| | |
|:---|:---|
| **80 \| 2026 PROXY STATEMENT** | **OUR SHAREHOLDERS** |

---

---

| | | |
|:---|:---|:---|
| **Title of Class** | **Amount and** <br>**Nature of** <br>**Beneficial** <br>**Ownership**<sup>(2)(3)</sup><br>| **Percent of Class** |
| Common Stock<br> The Vanguard Group, Inc.<sup>(10)</sup> <br>100 Vanguard Blvd. <br>Malvern, Pennsylvania 19355<br>| 1246460 | 5.5% |
| Common Stock<br> Pacific Ridge Capital Partners, LLC<sup>(11)</sup><br>4900 Meadows Rd, Ste 320<br>Lake Oswego, OR 97035<br>| 1145612 | 5.0% |

---

\* Less than 1% of the outstanding shares.

<sup>(1)</sup> The business address for each of the Directors and executive officers of the Company is c/o Sleep Number Corporation, 1001 Third Avenue South,

Minneapolis, Minnesota 55404.

<sup>(2)</sup> The shares shown include the following shares that Directors and executive officers have the right to acquire within 60 days through the exercise of

stock options: Ms. Barra, 44,596; Mr. Eyler, 4,285; Mr. Hellfeld, 41,305; Ms. Howard, 5,830; Ms. Ibach, 394,425; Ms. Kilpatrick, 9,860; Mr. Krusmark,

21,370, Ms. Lauderback, 15,477; Mr. Macadam, 2,373, Mr. Mendez, 4,285; and Ms. Schneider, 2,373.

<sup>(3)</sup> The shares shown include the following shares that executive officers have the right to acquire within 60 days through the vesting of restricted stock

units: Ms. Barra, 18,806; Ms. Findley, 181,029, Mr. Hellfeld, 17,199; and Mr. Krusmark, 10,343.

<sup>(4)</sup> The 2020 Plan permits non-employee Directors to receive Director fees in the form of common stock in lieu of cash and to defer receipt of such

shares. In addition, the 2020 Plan permits non-employee Directors to defer receipt of shares of the Company's common stock under an Incentive

Award granted under the 2020 Plan (referred to as Restricted Stock Units or RSUs). The Directors are entitled to the deferred shares and fully-vested

RSUs until the earlier of an elected date or separation of service from the Company. Mr. Eyler's amount includes 12,672 RSUs that were deferred.

Ms. Kilpatrick's amount includes 616 shares that were deferred in lieu of Director fees and 2,728 RSUs that were deferred. Ms. Lauderback's amount

includes 9,236 RSUs that were deferred. Ms. Howard's amount includes 12,233 shares that were deferred in lieu of Director fees and 12,737 RSUs

that were deferred. Mr. Macadam's amount includes 6,079 shares that were deferred in lieu of Director fees and 5,457 RSUs that were deferred. Mr.

Mendez's amount includes 9,652 RSUs that were deferred. In fiscal year 2025, non-employee Directors are not entitled to receive Director fees in the

form of common stock in lieu of cash.

<sup>(5)</sup> Included in this line are current Directors and executive officers as of February 28, 2026. Includes an aggregate of 147,036 shares that current

Directors and executive officers as a group have the right to acquire within 60 days through the exercise of stock options. Includes an aggregate of

239,219 shares that Directors and executive officers as a group have the right to acquire within 60 days through the vesting of restricted stock units.

Also includes 18,927 shares that were deferred by non-employee Directors in lieu of Director fees and 43,246 stock units that were deferred by non-

employee Directors.

<sup>(6)</sup> Stadium Capital Management LLC reported in a Schedule 13D/A filed with the Securities and Exchange Commission on August 6, 2025 that as of

August 6, 2025 it beneficially owned 2,616,459 shares of Common Stock of Sleep Number Corporation, and had shared power to vote or to direct the

vote and shared dispositive power with respect to 2,616,459 shares.

<sup>(7)</sup> M Partners Fund LP reported in a Schedule 13G/A filed with the Securities and Exchange Commission on August 14, 2025 that as of June 30, 2025 it

beneficially owned 2,263,729 shares of Common Stock of Sleep Number Corporation, and had shared power to vote or to direct the vote and shared

dispositive power with respect to 2,263,729 shares.

<sup>(8)</sup> FMR LLC reported in a Schedule 13G filed with the Securities and Exchange Commission on February 5, 2026 that as of December 31, 2025 it

beneficially owned 2,129,876 shares of Common Stock of Sleep Number Corporation, had sole power to vote or to direct the vote with respect to

2,125,213 shares and sole dispositive power with respect to 2,219,876 shares.

<sup>(9)</sup> BlackRock, Inc. reported in a Schedule 13G/A filed with the Securities and Exchange Commission on October 17, 2025 that as of September 30,

2025 it beneficially owned 1,455,050 shares of Common Stock of Sleep Number Corporation, had sole power to vote or to direct the vote with respect

to 1,417,441 shares and sole dispositive power with respect to 1,455,050 shares.

<sup>(10)</sup> The Vanguard Group, Inc. reported in a Schedule 13G/A filed with the Securities and Exchange Commission on January 10, 2024 that as of

December 29, 2023 it beneficially owned 1,246,460 shares of Common Stock of Sleep Number Corporation, had no sole power to vote or to direct the

vote with respect to any shares, shared power to vote or to direct the vote with respect to 27,467 shares, shared dispositive power with respect to

49,348 shares and sole dispositive power with respect to 1,197,112 shares.

<sup>(11)</sup> Pacific Ridge Capital Partners, LLC reported in a Schedule 13G filed with the Securities and Exchange Commission on February 6, 2026 that as of

December 31, 2025 it beneficially owned 1,145,612 shares of Common Stock of Sleep Number Corporation, had sole power to vote or to direct the

vote with respect to 704,330 shares and sole dispositive power with respect to 1,145,612 shares.

**SHAREHOLDER PROPOSALS FOR 2027 ANNUAL MEETING**

Any shareholder proposal requested to be included in the proxy materials for the 2027 Annual Meeting must (a) be

received by our Chief Legal and Risk Officer and Secretary on or before December 9, 2026, and (b) satisfy all of the

requirements of, and not otherwise be permitted to be excluded under, Rule 14a-8 promulgated by the SEC and our

Bylaws. In addition, shareholders who intend to solicit proxies in support of director nominees other than the Company's

nominees must also comply with the additional requirements the universal proxy rules that sets forth the information

required in Rule 14a-19(b) under the Exchange Act no later than March 22, 2027.

---

| | |
|:---|:---|
| **81 \| 2026 PROXY STATEMENT** | **OUR SHAREHOLDERS** |

---

Our Bylaws require advance written notice to our Company of shareholder-proposed business or of a shareholder's

intention to make a nomination for Director at an Annual Meeting. They also limit the business which may be conducted at

any special meeting of shareholders to business brought by the Board.

Specifically, the Bylaws provide that business may be brought before an Annual Meeting by a shareholder only if the

shareholder provides written notice to the Secretary of our Company not less than 120 days prior to the first anniversary of

the date that we first released or mailed our proxy materials to shareholders in connection with the preceding year's

Annual Meeting. Under these provisions, notice of a shareholder proposal to be presented at the 2027 Annual Meeting

(but that is not requested to be included in the proxy materials) must be provided to the Secretary of our Company on or

before December 9, 2026. In the event, however, that the date of the Annual Meeting is advanced by more than 30 days

or delayed by more than 60 days from the anniversary of the preceding year's Annual Meeting date, notice by the

shareholder to be timely must be so delivered not later than the close of business on the later of the 120th day prior to

such Annual Meeting or the 10th day following the day on which public announcement of the date of such meeting is first

made.

A shareholder's notice must set forth:

• A description of the proposed business and the reasons for it;

• The name and address of the shareholder making the proposal;

• The class and number of shares of common stock owned by the shareholder; and

• A description of any material interest of the shareholder in the proposed business.

Our Bylaws also provide that a shareholder may nominate a Director at an Annual Meeting only after providing advance

written notice to the Secretary of our Company within the time limits described above. The shareholder's notice must set

forth all information about each nominee that would be required under SEC rules in a proxy statement soliciting proxies for

the election of such nominee, as well as the nominee's business and residence address. The notice must also set forth

the name and record address of the shareholder making the nomination and the class and number of shares of common

stock owned by that shareholder.

Shareholders wishing to nominate director candidates must submit a written request with related and required information

to our corporate Secretary in accordance with the terms of our Bylaws at least 120 days prior to the first anniversary of the

date that the Company first released or mailed its proxy materials to shareholders in connection with the preceding year's

regular or Annual Meeting. The CGNC will review and evaluate these candidates in the same manner as other

nominations.

The shareholder's notice must include, for each director nominee: (a) the name, age, business address and residence

address of the nominee, (b) the principal occupation or employment of the nominee, (c) the class and number of shares of

capital stock of the Company that are beneficially owned by the nominee and (d) any other information concerning the

nominee that would be required under the rules of the SEC in a proxy statement soliciting proxies for the election of such

nominee. The shareholder's notice must also include: (a) the name and address of the nominating shareholder, as they

appear on the Company's books and (b) the class and number of shares of the Company that are owned beneficially and

of record by the shareholder. The shareholder's notice must also be accompanied by the proposed nominee's signed

consent to serve as a Director of the Company.

---

| | |
|:---|:---|
| **82 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

![Our Annual Meeting and Voting.jpg](snbr-20260408_g35.jpg)

**FREQUENTLY ASKED QUESTIONS ABOUT THE MEETING AND VOTING**

**When is the Annual Meeting?**

The Annual Meeting will be held at 8:30 a.m. Central Time on May 21, 2026.

If we determine to make any change to the date, time or procedures of our Annual Meeting, we will announce such

changes in advance on our website *http://ir.sleepnumber.com* and file with the Securities and Exchange Commission as

additional proxy materials.

**How can shareholders attend?**

The meeting will be conducted as a virtual meeting via the internet. Shareholders may participate in the meeting and

submit questions electronically during the meeting via live webcast by visiting the virtual meeting platform at

***www.virtualshareholdermeeting.com/SNBR2026****.* Shareholders must enter the 16-digit control number included in

Notice of Internet Availability of Proxy Materials, on the proxy card or in the instructions that accompanied the proxy

materials to enter the Annual Meeting. Shareholders may log into the virtual meeting platform beginning at 8:15 a.m.

Central Time on May 21, 2026.

The virtual meeting platform is fully supported across browsers (Internet Explorer, Firefox, Chrome and Safari) and

devices (desktops, laptops, tablets and cell phones) running the most updated version of applicable software and plugins.

Participants should confirm that they have a strong Internet connection and log in early to ensure that they can hear

streaming audio prior to the start of the meeting. If you encounter any technical difficulties, please call the technical

support number that will be posted on the virtual meeting platform log-in page.

If you wish to submit a question, you may do so during the meeting. Detailed guidelines for submitting written questions

during the meeting will be available at ***www.virtualshareholdermeeting.com/SNBR2026***. Questions pertinent to meeting

matters will be recognized and answered during the meeting, subject to time constraints. We reserve the right to edit or

reject questions that are profane or otherwise inappropriate. Appropriate questions pertinent to meeting matters that

cannot be answered during the meeting due to time constraints will be posted and answered online at *http://*

*ir.sleepnumber.com* and be available as soon as practical after the meeting. The information contained in or connected to

our website is not incorporated by reference into, or considered a part of, this Proxy Statement.

**What is up for shareholder vote?**

There are seven proposals up for shareholder vote:

• **Proposal 1:** Elect three persons to serve as Directors for three-year terms;

• **Proposal 2:** Approve amendments to our Articles and Bylaws **to declassify the Board**;

• **Proposal 3:** Approve an amendment to our Articles to eliminate the supermajority voting requirement in Article XIV

related to our Directors;

• **Proposal 4:** Approve an amendment to our Articles to eliminate the supermajority voting requirements in Article XV

related to approval of certain transactions;

• **Proposal 5:** Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for

the 2026 fiscal year ending January 2, 2027;

• **Proposal 6:** Cast an advisory vote to approve executive compensation (Say on Pay); and

---

| | |
|:---|:---|
| **83 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

• **Proposal 7:** Approve the amendment to the Sleep Number Corporation 2020 Equity Incentive Plan, as amended,

(2020 Plan) to increase the number of shares reserved for issuance by 750,000 shares.

**What are the voting choices?**

For Proposal 1 (the election of Directors) you may vote in favor of up to three nominees. You may mark instructions with

respect to any or all of the nominees, but you should mark a vote "**For**" only three nominees in total. If you vote for more

than three nominees, your votes on Proposal 1 will be invalid and will not be counted. You are permitted to vote for fewer

than three nominees.

For each of Proposal 2 (approve amendments to our Articles and Bylaws to declassify the Board); Proposal 3 (approve an

amendment to our Articles to eliminate the supermajority voting requirement in Article XIV); Proposal 4 (approve an

amendment to our Articles to eliminate the supermajority voting requirements in Article XV); Proposal 5 (ratify the

appointment of independent auditors); Proposal 6 (advisory vote to approve executive compensation (Say on Pay)); and

Proposal 7 (approve the amendment to the 2020 Plan) you may:

• Vote in favor of the proposal;

• Vote against the proposal; or

• Abstain from voting on the proposal.

**How does the Board recommend that shareholders vote?**

Sleep Number's Board unanimously recommends that shareholders vote as follows:

**•Proposal 1: "For"** the election of each of the nominees for Director nominated herein by the Board of Sleep Number.

• **Proposal 2:** "**For**" amendments to our Articles and our Bylaws to declassify the Board.

• **Proposal 3:** "**For**" an amendment to our Articles to eliminate the supermajority voting requirement in Article XIV

related to our Directors.

• **Proposal 4:** "**For**" an amendment to our Articles to eliminate the supermajority voting requirements in Article XV

related to certain transactions.

• **Proposal 5:** "**For**" the ratification of the appointment of Deloitte & Touche LLP as our independent registered public

accounting firm for the fiscal year ending January 2, 2027.

• **Proposal 6: "For"** the advisory vote to approve executive compensation (Say on Pay).

• **Proposal 7: "For"** the amendment to the 2020 Plan to increase the number of shares reserved for issuance by

750,000 shares.

If you are a Shareholder of Record, as defined below, and grant a proxy by telephone or Internet without voting

instructions, or sign and submit your proxy card without voting instructions, your shares will be voted "For" each Director

nominee and "**For**" each of the other proposals outlined above in accordance with the recommendations of the Board.

**Who is eligible to vote?**

Shareholders of record at the close of business on March 23, 2026 (the Record Date) are entitled to vote at the meeting.

As of the Record Date, there were 23,041,012 shares of common stock outstanding. Each share is entitled to one vote on

each matter to be voted on at the Annual Meeting. Shareholders do not have cumulative voting rights.

<u>What is the difference between "Shareholders of Record" and "Beneficial Owners"?</u>

If your shares are registered in your name in the records maintained by our stock transfer agent, you are a "Shareholder

of Record." If you are a Shareholder of Record, notice of the meeting was sent directly to you.

---

| | |
|:---|:---|
| **84 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

If your shares are held in the name of your bank, broker, nominee or other holder of record, your shares are held in "street

name" and you are considered the "Beneficial Owner." Notice of the meeting has been forwarded to you by your bank,

broker, nominee or other holder of record, who is considered, with respect to those shares, the Shareholder of Record. As

the Beneficial Owner, you have the right to direct your bank, broker, nominee or other holder of record how to vote your

shares by using the voting instructions you received.

**What constitutes a "quorum," or how many shares are required to be present to conduct business at the Annual** 

**Meeting?**

The presence, directly or by proxy, of the holders of a majority of the outstanding shares of common stock entitled to vote

(i.e., at least 11,520,507 shares) will constitute a quorum for the transaction of business at the Annual Meeting. In general,

shares of common stock represented by a properly signed and returned proxy card or properly voted by telephone or via

the Internet will be counted as shares represented and entitled to vote at the Annual Meeting for purposes of determining

a quorum, without regard to whether the card reflects abstentions and withhold votes (or is left blank) or reflects a "broker

non-vote" on a matter.

**How do shareholders vote their shares?**

If you are a *Shareholder of Record* as of the Record Date, you can vote your shares in any of the following ways:

• Over the *telephone* by calling the toll-free number on the proxy card,

• Over the *Internet* by following the instructions on the proxy card,

• Through the *mail* – if you received a paper copy of the Proxy Statement, you may vote by mail by signing, dating and

mailing your proxy card in the envelope provided to be received no later than May 19, 2026 or

• Over the Internet during the 2026 Annual Meeting by going to ***www.virtualshareholdermeeting.com/SNBR2026*** and

using your 16-digit control number (included on Notice of Internet Availability of Proxy Materials, on your proxy card or

in the instructions that accompanied your proxy materials).

Your vote is important. Whether or not you plan to attend the meeting, we urge you to vote your shares in time for our

May 21, 2026 meeting date.

<u>How Beneficial Owners vote</u>

If you are a Beneficial Owner of shares held in "street name," such as through a bank, broker, nominee or other holder of

record, you generally cannot vote your shares directly and must instead vote your shares in the manner prescribed by

your bank, broker, nominee or other holder of record. Your bank, broker, nominee or other holder of record has provided

notice by email or a printed voting instruction card for you to use in directing the bank, broker, nominee or other holder of

record how to vote your shares. Telephone and Internet voting are also encouraged for Beneficial Owners who hold their

shares in street name.

**What is a Broker Non-Vote?**

If a Beneficial Owner does not provide timely instructions, the broker will not have the authority to vote on any non-routine

proposals at the Annual Meeting, which includes Proposals 1, 2, 3, 4, 6 and 7. Brokers will have discretionary authority to

vote on Proposal 5 because the ratification of the appointment of independent auditors is considered a routine matter. If

the broker votes on Proposal 5 but does not vote on another proposal because the broker does not have discretionary

voting authority and has not received instructions from the Beneficial Owner, this results in a "broker non-vote" with

respect to such other proposal(s) and has the effect on each proposal as is set forth in the below table.

---

| | |
|:---|:---|
| **85 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

**What is the vote required to approve each proposal?**

The below table summarizes each of the proposals, votes required, and the effects of: votes withheld, abstentions and

broker non-votes.

---

| | | | |
|:---|:---|:---|:---|
| **Proposal** | **Votes Required** | **Effect of Votes Withheld /** <br>**Abstentions**<br>| **Effect of Broker**<br>**Non-Votes**<br>|
| **Proposal 1:** Election of <br>Directors<br>| For uncontested elections, <br>affirmative vote of the <br>holders of a majority of the <br>shares of common stock <br>represented and entitled to <br>vote in person or by proxy <br>on such action.<br>| In this contested election, <br>votes withheld will have no <br>effect.<br>| Broker non-votes will have <br>no effect.<br>|
| **Proposal 2:** Amendments <br>of our Articles and Bylaws <br>to Declassify the Board<br>| Affirmative vote of two-<br>thirds of the shares of <br>common stock outstanding <br>as of the Record Date for <br>the Annual Meeting.<br>| Abstentions will have the <br>effect of a vote against the <br>proposal.<br>| Broker non-votes will have <br>the effect of a vote against <br>the proposal.<br>|
| **Proposal 3:** Amendment <br>to our Articles to Eliminate <br>the Supermajority Voting <br>Requirements in Article <br>XIV<br>| Affirmative vote of two-<br>thirds of the shares of <br>common stock outstanding <br>as of the Record Date for <br>the Annual Meeting.<br>| Abstentions will have the <br>effect of a vote against the <br>proposal.<br>| Broker non-votes will have <br>the effect of a vote against <br>the proposal.<br>|
| **Proposal 4:** Amendment <br>to our Articles to Eliminate <br>the Supermajority Voting <br>Requirements in Article <br>XIV<br>| Affirmative vote of two-<br>thirds of the shares of <br>common stock outstanding <br>as of the Record Date for <br>the Annual Meeting.<br>| Abstentions will have the <br>effect of a vote against the <br>proposal.<br>| Broker non-votes will have <br>the effect of a vote against <br>the proposal.<br>|
| **Proposal 5:** Ratification of <br>Appointment of <br>Independent Auditors<sup>(1)</sup><br>| Affirmative vote of the <br>holders of a majority of the <br>shares of common stock <br>represented and entitled to <br>vote in person or by proxy <br>on such action.<br>| Abstentions will have the <br>effect of a vote against the <br>proposal.<br>| We do not expect any <br>broker non-votes on this <br>proposal.<br>|
| **Proposal 6:** Advisory Vote <br>to Approve Executive <br>Compensation<sup>(1)</sup><br>| Affirmative vote of the <br>holders of a majority of the <br>shares of common stock <br>represented and entitled to <br>vote in person or by proxy <br>on such action.<br>| Abstentions will have the <br>effect of a vote against the <br>proposal.<br>| Broker non-votes will have <br>no effect.<br>|
| **Proposal 7:** Amendment <br>to the 2020 Plan<br>| Affirmative vote of the <br>holders of a majority of the <br>shares of common stock <br>represented and entitled to <br>vote in person or by proxy <br>on such action.<br>| Abstention will have the <br>effect of a vote against the <br>proposal.<br>| Broker non-votes will have <br>no effect.<br>|

---

<sup>(1)</sup> These proposals are an "advisory" vote, meaning that the shareholder votes on this item are for purposes of enabling shareholders to express their

point of view or preference on the proposal, but are not binding on the Company or the Board and do not require the Company or the Board to take

any particular action in response to the shareholder vote. The Board intends to consider fully the votes of our shareholders in the context of any further

action with respect to these proposals.

<u>How to Revoke a Proxy or Change a Vote</u>

Any shareholder giving a proxy may revoke it at any time prior to its use at the Annual Meeting by:

• Delivering written notice of revocation to the corporate Secretary before 6:00 p.m., Eastern Daylight Time, on May 19,

2026;

• Submitting to the corporate Secretary before 6:00 p.m., Eastern Daylight Time, on May 19, 2026, a properly signed

proxy card bearing a later date than the prior proxy card;

• Voting again by Internet or telephone before 11:59 p.m., Eastern Daylight Time, on May 20, 2026; or

---

| | |
|:---|:---|
| **86 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

• Participating in the Annual Meeting and voting your shares electronically during the Annual Meeting. Participation in

the Annual Meeting will not cause your previously granted proxy to be revoked unless you specifically make that

request.

**OTHER MATTERS**

Management of our Company does not intend to present other items of business and knows of no items of business that

are likely to be brought before the Annual Meeting except those described in this Proxy Statement. However, if any other

matters should properly come before the Annual Meeting, the persons named in the enclosed proxy will have discretionary

authority to vote such proxy in accordance with the best judgment on such matters.

**What does it mean if I receive more than one proxy card or Shareholder Notice?**

You will receive multiple proxy cards if you hold your shares of common stock in different ways (e.g., different names,

trusts, custodial accounts, joint tenancy) or in multiple accounts. If your shares of common stock are held by a broker,

bank or other nominee (i.e., in "street name"), you will receive a voting instruction form directly from your broker, bank or

other nominee. It is important that you complete, sign and date each proxy card or voting instruction form you receive, or

by using the Internet as described in the instructions included herein and on your proxy card(s).

**Householding Information**

"Householding" is a program, approved by the SEC, which allows companies and intermediaries (e.g., banks and brokers

or other nominees) to satisfy the delivery requirements for proxy statements and annual reports by delivering only one

package of shareholder proxy material to any household at which two or more shareholders reside. If you and other

residents at your mailing address own shares of our common stock in a "street name," your broker or bank may have

notified you that your household will receive only one copy of our proxy materials. Once you have received notice from

your broker that they will be "householding" materials to your address, "householding" will continue until you are notified

otherwise or until you revoke your consent. Any shareholder who is receiving multiple copies of these documents and

would like to receive only one copy per household should contact the shareholder's bank, broker or other nominee record

holder. If you hold shares of our common stock in your own name as a holder of record, "householding" will not apply to

your shares.

We will promptly deliver an additional copy of any of these documents to you if you call us at (763) 551-7498, email us at

investorrelations@sleepnumber.com, or write us at the following address: Sleep Number Corporation, Investor Relations

Department, 1001 Third Avenue South, Minneapolis, Minnesota 55404.

**COPIES OF 2025 ANNUAL REPORT**

We will furnish to our shareholders without charge a copy of our Annual Report on Form 10-K (without exhibits) for the

2025 fiscal year ended January 3, 2026. Any request for an Annual Report should be sent to:

**Sleep Number Corporation** 

Investor Relations Department

1001 Third Avenue South

Minneapolis, Minnesota 55404

---

| | |
|:---|:---|
| **87 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

**HOW TO RECEIVE PROXY MATERIALS**

We furnish proxy materials to our shareholders primarily via the Internet. On or about April 8, 2026, we will begin mailing

to certain of our shareholders a Notice of Internet Availability of Proxy Materials (the Shareholder Notice), which includes

instructions on: (a) how to access our Proxy Statement and Annual Report on the Internet, (b) how to request that a

printed copy of these proxy materials be forwarded to you and (c) how to vote your shares. If you receive the Shareholder

Notice, you will not receive a printed copy of the proxy materials unless you request a printed copy by following the

instructions in the Shareholder Notice. All other shareholders will be sent the proxy materials by mail beginning on or

about April 8, 2026.

Requests for printed copies of the proxy materials can be made by Internet at ***www.proxyvote.com***, by telephone at

1-800-579-1639 or by email at sendmaterial@proxyvote.com by sending a blank email with your control number in the

subject line. The Proxy Statement and Annual Report for the year ended January 3, 2026, and related materials are

available at *http://ir.sleepnumber.com*. The information contained in or connected to our website is not incorporated by

reference into, or considered a part of, this Proxy Statement.

**HOW TO RECEIVE FUTURE PROXY MATERIALS ELECTRONICALLY**

Shareholders of Record who received a paper copy of the proxy materials may elect to receive future Proxy Statements

and Annual Reports online as described in the next paragraph. Shareholders electing this feature will receive an email

message notification when the materials are available, along with a web address for viewing the materials. No action is

necessary to continue receiving proxy materials electronically in the future.

Whether you are a Shareholder of Record or a Beneficial Owner holding shares through a bank or broker, you can enroll

for future electronic delivery of Proxy Statements and Annual Reports by following these steps:

• Go to our website at ***www.sleepnumber.com;***

• In the **Investors** section, click on **Resources** and then **Electronic Fulfillment;**

• Click on the check-marked box next to the statement **"Shareholders can register for electronic delivery of** 

**proxy-related materials";** and

• Follow the prompts to submit your request to receive proxy materials electronically.

You may view this year's proxy materials at ***www.proxyvote.com****.* Generally, banks and brokers offering this choice

require that shareholders vote through the Internet in order to enroll. Beneficial Owners whose bank or broker is not

included in this website are encouraged to contact their bank or broker and ask about the availability of electronic delivery.

As is customary with Internet usage, the user must pay all access fees.

There is no cost to you for electronic delivery of Annual Meeting materials. You may incur the usual expenses associated

with Internet access as charged by your Internet service provider. Electronic delivery enables quicker delivery, allows you

to view or print the materials at your computer and makes it convenient to vote your shares online. Electronic delivery also

conserves natural resources and saves the Company printing, postage and processing costs.

**THE COMPANY BEARS THE PROXY SOLICITATION COSTS**

The proxies being solicited hereby are being solicited by the Board. The cost of preparing and mailing the notice of Annual

Meeting, this Proxy Statement and the accompanying proxy and the cost of solicitation of proxies on behalf of the Board

will be borne by the Company. The Company may solicit proxies by mail, Internet (including by email, social media, the

---

| | |
|:---|:---|
| **88 \| 2026 PROXY STATEMENT** | **OUR ANNUAL MEETING AND VOTING** |

---

use of our Investor Relations website and other online channels of communication), telephone and other electronic

channels of communication, town hall meetings, personal interviews, press releases and press interviews. Our Directors,

officers and regular team members may, without compensation other than their regular compensation and the

reimbursement of expenses, solicit proxies by telephone or personal conversation. In addition, we may reimburse

brokerage firms and others for their reasonable and documented expenses incurred in connection with forwarding proxy

materials to the Beneficial Owners of our common stock.

**DELINQUENT SECTION 16(a) REPORTS**

Section 16(a) of the Securities Exchange Act of 1934 requires our Directors and officers and all persons who beneficially

own more than 10% of the outstanding shares of our common stock to file with the SEC initial reports of ownership and

reports of changes in ownership of our common stock. Section 16(a) officers, directors and greater than 10% beneficial

owners are also required to furnish us with copies of all Section 16(a) forms they file. Based solely on a review of Section

16 reports filed electronically with the SEC and written representations from certain reporting persons, we believe that all

forms required to be filed by such persons under Section 16(a) were filed on a timely basis, with the exception of two

Form 3 filings, one reporting the initial statement of beneficial ownership for Tanya C. Skogerboe and the other for Hitesh

Patel, in each case filed thirteen days late as a result of delays in procuring SEC EDGAR filing codes.

**INCORPORATION BY REFERENCE**

In accordance with SEC rules, notwithstanding anything to the contrary set forth in any of our previous or future filings

under the Securities Act of 1933, as amended, or the Exchange Act that might incorporate this Proxy Statement or future

filings made by the Company under those statutes, the information included under the section entitled "Compensation

Committee Report" and those portions of the information included under the section entitled "Audit Committee Report"

required by the SEC's rules to be included therein, shall not be deemed to be "soliciting material" nor shall the information

included under the section entitled "Compensation Committee Report," or those portions of the information included under

the section entitled "Audit Committee Report" required by the SEC's rules to be included therein, be "filed" with the SEC

or, along with the information included under the section entitled "Pay Versus Performance," be deemed incorporated by

reference into any of those prior filings or into any future filings made by the Company under those statutes, except to the

extent we specifically incorporate these items by reference.

Web links throughout this document are provided for convenience only, and the content on the referenced websites does

not constitute a part of this Proxy Statement.

Your vote is important. Whether or not you plan to attend the Annual Meeting, please vote your shares of common stock

"**For**" the Board's nominees and "**For**" each of Proposals 2, 3, 4, 5, 6, and 7 promptly by mail, telephone or Internet as

instructed on your proxy card.

---

| |
|:---|
| By Order of the Board of Directors |
| ![Sleep-Img_04.jpg](snbr-20260408_g36.jpg) |
| Samuel R. Hellfeld |
| *Chief Legal and Risk Officer and Secretary* |

---

April 8, 2026

Minneapolis, Minnesota

---

| | |
|:---|:---|
| **89 \| 2026 PROXY STATEMENT** | **APPENDIX A** |

---

APPENDIX A

**PROPOSED AMENDMENTS TO OUR ARTICLES AND OUR BYLAWS TO DECLASSIFY THE BOARD**

The following are proposed changes to our Third Restated Articles of Incorporation, as amended, and to our Restated

Bylaws to declassify our Board of Directors as described in Proposal 2 (new text appears in <u>blue underline</u> and deleted

text appears in red strikethrough).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**ARTICLES OF AMENDMENT TO**

**THIRD RESTATED ARTICLES OF INCORPORATION OF**

**SLEEP NUMBER CORPORATION**

The undersigned, Samuel R. Hellfeld, being the Secretary of Sleep Number Corporation (the "Corporation"), a corporation

organized under and subject to the provisions of Minnesota Statutes, Chapter 302A, does hereby certify that pursuant to

actions duly taken by the Board of Directors and shareholders of the Corporation, a resolution was adopted that the first

three sentences of Article XIV of the Third Restated Articles of Incorporation of the Corporation, as amended, and be

amended and restated in their entirety as follows:

**ARTICLE XIV**

The number of directors which shall constitute the entire Board of Directors shall not be less than one (1) nor

more than twelve (12), which number shall be determined from time to time by the Board of Directors. The

Directors shall be divided into three (3) classes, as nearly equal in number as possible. The term of office of the

first class shall expire at the 1999 annual meeting of the shareholders of the Corporation; the term of office of the

second class shall expire at the 2000 annual meeting of the shareholders of the Corporation; and the term of

office of the third class shall expire at the 2001 annual meeting of the shareholders of the Corporation. At each

annual meeting of the shareholders after such classification, the number of directors equal to the number of the

class whose term expires on the day of such meeting shall be elected for a term of three (3) years. <u>Commencing</u> 

<u>with the election of directors at the annual meeting of shareholders to be held in 2027, all directors shall be</u> 

<u>elected for a one year term expiring at the next annual meeting of shareholders and the prior classification of the</u> 

<u>Board of Directors shall terminate.</u> Directors shall hold office until expiration of the terms for which they were

elected and qualified; provided, however, that a director may be removed from office as a director at any time by

the shareholders, but only for cause, and only by the affirmative vote of a majority of the outstanding voting power

entitled to elect such director. If the office of any director becomes vacant by reason of death, resignation,

retirement, disqualification, removal from office, increase in the number of directors or otherwise, a majority of the

remaining directors, although less than a quorum, at a meeting called for that purpose, may choose a successor,

who, unless removed for cause as set forth above, shall hold office until the expiration of the term of the class for

which appointed or until a successor shall be elected and qualified. This Article XIV may not be altered, amended

or repealed, in whole or in part, unless authorized by the affirmative vote of the holders of not less than two-thirds

of the outstanding voting power entitled to vote.

---

| | |
|:---|:---|
| **90 \| 2026 PROXY STATEMENT** | **APPENDIX A** |

---

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**AMENDMENT TO RESTATED BYLAWS OF**

**SLEEP NUMBER CORPORATION**

The undersigned, Samuel R. Hellfeld, being the Secretary of Sleep Number Corporation (the "Corporation"), a corporation

organized under and subject to the provisions of Minnesota Statutes, Chapter 302A, does hereby certify that pursuant to

actions duly taken by the Board of Directors and shareholders of the Corporation, a resolution was adopted that Article III,

Section 2 of the Restated Bylaws of the Corporation be amended and restated in its entirety as follows:

**ARTICLE III**

**Board of Directors**

\*\*\*\*\*

Section 2. <u>Number and Term of Office</u>. The number of directors which shall constitute the entire Board of Directors

shall not be less than one (1) nor more than twelve (12), which number shall be determined from time to time by

the Board of Directors. The Directors shall be divided into three (3) classes, as nearly equal in number as

possible. The term of office of the first class shall expire at the 1999 annual meeting of the shareholders of the

Corporation; the term of office of the second class shall expire at the 2000 annual meeting of the shareholders of

the Corporation; and the term of office of the third class shall expire at the 2001 annual meeting of the

shareholders of the Corporation. At each annual meeting of the shareholders after such classification, the number

of directors equal to the number of the class whose term expires on the day of such meeting shall be elected for a

term of three (3) years. <u>Commencing with the election of directors at the annual meeting of shareholders to be</u> 

<u>held in 2027, all directors shall be elected for a one year term expiring at the next annual meeting of shareholders</u> 

<u>and the prior classification of the Board of Directors shall terminate.</u> Directors shall hold office until expiration of

the terms for which they were elected and qualified.

---

| | |
|:---|:---|
| **91 \| 2026 PROXY STATEMENT** | **APPENDIX B** |

---

APPENDIX B

**PROPOSED AMENDMENT TO OUR THIRD RESTATED ARTICLES OF INCORPORATION, AS AMENDED, TO** 

**ELIMINATE THE SUPERMAJORITY VOTING REQUIREMENT IN ARTICLE XIV RELATED TO OUR DIRECTORS**

The following are proposed changes to our Third Restated Articles of Incorporation, as amended, to eliminate the

supermajority voting requirement in Article XIV related to our Directors as described in Proposal 3 (new text appears in

<u>blue underline</u> and deleted text appears in red strikethrough).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**ARTICLES OF AMENDMENT TO**

**THIRD RESTATED ARTICLES OF INCORPORATION OF**

**SLEEP NUMBER CORPORATION**

The undersigned, Samuel R. Hellfeld, being the Secretary of Sleep Number Corporation (the "Corporation"), a corporation

organized under and subject to the provisions of Minnesota Statutes, Chapter 302A, does hereby certify that pursuant to

actions duly taken by the Board of Directors and shareholders of the Corporation, a resolution was adopted that the last

sentence of Article XIV of the Third Restated Articles of Incorporation of the Corporation, as amended, be amended and

restated in its entirety as follows:

**ARTICLE XIV**

The number of directors which shall constitute the entire Board of Directors shall not be less than one (1) nor

more than twelve (12), which number shall be determined from time to time by the Board of Directors. The

Directors shall be divided into three (3) classes, as nearly equal in number as possible. The term of office of the

first class shall expire at the 1999 annual meeting of the shareholders of the Corporation; the term of office of the

second class shall expire at the 2000 annual meeting of the shareholders of the Corporation; and the term of

office of the third class shall expire at the 2001 annual meeting of the shareholders of the Corporation. At each

annual meeting of the shareholders after such classification, the number of directors equal to the number of the

class whose term expires on the day of such meeting shall be elected for a term of three (3) years. Directors shall

hold office until expiration of the terms for which they were elected and qualified; provided, however, that a

director may be removed from office as a director at any time by the shareholders, but only for cause, and only by

the affirmative vote of a majority of the outstanding voting power entitled to elect such director. If the office of any

director becomes vacant by reason of death, resignation, retirement, disqualification, removal from office,

increase in the number of directors or otherwise, a majority of the remaining directors, although less than a

quorum, at a meeting called for that purpose, may choose as successor, who, unless removed for cause as set

forth above, shall hold office until the expiration of the term of the class for which appointed or until a successor

shall be elected and qualified. This Article XIV may not be altered, amended or repealed, in whole or in part,

unless authorized by the affirmative vote of the holders of not less than two-thirds <u>a majority</u> of the outstanding

voting power entitled to vote.

---

| | |
|:---|:---|
| **92 \| 2026 PROXY STATEMENT** | **APPENDIX C** |

---

APPENDIX C

**AMENDMENT TO OUR THIRD RESTATED ARTICLES OF INCORPORATION, AS AMENDED, TO ELIMINATE THE** 

**SUPERMAJORITY VOTING REQUIREMENTS IN ARTICLE XV** 

**RELATED TO APPROVAL OF CERTAIN TRANSACTIONS**

The following are proposed changes to our Third Restated Articles of Incorporation, as amended, to eliminate the

supermajority voting requirements in Article XV related to certain transactions as described in Proposal 4 (new text

appears in <u>blue underline</u> and deleted text appears in red strikethrough).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**ARTICLES OF AMENDMENT TO**

**THIRD RESTATED ARTICLES OF INCORPORATION OF**

**SLEEP NUMBER CORPORATION**

The undersigned, Samuel R. Hellfeld, being the Secretary of Sleep Number Corporation (the "Corporation"), a corporation

organized under and subject to the provisions of Minnesota Statutes, Chapter 302A, does hereby certify that pursuant to

actions duly taken by the Board of Directors and shareholders of the Corporation, a resolution was adopted that Article XV

of the Third Restated Articles of Incorporation of the Corporation, as amended, and be amended and restated in its

entirety as follows:

**ARTICLE XV**

The affirmative vote of the holders of not less than two-thirds <u>a majority</u> of the outstanding voting power of the

corporation entitled to vote for approval shall be required if (a) this Corporation merges or consolidates with any

other corporation, or if (b) this Corporation sells or exchanges all or a substantial part of its assets to or with any

other corporation, or if (c) this Corporation issues or delivers any stock or other securities of its issue in exchange

or payment for any properties or assets of any other corporation, or securities issued by any other corporation, or

in a merger of any subsidiary of this Corporation (80% or more of the common stock of which is held by this

Corporation) with or into any other corporation; provided, however, that the foregoing shall not apply to any plan of

merger or consolidation, or sale or exchange of assets, or issuance or delivery of stock or other securities which

was approved (or adopted) and recommended without condition by the affirmative vote of not less than two-thirds

of the directors, nor shall it apply to any such transaction solely between this Corporation and another corporation

50% or more of the voting stock of which is owned, directly or indirectly, by this Corporation. The Board of

Directors shall be permitted to condition its approval (or adoption) of any plan of merger or exchange of assets, or

issuance or delivery of stock or securities upon the approval of holders of two-thirds <u>a majority</u> of the outstanding

stock of this Corporation entitled to vote on such plan of merger or consolidation, or sale or exchange of assets, or

issuance or delivery of stock or securities. This Article XV may not be altered, amended or repealed, in whole or in

part, unless authorized by the affirmative vote of the holders of not less than two-thirds <u>a majority</u> of the

outstanding voting power entitled to vote.

---

| | |
|:---|:---|
| **93 \| 2026 PROXY STATEMENT** | **APPENDIX D** |

---

APPENDIX D

**AMENDMENT NO. 3 TO THE**

**SLEEP NUMBER CORPORATION 2020 EQUITY INCENTIVE PLAN** 

This Amendment No. 3 (this "Amendment") to the Sleep Number Corporation 2020 Equity Incentive Plan (as amended,

the "Plan") made and adopted by Sleep Number Corporation (the "Company") effective as of __________, 2026, the date

it was approved by the Company's shareholders. Capitalized terms used but not otherwise defined herein shall have the

meanings ascribed to them in the Plan.

WHEREAS, the Company maintains the Plan.

WHEREAS, pursuant to Section 19.1 of the Plan, the Management Development and Compensation Committee,

at any time and from time to time, may amend the Plan.

WHEREAS, pursuant to Section 19.2 of the Plan, no amendments to the Plan will be effective without approval of

the Company's shareholders if, among other things, such amendment would, subject to Section 4.5 of the Plan, increase

the aggregate number of shares of Common Stock issued or issuable under the Plan.

WHEREAS, the Management Development and Compensation Committee approved this Amendment on March

11, 2026, subject to the approval of the Company's shareholders, to increase the number of shares of Common Stock

reserved for issuance under the Plan by 750,000 shares, as set forth in this Amendment.

NOW, THEREFORE, in consideration of the foregoing, the Plan is hereby amended as follows:

1. Section 4.1 of the Plan is hereby amended and restated in its entirety to read as follows:

4.1 Maximum Number of Shares Available. Subject to adjustment as provided in Section 4.5 of this

Plan, the maximum number of shares of Common Stock that will be available for issuance under this Plan

will be 5,990,000 shares less one share for every share subject to an Award granted under the Prior Plan

after December 28, 2019. Upon effectiveness of this Plan, no further awards will be granted under the

Prior Plan.

2. This Amendment shall be and is hereby incorporated in and forms a part of the Plan.

3. Except as expressly provided herein, all other terms and provisions of the Plan shall remain unchanged and in full

force and effect.

---

| | |
|:---|:---|
| **94 \| 2026 PROXY STATEMENT** | **ANNEX A** |

---

**ANNEX A - RECONCILIATIONS OF GAAP AND NON-GAAP FINANCIAL MEASURES**

The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP).

However, management believes that certain non-GAAP financial measures provide investors with additional meaningful

financial information that should be considered when assessing the Company's underlying business performance and

trends. Management also uses these non-GAAP financial measures in evaluating the Company's performance. Non-

GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's results prepared in

accordance with GAAP.

The following table summarizes the Company's non-GAAP operating expenses calculations (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Year** | **Year** |
|  | **2025** | **2024** |
| Operating expenses | $879543 | $979901 |
| Subtract: Restructuring costs | 50697 | 18066 |
| Subtract: Asset impairments |  | 1220 |
| Subtract: Other non-recurring items<sup>(1)</sup> | 5134 | 998 |
| Non-GAAP operating expenses | $823712 | $959617 |
| Operating expense reduction versus prior period, excluding restructuring costs and <br>non-recurring items<br>| $135905 |  |

---

<sup>(1)</sup> Excludes inventory obsolescence write off of $9.6 million, which is included in the cost of sales line on the Company's consolidated statement of

operations.

![Proxy Card - Prelim.jpg](snbr-20260408_g37.jpg)

![Proxy Card PG 2 - FINAL.jpg](snbr-20260408_g38.jpg)

![Proxy Card PG 3 - FINAL.jpg](snbr-20260408_g39.jpg)

![Proxy Card PG 4 - Prelim.jpg](snbr-20260408_g40.jpg)